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dsDNA Double-stranded DNA 
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SUMMARY 
 
This PhD thesis presents the diversity of Porcine Reproductive and Respiratory Syndrome 
viruses (PRRSV) circulating in the Danish pig population.  PRRS is a disease in pigs caused by the 
PRRS virus resulting in reproductive failures in sows and gilts and respiratory diseases in pigs. Due 
to genetic heterogeneity, PRRSV is divided into two genotypes, Type 1 and Type 2. Type 1 PRRS 
viruses are further divided into at least 3 subtypes. The virus evolves rapidly and reports of high 
pathogenic variants of both Type 1 and Type 2 appearing in Europe, North America, and Asia have 
been reported within recent years. This abrupt occurrence of highly pathogenic PRRSV strains 
emphasizes the significance of monitoring the diversity of circulating strains around the world both 
in respect to the sensitivity and specificity of diagnostic tests as well as efficacy of available 
vaccines.  
The aims and objectives of the PhD project will be introduced in the objectives section together 
with a short introduction to the situation of PRRSV in Denmark at the start of this study. The 
background chapter will provide a review on PRRSV with the emphasis on genetic diversity.  
The results of the work performed during the PhD are presented in the four manuscripts included 
in the PhD thesis and a short summary of each manuscript is depicted below: 
Manuscript I is focusing on the development of methods for complete genome sequencing of 
PRRSV. The sequencing strategy was based on the production of long range PCR fragments 
covering the PRRSV genome in two or four fragments with full-length cDNA as template. The 
sequencing of the PCR fragments was performed using Next Generation Sequencing (NGS) 
technologies and three different platforms were used. A total of 18 complete PRRSV genomes were 
obtained using this new method. 
Manuscript II is focusing on the diversity of Type 1 PRRSV in Denmark. For the first time 
genetic and antigenic examinations of complete genomes of Danish isolated Type 1 PRRSV was 
conducted. Furthermore, extensive studies of ORF5 and ORF7 sequences were performed from 44 
viruses collected from 2003 to February 2013. The diversity study confirmed that only Type 1 
subtype 1 PRRSV is circulating in the Danish pig population. The examination of the Danish PRRS 
field viruses confirmed that there is a high overall diversity among Type 1 viruses in Europe. The 
phylogenetic study also indicated the presence of two Danish virus clusters, one dominating 
vaccine/LV like and one resembling an early introduced strain.  
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Manuscript III is focusing on the diversity of Type 2 PRRSV in Denmark. For the first time 
examinations of complete genomes of European isolated Type 2 PRRSV were performed. 
Furthermore, ORF5 and ORF7 sequences obtained from 57 viruses collected in the years 2003-2012 
were examined. The diversity study confirmed that Danish Type 2 PRRS viruses share high genetic 
similarity to the vaccine strain and there was no obviously reason to believe that new Type 2 
PRRSV strains have been introduced. However, a few viruses showed both a higher diversity to the 
other Danish viruses and to the vaccine strain and one virus harbored the largest deletion in NSP2 
reported in Danish Type 2 PRRSV. 
Manuscript IV is focusing on an experimental infection study in pigs with a Type 2 PRRS virus 
causing significant clinical disease in the field. Genetic and antigenic examination of ORF5 and 
partial NSP2 sequences obtained from the case virus revealed several variations compared to the 
vaccine strain. However, complete genome comparison of the case virus to the vaccine strain 
showed high genetic similarity and no obvious virulence maker was found. The results of the 
experimental infection study revealed that the strain induced only sparse clinical symptoms and the 
magnitude and duration of viraemia was comparable to an older Danish Type 2 strain. The results 
emphasized that infections in the field is often more severe than in experimental studies due to the 
multifactorial nature of PRRSV. Furthermore, the study underlined the need for more research on 
virulence markers of PRRSV. 
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DANSK SAMMENDRAG 
 
 I denne Ph.d.-afhandling præsenteres diversiteten af Porcine Reproductive and Respiratory 
Syndrom Virus (PRRSV) som cirkulerer i de danske grise. PRRS er en sygdom hos grise som er 
forårsaget af PRRS virussen som medfører forplantnings problemer hos søer og gylte og luftvejs 
problemer hos grise. På grund af genetisk heterogenitet, er PRRSV inddelt i to genotyper, Type 1 
og Type 2. Type 1 PRRS virus er endvidere inddelt i mindst 3 undertyper. Virussen ændre sig 
hurtigt og indenfor de seneste år er der rapporteret om høj-patogene varianter af både Type 1 og 
Type 2 in Europa, Nord Amerika og Asien. Denne pludselige opståen af høj-patogene PRRSV 
stammer understreger, hvor vigtigt monitoreringen af diversiteten af de PRRSV stammer som 
cirkulerer rundt om i verdenen, med henblik på sensitiviteten og specificiteten af de diagnostiske 
analyser og ikke mindst effekten af de tilgængelige vacciner. 
 Formålet med dette Ph.d. projekt og en kort introduktion til situationen angående PRRSV i 
Danmark ved starten af projektet, vil blive omtalt i kapitlet ’Objectives’. Baggrundskapitlet vil give 
et overblik over PRRSV med vægt på den genetiske diversitet. 
Resultaterne opnået under Ph.d. projektet er præsenteret i de 4 manuskripter som er inkluderet i 
denne Ph.d.-afhandling hvor et kort resumé er givet herunder: 
Manuskript I fokuserer på udviklingen af metoder til brug for komplet genom sekventering af 
PRRSV. Sekventeringsstrategien var baseret på produktionen af lange PCR fragmenter som 
dækkede PRRSV genomet i to eller fire fragmenter hvortil fuld-længde cDNA blev brugt som 
template. Sekventeringen af PCR fragmenterne blev udført ved brug af ’Next Generation 
Sequencing’ (NGS) teknologier hvor tre forskellige platforme blev brugt. I alt blev 18 komplette 
genomer sekventeret ved brug af denne nye metode. 
Manuskript II fokuserer på diversiteten af Type 1 PRRSV i Danmark. For første gang blev 
komplette genomer af danske Type 1 PRRSV undersøgt på både genetisk og antigen niveau. 
Derudover blev omfattende studier af ORF5 og ORF7 diversiteten udført fra 44 virusser indsamlet 
fra 2003 til februar 2013. Fra dette studie blev det bekræftet, at det kun er Type 1 undertype 1 
PRRSV som cirkulerer blandt de danske grise. Den videre undersøgelse af de danske PRRS virus 
bekræftede, at der er en overordnet høj diversitet blandt Type 1 virusser i Europa. De fylogenetiske 
studier viste tilstedeværelsen af to danske virus klynger, en dominerende vaccine/LV-lignende 
klynge og en klynge med virus som lignede en tidligere introduceret Type 1 PRRSV stamme. 
Dansk sammendrag 
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Manuskript III fokuserer på diversiteten af Type 2 PRRSV i Danmark. For første gang blev 
komplette Type 2 PRRSV genomer isoleret i Europa undersøgt. Derudover blev ORF5 og ORF7 
sekvenser fra 57 virusser indsamlet i årene 2003-2012 analyseret. Diversitetsstudiet bekræftede at 
de Danske Type 2 PRRS virusser deler en høj genetisk lighed til vaccine stammen og at der ikke var 
nogen åbenlys grund til at tro, at der er blevet introduceret nye Type 2 stammer til Danmark. Dog 
viste det sig at et par virusser havde en større diversitet både til de andre danske virusser og til 
vaccine stammen samt en virus der havde den længste rapporteret deletion i NSP2. 
Manuskript IV fokuserer på et eksperimentelt infektionsforsøg i grise ved brug af en Type 2 
PRRS virus som forårsagede alvorlig klinisk sygdom i besætningen. Genetiske og antigenetiske 
undersøgelser af ORF5 sekvenser og partiel NSP2 sekvenser sekventeret fra case virusser viste at 
disse virus havde flere variationer ved sammenligning med vaccine stammen. Sammenligningen af 
komplette genomer opnået fra casen mod vaccine stammen viste dog overordnet høj genetisk lighed 
mellem disse og ingen åbenlyse virulensmarkører blev fundet. Resultaterne fra det eksperimentelle 
infektionsforsøg viste, at case virussen kun kunne inducerer milde kliniske symptomer og styrken 
samt varigheden af viræmien var sammenlignelig med en ældre dansk Type 2 stamme. Resultaterne 
opnået her understreger at infektioner i felten ofte er mere alvorlige end set ved eksperimentelle 
infektioner grundet den multifaktorielle natur som PRRSV besidder. Yderligere så understreger 
dette studie behovet for yderligere forskning i virulensmarkører for PRRSV. 
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OBJECTIVES 
 
The surveillance of the genetic and antigenic diversity of circulating PRRS viruses worldwide is 
very important for the advancement of vaccines and development and maintenance of diagnostic 
tools. Since 2010, the virology group at the National Veterinary Institute, DTU, Denmark has 
participated in an EU project: New tools and approaches to control Porcine Reproductive and 
Respiratory Syndrome in the EU and Asia (PoRRSCon). The final goal of the EU project is to 
develop new generation, efficacious and safe maker vaccines that can be adapted to temporary 
changes and geographical differences. Our contribution to the EU project lies in work package 3: 
Geno- and serotyping of PRRSV isolates/strains with Professor Lars E. Larsen as work package 
leader. 
 After the first incidence of PRRS in Denmark in 1992 and until 2002 all research and 
diagnostics of PRRSV at the National Veterinary Institute took place at the Virus department at the 
island Lindholm. In 2003 the PRRSV activities were moved to the department at Frederiksberg. 
Virus detection was at first carried out by inoculation of cell cultures followed by 
immunohistochemically staining but in the fall of 2007 implementation of PCR for PRRS virus 
detection was conducted. 
 Since the move of PRRSV activities to the department at Frederiksberg, the research on PRRSV 
has been minimal and there has not been published any ORF5 and ORF7 Type 1 or Type 2 PRRSV 
sequences obtained from viruses isolated since the late 1990s. 
Regarding complete genome sequences, none Danish Type 1 or Type 2 PRRSV sequencing have 
been performed prior the start of this project. On European level, only 10 complete (or near 
complete) genomes of Type 1 PRRSV are as of this date public available and globally an additional 
eight sequences of Type 1 PRRSV genomes has been published. Of European isolated Type 2 
PRRSV none complete genomes have to date, been made public available or even sequenced. 
The export of Danish pigs to Eastern and central Europe is significant i.e. in 2012 Denmark 
exported more than 9 million living pigs and more than ¼ of a million breeding animals whereas 
less than 100 breeding animals were imported to Denmark. Despite this limited import of living 
pigs the possibility that foreign PRRSV isolates may be introduced into Denmark by contaminated 
transport carriers or persons cannot be excluded but this will probably be rare events. Nevertheless, 
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the diversity of PRRSV circulating in Denmark is of mutual interest for a range of European pig 
producing countries. 
The main objective of this PhD was to develop methods and protocols for full genome 
sequencing of PRRSV in order to close the gap in knowledge on the genetic diversity of circulating 
Type 1 and Type 2 PRRS viruses in Danish pigs and to participate in the elucidation of the genetic 
variability of PRRSV genomes in Europe. 
A more detailed knowledge of the variability of circulating Danish PRRSV ioslates are necessary 
for the evaluation of the sensitivity of diagnostic tests and for the evaluation of existing and future 
control of this important porcine pathogen. 
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1. BACKGROUND 
 
1.1. The discovery of Porcine Reproductive and Respiratory Syndrome Virus 
A mystery swine disease causing reproductive failure and respiratory disease was first described 
in the late 1980s in North America (Collins, 1991, Keffaber, 1989). A few years later a syndrome 
with similar clinical signs was observed in Western Europe (Terpstra et al., 1991, Wensvoort et al., 
1991). During the winter of 1990-91 the disease appeared in Germany and in the Netherlands and 
since then spread through the rest of Western Europe (Wensvoort et al., 1991). In 1991, a large-
scale laboratory investigation was conducted to search for the etiological agent and it was found 
that the disease causing agent was viral (Wensvoort et al., 1991). The first isolate of this agent was 
named Lelystad Virus (LV) after the Dutch city where it was isolated (Wensvoort et al., 1991). 
Shortly after the isolation of LV, a virus showing resembling clinical field signs was isolated in 
USA and designated American Type Culture Collection VR-2332 (ATCC VR-2332), hereafter 
referred to as VR-2332 (Collins et al., 1992). 
Antigenic studies of LV and VR-2332 revealed antigenic differences between the European and 
North American isolated viruses, but also serological variations among the North American virus 
isolates were detected (Wensvoort et al., 1992). Genomic sequence analysis revealed significant 
genetic differences between viruses isolated in Europe and North America, with only 60 % 
nucleotide identity (Allende et al., 1999). These genomic differences confirmed the presence of two 
distinct genotypes, today known as Type 1 for the European isolates and Type 2 for the North 
American isolates. 
 Before the etiological agent causing the disease was known, the syndrome was given various 
names such as disease 89, pig plague 89, Swine Reproductive and Respiratory Syndrome (SRRS), 
Swine Infertility and Respiratory Syndrome (SIRS), Porcine Epidemic Abortion and Respiratory 
Syndrome (PEARS), Blue ear disease, Porcine Reproductive and Respiratory Syndrome (PRRS) 
(Goyal, 1993). However, at the First International Symposium on SIRS/PRRS held at St. Paul, 
Minnesota, USA, in 1992, it was decided to name the syndrome Porcine Reproductive and 
Respiratory Syndrome (PRRS) and its virus Porcine Reproductive and Respiratory Syndrome Virus 
(PRRSV). 
Today, PRRSV is endemic in all pork producing countries with both genotypes distributed 
worldwide (Shi et al., 2010a).  
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1.2. Taxonomy 
PRRSV is a small enveloped RNA virus belonging to the Arteriviridae family (Benfield et al., 
1992, Conzelmann et al., 1993, Wensvoort et al., 1991). Other members of this family are Equine 
Arteritis Virus (EAV), Lactate Dehydrogenase Elevation Virus (LDV) of mice, and Simian 
Hemorrhagic Fever Virus (SHFV). Based on the similarities in the genomic orientation and 
replication mechanism, the Arteriviridae family together with the Coronaviridae, Roniviridae, and 
Mesoniviridae families is placed in the order Nidovirales (Cavanagh, 1997). 
 
1.3. Genomic organization 
The genome of PRRSV is a single-stranded RNA molecule with a positive-sense orientation. 
The genome is 15-15.5 kb long with a 5’-end methylated cap structure and a 3’-end polyadenylated 
tail (Fig. 1). Untranslated regions (UTR) are present at both termini (Allende et al., 1999, 
Meulenberg et al., 1993, Meulenberg et al., 1998a). The genome encodes at least 10 open reading 
frames (ORFs), including the recently discovered ORF5a (Firth et al., 2011, Johnson et al., 2011, 
Meulenberg et al., 1993, Wu et al., 2001). ORF1a and ORF1b constitute about 75 % of the genome, 
and encodes two long non-structural polyproteins, pp1a and pp1ab, with the synthesis of the latter 
depending on a ribosomal frameshift near the 3’-end of ORF1a (Meulenberg et al., 1993, Snijder, 
1998a). ORF2-5 encodes the membrane glycoproteins (GP), GP2-GP5, and ORF6 and ORF7 
encodes a non-glycosylated membrane protein (M) and the nucleocapsid (N) protein, respectively. 
Two small genes, ORF2b and ORF5a, are fully embedded in ORF2 and depending on the genotype 
partially or fully embedded in ORF5, encodes the non-glycosylated proteins E and ORF5a protein, 
respectively (Firth et al., 2011, Johnson et al., 2011, Wu et al., 2001) (Fig. 1.1). 
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Fig. 1.1. Schematic representation of PRRSV genome orientation. Each ORF encoded by the 
PRRSV genome is represented as a rectangle marked with the respective name of the gene. The 5’ 
methylated cap structure is shown as a black sphere and the ribosomal frameshift is marked with a 
red sphere. The black lines at both termini represent the UTRs. The green box at the 5’-UTR 
represents the common leader sequence and the orange boxes located 5’ to the ORF of the 
structural proteins represent the mRNA bodies. sg mRNA2-7 is shown to the right of the figure and 
the polyproteins pp1a and pp1ab are shown to the left. 
 
 
1.4. Structure  
The PRRS virus has pleomorphic morphology. The virion has a spherical to oval shape with a 
size ranging from about 50 to 65 nm, a hollow, layered core of around 40 nm diameter and a 
smooth outer surface with the envelope protein complexes embedded (Spilman et al., 2009).  
A schematic representation of the PRRS virion is illustrated in fig. 1.2. The genome is enclosed 
by the nucleocapsid which is constituted of a double-layered chain of nucleocapsid protein 
homodimers that bundle into a hollow ball (Spilman et al., 2009). The nucleocapsid core is 
surrounded by a lipid membrane, the envelope where the structural proteins are embedded (Benfield 
et al., 1992, Wensvoort et al., 1991). The major protein components of the lipid envelope are GP5 
and M, which together encompass at least half the amount of the viral proteins. GP5 and M forms a 
disulfide-linked heterodimer through conserved cysteine residues in both proteins (Verheije et al., 
2002). The minor structural proteins GP2, GP3, and GP4 forms a multimeric complex incorporated 
in the lipid envelope and for at least the Type 1 PRRS viruses E is also a part of this complex (Das 
et al., 2010, Wissink et al., 2005). The recently discovered ORF5a protein is believed to be the 
eighth structural protein of PRRSV, but its orientation in the virion particle and its interaction with 
the other structural proteins still needs to be clarified (Firth et al., 2011, Johnson et al., 2011). 
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Fig. 1.2. Schematic representation of the PRRSV virion. The orientation of the structural 
proteins of GP2, E, GP3, GP4, GP5, M, and N protein are shown. GP5/M forms a heterodimer and 
the minor glycoproteins and E forms a multimeric complex. The N protein homodimers are shown 
surrounding the PRRSV RNA genome. The figure is modified from Music and Gagnon (2010). 
 
 
1.5. Stability 
Because PRRSV posses a lipid envelope, the survivability outside the host is affected by 
temperature, pH, and detergents. PRRSV is heat labile, but relatively stable at 4°C and -70°C and 
solvents such as chloroform and ether are particularly efficient at disrupting the lipid envelope 
(Benfield et al., 1992). pH values between 6.5-7.5 keeps the virus stable however below and above 
this pH range the virus’ infectivity is reduced (Bloemraad et al., 1994). 
 
1.6. Attachment and entry into host cells 
PRRSV has a very restricted cell tropism in vivo and in vitro. In vivo, PRRSV only replicate 
within macrophages in the respiratory and lymphoid systems of the pig (Halbur et al., 1995a, 
Halbur et al., 1995b, Duan et al., 1997).   
PRRSV entrance into the host cell occurs by receptor-mediated endocytosis (Duan et al., 1998). 
Initial binding of PRRSV to its host cell occurs via interactions with heparan sulphate 
glycosaminoglycans (GAGs) (Delputte et al., 2005). This interaction with heparan sulphate GAGs 
does not internalize the virus particles, but concentrate the virions at the cell surface (Delputte et al., 
2005). The receptor involved in internalization of PRRSV, is the sialoadhesin (Sn) receptor 
(Vanderheijden et al., 2003). The binding of the virus particle to the Sn receptor occur through 
Background 
 
18 
 
binding of sialic acid present on the viral M/GP5 complex (Van Breedam et al., 2010b). Upon 
binding of the virus to the Sn receptor, the virus is internalized via clathrin-mediated endocytosis 
and hence enters the endocytic pathway (Nauwynck et al., 1999, Vanderheijden et al., 2003). After 
entry into the host cell, PRRSV enters the early endosome where it co-localizes with the scavenger 
receptor CD163 (Van Gorp et al., 2009). The receptor CD163 together with at drop in pH is 
believed to be involved in the uncoating of the virus and release of its genome into the cytosol (Van 
Gorp et al., 2008, Van Gorp et al., 2009). The exact mechanism for this uncoating and the role of 
CD163 is not yet clear. However, it has been shown that two of the minor PRRSV glycoproteins 
embedded in the virion surface, GP2 and GP4, interact with the CD163 receptor (Das et al., 2010).  
In vitro, PRRSV are able to proliferate in the primary cell lines porcine alveolar macrophages 
(PAM) and blood monocytes (Voicu et al., 1994, Wensvoort et al., 1991). Two non-porcine cell 
sub-clones; Marc-145 and CL2621 cells, both derived from the African green monkey cell line 
MA104, are routinely used for in vitro propagation of PRRSV (Bautista et al., 1993, Kim et al., 
1993). However the infection process in these cell lines differs from porcine macrophages since the 
MA104 cell line does not express the Sn receptor and the virus propagation in this cell line can lead 
to new mutations in the structural proteins to improve infection (Van Breedam et al., 2010a, 
Nauwynck et al., 2012). 
 
1.7. Replication and translation 
The replication of the PRRSV genome takes place in the cytoplasm of the host cell. The proteins 
involved in replication are encoded in the two major ORFs, ORF1a and ORF1b. Before the 
replication of the viral genome can take place, the viral proteins involved in this process have to be 
synthesized. ORF1a is translated directly from the genomic RNA to the polyprotein 1a (pp1a) 
where ORF1b is translated through a -1 ribosomal frameshift just upstream of the ORF1a 
termination codon resulting in the synthesis of polyprotein 1ab (pp1ab) from ORF1ab (Snijder and 
Meulenberg, 1998). After the protein synthesis, the polyproteins are cleaved into 14 functional 
nonstructural proteins (nsps). The key enzymes for the RNA replication are the RNA-dependent 
RNA polymerase (RdRp) and the RNA helicase both encoded in ORF1b (nsp9 and nsp10) (van 
Dinten et al., 1996). The structural proteins are not translated from the genomic RNA, as the 3’ 
proximal third of the genome is not accessible for ribosomes involved in genome translation, but 
instead the structural proteins are translated from a nested set of subgenomic (sg) mRNA’s (sg 
mRNA2-7) (Pasternak et al., 2006, Conzelmann et al., 1993) (Fig. 1.1). The replication of the 
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genomic RNA (mRNA1) starts with the synthesis of full-length minus-strand RNA by the binding 
of the RdRp enzyme complex to RNA signals at the genomic 3’ end. The full-length minus-strand 
RNA molecule then acts as template for the synthesis of positive-sense RNA, the genomic RNA 
(Snijder and Meulenberg, 1998). The sg RNA templates for sg mRNA synthesis are believed to be 
generated by discontinuous minus-strand RNA synthesis. The 5’terminal common leader sequence 
derived from the 5’-UTR region of mRNA1 is fused with mRNA bodies located at the 5’ end of the 
structural ORFs (Pasternak et al., 2006) (fig. 1.1). Each sg mRNA2-6 is structurally polycistronic 
(except sg mRNA7 only encodes ORF7) but only the 5’ proximal ORF is translated into protein and 
hence functionally monocistronic (Pasternak et al., 2006). PRRSV RNA synthesis is asymmetric 
and produces more positive-sense RNA than minus-sense RNA (Sawicki et al., 2001).  
 
1.8. Non-structural proteins, - processing and function 
The ORF1a and ORF1ab encode the two long non-structural proteins, pp1a and pp1ab (Snijder, 
1998b). The pp1a and pp1ab are processed into 14 non-structural proteins (nsp1α, nap1β, nsp2-6, 
nsp7α, nsp7β, and nsp8-nsp12) by a complex proteolytic cascade that is directed by four proteinase 
domains encoded in ORF1a (Fang and Snijder, 2010, Ziebuhr et al., 2000). The four proteases 
involved in the cleavage of the polyproteins are nsp1α, nap1β, nsp2, and nsp4 (Ziebuhr et al., 2000). 
The first step in the processing of pp1a or pp1ab is the rapid auto-release of nsp1α nsp1β. These 
proteases both contain a papain-like cysteine protease domain, called PCPα and PCPβ respectively, 
and cleave themselves from the polyprotein at their C-terminal junctions (den Boon et al., 1995, 
Chen et al., 2010). The nsp2/nsp3 proteolytic cleavage is processed by a cysteine protease located at 
the N-terminal domain of nsp2 (den Boon et al., 1995). After release of nsp1α, nsp1β, and nsp2, the 
remaining cleavages in both pp1a and pp1ab are carried out by the viral ‘main’ protease, the nsp4, a 
3C-like protease (Snijder et al., 1996). 
Even though the non-structural proteins constitute more than ¾ of the PRRSV genome, little is 
known about their function (Chen et al., 2010). The nsp1α is believed to be important for sg mRNA 
synthesis where as nsp1β is mostly required for genome replication (Kroese et al., 2008). 
Furthermore, nsp1α and nsp1β have been found to be involved in the blockage of the type I 
interferon synthesis and signaling pathway (Chen et al., 2010). nsp2 is the largest of the non-
structural proteins although it vary in length as both deletions and insertions are common in this 
region of the PRRSV genome (Fang et al., 2004, Han et al., 2006, Gauger et al., 2012). The amino 
acid variation of the nsp2 protein is also very high both within the same genotype and between the 
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two genotypes (Fang et al., 2004, Han et al., 2006, Gauger et al., 2012, Allende et al., 1999). 
Besides being involved in the proteolysis of pp1a and pp1ab nsp2 may also be a potential interferon 
(IFN) antagonist and involved in replication-associated membrane rearrangements in collaboration 
with nsp3 (Fang and Snijder, 2010). nsp2 is the viral protein containing the highest frequency in B-
cell epitopes (Oleksiewicz et al., 2001, de Lima et al., 2006, Yan et al., 2007) and the humoral 
antibody response to nsp2 is greater than towards any other PRRSV protein, however it is non-
neutralizing (Han et al., 2007, Johnson et al., 2007, Brown et al., 2009).    
The pp1a protein products nsp5-8 are not well described and have currently unknown function 
and structure (Dokland, 2010). Nevertheless a recent study showed that at 6 hours PI most of the 
nsps co-localized in the cell cytoplasm, at a perinuclear site assumed to be the site of the replication 
complex (Chen et al., 2010, Snijder and Meulenberg, 1998). ORF1b encodes the key enzymes for 
RNA replication. The nsp9 encodes the RNA-dependent RNA polymerase (RdRp) and nsp10 
encodes the helicase involved in the unwinding of double-stranded RNA (dsRNA) (van Dinten et 
al., 1996). The nsp11 encodes a nidovirus endoribonuclease (NendoU) domain and have a critical 
role in the replicative cycle (Posthuma et al., 2006). Nsp12 is of unknown structure and function 
(Fang and Snijder, 2010). 
 
1.9. The structural proteins 
PRRSV encodes at least seven structural proteins: GP2, E, GP3, GP4, GP5, M, and N protein 
(fig. 1.2). An eight structural protein, ORF5a protein, was recently discovered, however its function 
and location among the structural proteins is unknown (Firth et al., 2011, Johnson et al., 2011).  
GP2 is encoded in ORF2, constitute 249 and 256 amino acids in Type 1 and Type 2 PRRSV 
respectively. The protein contains two highly conserved N-glycosylation motifs (N-X-S/T-X, X ≠ 
P) at N173 and N179 for Type 1 and N178 and N184 for Type 2 (Dea et al., 2000). The importance 
of the N-glycosylation of GP2 has been studied. For the Type 1 PRRSV, the role of N-glycosylation 
of GP2 showed that lack of glycosylation at either one or both sites did not affect the formation or 
infectivity of virions (Wissink et al., 2004). On the other hand for Type 2, the N-glycosylation at 
N184 was required for infectious virus production (Das et al., 2011). GP2 has been found to interact 
with the CD163 receptor, thus GP2 may be involved in the uncoating and genome release of 
PRRSV (Das et al., 2010). 
The E protein is synthesized from the same sg mRNA (mRNA2) as GP2 and is 70 and 73 amino 
acid long for Type 1 and Type 2 PRRSV, respectively (Wu et al., 2001). The protein is 
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unglycosylated and has a central hydrophobic domain and a hydrophilic C-terminus (Snijder et al., 
1999). The E protein likely functions as an ion-channel protein and allows ions to enter the virion 
and hereby triggering internal capsid disassembly and promote the release of the viral genome into 
the cytosol (Lee and Yoo, 2006). The expression of GP2 and E as enhanced green fluorescent 
fusion proteins has shown that E is preferentially expressed which suggest that E is the principal 
product of ORF2 (Wu et al., 2001). 
GP3 is encoded by ORF3 and the mature protein is 265 and 254 amino acid long in Type 1 and 
Type 2, respectively. GP3 is the most variable structural protein and Type 1 GP3 is prone for 
deletion in a highly variable region located at the C-terminal (Oleksiewicz et al., 2000, Darwich et 
al., 2011). The GP3 is heavily N-glycosylated and contains seven N-glycosylation motifs (N27, 
N42, N50, N130, N151, N159, and N 194 for Type 1 and N29, N42, N50, N131, N152, N160, 
N196 for Type 2) (Dea et al., 2000). Recent findings revealed that the first six N-glycosylation sites 
in GP3 are glycosylated in Type 2 PRRSV (Das et al., 2011). The seventh N-glycosylation site, 
N195, did not constitute glycosylation however this position is believed to be located in the 
transmembrane region of GP3, hence unlikely to be glycosylated (Das et al., 2011).  Glycosylation 
at N42, N50, and N131 for Type 2 PRRSV is necessary for infectious virus production (Das et al., 
2011). GP3 of Type 1 PRRSV encodes a B-cell epitope at aa60-87 which has been shown to induce 
neutralizing antibodies (Oleksiewicz et al., 2001, Oleksiewicz et al., 2002). For Type 2 PRRSV, 
four overlapping B-cell epitopes has been predicted at position aa61-105 and were strongly 
immunoreactive to tested sera (de Lima et al., 2006). 
GP4 is encoded by ORF4 and is 183 and 178 amino acid long for Type 1 and Type 2 PRRSV, 
respectively. The 5’ end of ORF4 and the 3’ end of ORF3 coding regions overlap and hence any 
deletion found in ORF3 will also affect ORF4. The GP4 protein encodes four N-glycosylation 
motifs, N37, N 88, N124, and N134 for Type 1 PRRSV and N37, N84, N120, and N130 for Type 2 
PRRSV (Dea et al., 2000). Any three of the four putative N-glycosylation sites (N37, N84, N120, 
and N130 in GP4 PRRSV Type 2) has been found to be necessary for recovery of infectious virus 
(Das et al., 2011). Together with GP2, GP4 has been found to interact with the CD163 receptor, 
thus GP4 may be involved in the uncoating and genome release of PRRSV (Das et al., 2010). GP4 
of Type 1 PRRSV encodes a B-cell epitope at position aa58-70 that induces neutralizing antibodies 
(Oleksiewicz et al., 2001, Oleksiewicz et al., 2002). For Type 2, a B-cell epitope has been predicted 
however the ability to induce neutralizing antibodies needs more research (de Lima et al., 2006). 
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 The minor structural proteins GP2, GP3, and GP4 are all required for generation of infectious 
virions (Wissink et al., 2005). The three minor glycoproteins forms a multimeric complex 
incorporated in the lipid envelope and for at least the Type 1 PRRS viruses E is also a part of this 
complex (Das et al., 2010, Wissink et al., 2005). The recently discovered ORF5a protein is believed 
to be the eighth structural protein of PRRSV, but its orientation in the virion particle and its 
interaction with the other structural proteins still needs to be clarified (Firth et al., 2011, Johnson et 
al., 2011). 
GP5 is the most abundant glycoprotein found on the surface of the PRRSV virion and form a 
heterodimer with M protein (Van Breedam et al., 2010b). GP5 is encoded by ORF5 which is one of 
the most variable regions of the PRRSV genome and it is the most examined gene in regard to 
diversity studies (Shi et al., 2010a, Shi et al., 2010b). The GP5 harbors various numbers of putative 
N-glycosylation sites where glycosylation at N46 and N53 for Type 1 PRRSV and at N44 and N51 
for Type 2 PRRSV are highly conserved (Music and Gagnon, 2010) (Manuscript II and III). N-
glycosylation at position N44 in Type 2 PRRSV has previously been shown to be important for 
infectious virus production (Ansari et al., 2006). The GP5 harbors a neutralizing epitope at position 
aa38-54 for Type 1 PRRSV and at position aa37-47 in Type 2 PRRSV (Oleksiewicz et al., 2002, 
Ostrowski et al., 2002, Plagemann, 2004a, Plagemann, 2004b). For Type 2 PRRSV strains the GP5 
also contains a decoy epitope at position aa27-30 which is not neutralizing but may function to 
distract the humoral immune response hence delaying the induction of neutralizing antibodies 
against PRRSV (Ostrowski et al., 2002).  
The M protein encoded by ORF6 is composed of 173 and 174 amino acid residues in Type 1 and 
Type 2 PRRSV, respectively. The M protein is unglycosylated and is highly conserved among the 
structural proteins (Meulenberg et al., 1993, Mardassi et al., 1995) (Manuscript II and III). The M 
protein and GP5 forms disulfide-linked heterodimers through conserved cysteine residues in both 
proteins. This conformation of M and GP5 is essential for virus infectivity (Van Breedam et al., 
2010b). 
The N protein encoded by ORF7 is the most abundant viral protein in the infected cell (Dea et 
al., 2000, Snijder and Meulenberg, 1998). The N protein has shown size polymorphism for the Type 
1 PRRSV and previous reports have suggested that the length of ORF7 could be a subtype marker 
(Stadejek et al., 2008, Jackova et al., 2012). The N protein is highly immunogenic in pigs although 
not neutralizing (Diaz et al., 2009, Meulenberg et al., 1998b). 
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1.10. Pathogenesis 
By definition, PRRSV is not a ‘persistent’ virus. Nevertheless, since the average lifetime of 
production pigs is 180 days, PRRSV infection is ‘life-long’ for the majority of pigs (Chand et al., 
2012). Within a production system, PRRSV infection predominantly exists as a subclinical 
infection, participating as a co-factor in various polymicrobial disease syndromes, such as Porcine 
Respiratory Disease Complex (PRDC) and Porcine Circovirus Associated Disease (PCVAD) 
(Chand et al., 2012).  
PRRSV has been recovered from a variety of porcine secretions and excretions including blood, 
semen, saliva, feces, aerosols, milk, and colostrum (Rossow et al., 1994, Swenson et al., 1994, 
Wagstrom et al., 2001, Wills et al., 1997b). Fecal shedding remains a highly debated issue as 
studies reports the presence of PRRSV in feces from 28 to 35 days post infection (PI), whereas 
others report no detection of virus in fecal samples (Wills et al., 1997b, Yoon et al., 1993). 
Transmission of PRRSV primarily occurs through direct contact between the infected and naïve 
pigs (Rossow, 1998). Aerosol transmission is also a route of transmission of PRRSV (Wills et al., 
1997a, Kristensen et al., 2004), although experimental studies have shown that effective aerosol 
transmission may be influenced by the pathogenicity of the circulating viruses (Cho et al., 2007). 
Transmission of PRRSV to sows and gilts via semen from infected boras is also a contagious risk 
(Yaeger et al., 1993, Christopher-Hennings et al., 1995). 
In the acute PI phase, PRRS virus replicate in alveolar and other tissue macrophages (Pol et al., 
1991). The acute PI phase is characterized by high viral load in tissue and by the presence of 
viremia in serum, which may last up to 28 days PI (Halbur et al., 1995a, Halbur et al., 1995b, Duan 
et al., 1997). Past the acute PI stage, a persistent phase of infection follows with lymphoid tissues as 
the primary site of virus replication. PRRS virus can be isolated from lymph nodes for more than 
100 days PI and virus is easily transmitted to naïve pigs during asymptomatic periods (Horter et al., 
2002, Rowland et al., 2003).  
 
1.11. Clinical signs and pathology 
The clinical presentation and clinical signs of PRRS varies greatly between herds. Infection with 
PRRSV shows two different sets of clinical signs: reproductive and respiratory (Keffaber, 1989, 
Wensvoort et al., 1991). The clinical presentation of PRRSV infections depends on the age of the 
pig infected and on the pregnancy status and trimester of gestation of the infected sow/gilt (Rossow, 
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1998). Studies found that pigs experimentally infected with nine different isolates of Type 2 
PRRSV had major differences in clinical disease, rectal temperatures, and gross and histological 
lung lesions (Halbur et al., 1995a, Halbur et al., 1995b, Halbur et al., 1996). Animals infected with 
mildly virulent isolates or the LV had transient pyrexia, dyspnea and tachypnea, whereas infection 
with highly virulent isolates induced labored breathing, pyrexia, lethargy, and anorexia. 
Furthermore, studies have reported that the impact on reproductive performance may be isolate 
dependent (Halbur et al., 1995a, Halbur et al., 1995b, Mengeling et al., 1996). 
The clinical signs in sows are characterized by inappetence, anorexia, and reproductive disorders 
such as abortion, premature birth, birth of dead or weak piglets, and foetal death with or without 
mummification. A less frequently observed sign is transient blue discoloration of, the ears, 
abdomen, or vulva (Terpstra et al., 1991). 
PRRSV infection in weaned pigs is characterized by fever, pneumonia, lethargy, and failure to 
thrive (Rossow, 1998).  
Gross lesions observed following PRRSV infection vary widely and may be dependent on the 
virus isolate, genetics of the infected pig, and stress factors (environment and health status of the 
pig herd). Lung lesions vary from none to diffuse consolidation and are commonly complicated by 
lesions resulting from concurrent bacterial infections which can localize separate or intermixed 
(Rossow, 1998).  
 
1.12. Immune response 
The pig’s adaptive immune response against PRRSV is characterized by being delayed and 
defective (Beura et al., 2010). Following a natural infection, it takes at least 3 months to reach 
immunity peak levels and it does not appear to be solid enough to prevent reinfection, especially if 
the reinfection is caused by antigenically heterologous PRRSV strains (Murtaugh et al., 2002, 
Zuckermann et al., 2007). Pigs infected with PRRSV fail to generate any significant inflammatory 
cytokine expression in the lungs, including the type I interferons (IFN-α/β), interleukin (IL)-1, and 
TNF-α (Thanawongnuwech et al., 2001, Van Reeth et al., 1999). The expression of type I interferon 
is important for the activation of innate immune response (Kimman et al., 2009). The 
downregulation of INF-α can be a crucial step in PRRSV pathogenesis as INF-α has been shown to 
inhibit PRRSV replication (Albina et al., 1998, Le Bon et al., 2001), hence the weak initial innate 
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immune response may lead to longer survival of the virus in the infected animal (Kimman et al., 
2009). 
Following infection, the earliest and strongest antibody response is directed against the N protein 
which is measureable 5-9 days PI (Johnson et al., 2004, Kimman et al., 2009). Antibodies against 
the two non-structural proteins nsp1 and nsp2 are evident at 14 days PI, and reach peak levels at 28-
35 days PI (Johnson et al., 2007, Brown et al., 2009, de Lima et al., 2006, Oleksiewicz et al., 2001). 
All these early produced antibodies are non-neutralizing whereas the neutralizing antibodies first 
appear 4 weeks PI or even later (Lopez and Osorio, 2004). The neutralizing antibody response 
against the GP5 neutralizing epitope is weak and delayed, and some animals fail to make a 
detectable antibody response against GP5 (Chand et al., 2012, Yoon et al., 1994). The mechanism 
for the weak antibody response towards GP5 is linked to the N-glycosylations surrounding the 
neutralizing epitope, a phenomenon called N-glycan shielding (Chand et al., 2012). Furthermore, 
for Type 2 PRRSV, GP5 encodes a decoy epitope at position aa27-30 which is not neutralizing but 
may function to distract the humoral immune response hence delaying the induction of neutralizing 
antibodies against PRRSV (Ostrowski et al., 2002).  
 
1.13. The origin of PRRSV 
When and where PRRSV came from is still a mystery. It is assumed that PRRSV has evolved 
from LDV, it’s most similar Arteriviridae relative, however PRRSV does not infect rodents and 
LDV has not been found in pigs (Murtaugh et al., 2010). Even though there were no reports of 
clinical outbreaks of PRRS before 1987 in North America and 1990 in Europe, antibodies against 
PRRSV has been detected in archive serum samples originated from East German herds in 1988 
and as early as 1979 in Canadian herds (Carman et al., 1995).  
Despite the concurrence in emergence and disease symptoms, viruses isolated from the two 
continents were genetically distinct and divided into two genotypes, today known as Type 1 for the 
European isolates and Type 2 for the North American isolates. There is no unanimous hypothesis 
that explains the simultaneous emergence of the virus however it is commonly assumed that they 
genetically diversified in separate reservoirs prior to emergence (Nelsen et al., 1999, Plagemann, 
2003). Studies to find the most resent common ancestor estimated that Western Europe PRRSV 
isolates existed in 1980, approximately 10 years before the epidemic emergence (Forsberg et al., 
2001, Forsberg, 2005). Furthermore, due to the genetic diversity between the Type 1 viruses, it was 
found that the Western Europe epidemic was caused by transfer of several lineages from the 
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original reservoir (Forsberg et al., 2001). The likely origin of transfer was located in Eastern 
Europe, as Eastern European pigs harbored highly diverse Type 1 PRRSV lineages, that was shown 
to diversify before the Western Europe Type 1 PRRSV lineages (Stadejek et al., 2002). Thus, a 
plausible hypothesis is that Type 1 PRRSV originated in Eastern European pigs and was transmitted 
to Western European pigs following the increased East-West European contact that began in the late 
1980s (Stadejek et al., 2002). The division of PRRSV into two distinct genotypes was proposed to 
occur as recently as 1980 (Hanada et al., 2005) however this estimate was questioned by Forsberg 
(2005) who on the basis of ORF3 sequences estimated the most resent common ancestor around 
1880 although caution should be taken for this estimate as well (Forsberg, 2005). A more plausible 
hypothesis was proposed that PRRSV originated in European wild boars and that the virus was 
transferred to North America through these animals when imported in 1912 (Plagemann, 2003). 
This hypothesis may explain the long period of independent evolution on the two continents and 
implies a divergence time in agreement with the estimations performed by Forsberg (2005). 
 
1.14. Geographical distribution 
PRRSV is endemic in the majority of the pork producing countries, and both genotypes are 
distributed worldwide (Shi et al., 2010a). A PRRSV Type 1 isolate was identified in a swine herd in 
the United States in 1999 (Fang et al., 2004, Ropp et al., 2004) and Type 1 PRRSV has been 
introduced to four other non-European countries beside U.S.A. These countries are Canada (Dewey 
et al., 2000), South Korea (Lee et al., 2010), China (Jiang et al., 2000), and Thailand 
(Thanawongnuwech et al., 2004). 
PRRSV Type 2 was introduced in Europe in 1996 probably through the use of a live attenuated 
vaccine that reverted back to virulence in Danish pig herds (Botner et al., 1997, Madsen et al., 
1998). Subsequently, PRRSV has been reported sporadically in the rest of Europe (Stadejek et al., 
2013). Type 2 PRRS also circulate throughout most of Asia (An et al., 2007, Feng et al., 2008). 
 
1.15. Genetic diversity 
 At first it was believed that Type 2 PRRS viruses were more genetically diverse, while Type 1 
PRRS viruses exhibited a lower degree of variations (Meng et al., 1995, Kapur et al., 1996, Suarez 
et al., 1996). This perception changed following extensive sampling of Type 1 viruses which 
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revealed an even greater diversity among European isolated viruses than North American isolated 
viruses (Stadejek et al., 2002, Stadejek et al., 2006, Stadejek et al., 2008). 
The first PRRSV isolated in Europe following the first epidemic was the Dutch isolate LV and 
this virus was then regarded as the protogenotype of Type 1 PRRSV (Wensvoort et al., 1991). 
However the genetic differences between the Type 1 viruses soon became evident and consequently 
LV could not be viewed as the ancestral virus type for all the Type 1 viruses isolated in Europe 
(Drew et al., 1997, Forsberg et al., 2002, Le Gall et al., 1998, Suarez et al., 1996, Wensvoort et al., 
1991). Country-specific clusters were formed by viruses isolated in Great Britain, Italy, and 
Denmark (Forsberg et al., 2002, Frossard et al., 2013).  
Further sampling and sequencing revealed even more diversity among the Type 1 PRRSV 
isolated in Europe. Especially, the viruses isolated in Eastern Europe showed high divergence and 
diversity compared to Western European isolates and a subtyping of Type 1 PRRS viruses were 
proposed by Stadejek et al. (2002, 2006, 2008). Originally, 3 subtypes were defined on the basis of 
their ORF5 sequences (Stadejek et al., 2006). However, ORF7, the ORF encoding the nucleocapsid 
have shown size polymorphism and hence it was recommended as a stable and independent 
indicator for subtyping and on the basis of the length of ORF7 it was possible to confirm the 
previous identified subtypes using this classification (Stadejek et al., 2008). Nevertheless, caution 
may be taken when subtyping based on the size polymorphism of ORF7 since a recently isolated 
virus from Slovakia encoded a 132 amino acid N protein (compared to 128 amino acids N protein in 
the LV) but otherwise resembled the subtype 1 PRRSV (Jackova et al., 2012).  
Type 1 PRRSV has been introduced to 5 countries outside Europe and so far only subtype 1 has 
been detected (Shi et al., 2010a). Several Thai and Chinese viruses showed to be genetically related 
to two types of live-attenuated vaccine strains which was surprising as Type 1 live-attenuated 
vaccines was not officially applied in these countries (Thanawongnuwech et al., 2004). 
The global evolutionary history of Type 1 PRRS viruses based on their ORF5 sequences was 
illustrated by Shi et al. (2010a) by phylogenetic analysis (fig. 1.3.). Here, the diversity among Type 
1 subtype 1 viruses is evident, as it was possible to further divide this subtype into 12 clades (A-L, 
fig. 1.3.). The diversity of Type 1 PRRSV isolated outside Europe suggests multiple introductions 
of PRRSV in these countries, confirmed by the appearance of viruses from the same country in 
different clades (Shi et al., 2010a). 
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Fig. 1.3. Global phylogenetic analysis of Type 1 PRRSV ORF5 sequences. For Western 
European subtype 1, a further division into clades (A-L) was possible and the Nationality of the 
viruses is stated on the right. The numbers in brackets corresponds to the number of sequences 
within the clade. The other Type 1 subtypes are orientated in the bottom of the tree. The figure is 
borrowed from Shi et al. 2010a. 
 
 
On the basis of ORF5 sequences, Type 2 PRRSV can be divided into 9 different lineages (fig. 
1.4.) (Shi et al., 2010b). The Type 2 viruses isolated in North America showed the greatest diversity 
as they were distributed throughout seven of the nine lineages (fig. 1.4). Lineage 3 and 4 only 
included Asian isolated viruses. Within the seven lineages constituting the North American viruses, 
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Asian and European isolated viruses were also represented. Lineage 5 is the cluster with most 
countries represented, including Denmark. This lineage also harbored the Ingelvac MLV vaccine, 
which is the preferred vaccine against Type 2 PRRSV in most European countries (Stadejek et al., 
2013) and the Type 2 protogenotype VR-2332 (Collins et al., 1992). The European interest for the 
diversity of Type 2 PRRSV isolated in Europe has been minor, since so far the majority of Type 2 
PRRSV circulating in the European pig herds were vaccine-like (> 98 % identical) (Greiser-Wilke 
et al., 2010, Stadejek et al., 2013). However, in Hungary two Type 2 PRRSV isolates showed major 
divergence compared to the vaccine-strain on the basis of partial ORF5 sequences and the origin of 
these viruses could not be explained (Balka et al., 2008). 
 
1.16. Quasispecies and recombination  
  The simplest explanation for the diversity of PRRSV is the RNA polymerase infidelity, as the 
RdRp does not harbor a proof-reading mechanism and mutation rates of the RdRp has been 
measured to roughly 10-4 (Lauring and Andino, 2010). This infidelity of the RdRp results in the 
formation of quasispecies (Lauring and Andino, 2010). Quasispecies of PRRSV frequently occur 
during replication (Rowland et al., 1999, Schommer and Kleiboeker, 2006, Zhao et al., 2012). 
However the survival of a quasispecies and evolution to a stable PRRSV strain depends on the 
mutations, as distribution of viral strains depends on how the viruses fits into the environment; 
popularly speaking: it is survival of the fittest (Lauring and Andino, 2010).  
Another mechanism explaining the high diversity of PRRSV is recombination. Some viruses 
may belong to one clade/lineage on the basis of one gene and then to another clade/lineage when 
investigating another gene. This phenomenon was seen for Russian Type 1 viruses which were 
classified to belong to subtype 1, originally on the basis of their ORF7 length and phylogeny, 
however phylogenic analysis of their ORF5 sequence placed them further away from subtype 1 than 
subtype 2 and 3 (fig. 1.3) (Shi et al., 2010a). This diversity of the Russian viruses may be explained 
by recombination. Recombination plays an essential role for PRRSV biology since it is required for 
the formation of sg mRNA (Conzelmann et al., 1993, Pasternak et al., 2006). If a host cell is 
infected with two different PRRSV viruses at the same time, recombination between these two 
could occur during genomic replication and a scenario as with the Russian viruses could be the 
result. On the other hand, if the two viruses were genetically alike, the recombination genomes 
would be indistinguishable from non-recombinant genomes (van Vugt et al., 2001, Murtaugh et al., 
2010). Recombination preferentially occurs between genomes with high similarity (van Vugt et al., 
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2001). The Russian subtype 1 viruses may be a product of two ancestral variants in Russia, one 
closely related to the Western Europe subtype 1 viruses and one distantly related. The resultant 
recombinant then became prevalent in the field and the two parental viruses went extinct (Shi et al., 
2010a).  
 
 
Fig. 1.4. Global phylogenetic analysis of PRRSV Type 2 ORF5 sequences. Each of the nine 
lineages representing the diversity of Type 2 PRRSV ORF5 sequences are separated with a dotted 
line. One the left, sample size, diversity within the lineage, major distribution, and historical 
samples are listed. The figure is modified from Shi et al (2010b). 
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1.17. High Fever Disease 
From time to time highly virulent PRRSV strains evolve, which results in poor welfare for the 
pigs and huge economical losses for the swine industry (Han et al., 2006, Gauger et al., 2012, 
Karniychuk et al., 2010, Neumann et al., 2005).  
In China in 2006, a severe ‘high fever’ disease occurred in several pig farms and subsequently 
overwhelmed almost half of China (Tian et al., 2007). The list of clinical symptoms was long: 
rubification, blood spots, petechiae, erythematous blanching rashes, and pimples, frequently 
observed in ears, mouth, noses, back, and the inner thigh. Other common symptoms were high fever 
(40-42°C), depression, anorexia, cough, asthma, lameness, shivering, and disorder in the respiratory 
tract, diarrhea, and subsequently death. Initially, the ‘high fever’ was suspected to be caused by hog 
cholera or African swine fever and PRRSV was not suspected as the etiology agent because many 
grown pigs died, which is unlike typical PRRSV infections (Tian et al., 2007). The course of the 
disease varied from 5 to 20 days, and pigs infected were highly contagious affecting the whole pig 
herd within 3-5 days. The epidemic persisted for several months partly due to the limited 
knowledge of the etiological agent (Tian et al., 2007). According to the China Animal Disease 
Control Center (CADC), the epidemic affected more than 2 million pigs with more than 400,000 
fatal cases in just 4 month of duration (Tian et al., 2007). The etiological agent was found by 
extensive and systematic investigations, and by PCR and immunohistochemistry experiments the 
‘high fever’ agent was determined to be PRRSV (Tian et al., 2007). Today the atypical PRRSV 
strain is referred to as highly pathogenic PRRSV (HP-PRRSV). Shortly after the epidemic of HP-
PRRSV in China, it rapidly spread to pigs in Southeast Asia and nearby countries (An et al., 2011).  
Phylogenetic analysis of HP-PRRSV ORF5 sequences revealed that they were very similar to 
typical Chinese PRRSV isolates (Tian et al., 2007). To study the evolutionary origin of the HP-
PRRSV, complete HP-PRRSV genome sequences were compared to typical Chinese PRRSV 
genomes and it was suggested that the HP-PRRSV had gradually evolved from an early Chinese 
PRRSV, CH-1a, and the evolutionary path could be traced through intermediate PRRSV isolates 
(An et al., 2011, Feng et al., 2008). Furthermore, genetic analysis found in all HP-PRRSV isolates 
examined, a distinct 1 plus 29 amino acid deletion in nsp2 (Tian et al., 2007) which at first was 
believed to be a virulence marker, however chimeric infectious clone constructs and the finding of a 
low pathogenic field virus also harboring deletion at the same position showed that this unique 
deletion was not directly related to virulence (Li et al., 2010, Zhou et al., 2009). 
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1.18. Lena and SU1-bel 
The genetic diversity between the Type 1 subtypes has lead to the question of these as source of 
differences in pathogenicity between these subtypes. In the winter of 2007, a Belarusian farm 
confirmed positive for PRRSV experienced abortions, birth of mummified, dead and weak piglets, 
high mortality rate before waning, respiratory disorders and mortality (up to 70 %) in growing pigs 
(Karniychuk et al., 2010). PRRSV was isolated from lung tissues obtained from weak-born piglets 
and from the ORF5 and ORF7 sequences the virus were classified to belong to PRRSV Type 1 
subtype 3 and the virus strain was designated ‘Lena’ (Karniychuk et al., 2010). The complete 
genome of Lena has been sequenced and alignments of Lena with the Type 1 subtype 1 reference 
sequence, LV, showed variations over the entire genome (Van Doorsselaere et al., 2012). 
 Three experimental infection studies with subtype 3 PRRS viruses have been performed 
(Karniychuk et al., 2010, Morgan et al., 2013, Weesendorp et al., 2013). Two of these studies were 
conducted using the Lena strain and Type 1 PRRS viruses belonging to subtype 1 for comparison 
(Karniychuk et al., 2010, Van Doorsselaere et al., 2012, Weesendorp et al., 2013). The study by 
Karniychuk (2010) showed that Lena induced high fever, lasting for several weeks, viremia 
detectable for 4 weeks PI, and fibrinous pleuropneumonia, pericarditis, and peritonitis were 
observed gross lesions   (Karniychuk et al., 2010). The second infection study with Lena showed 
less severe clinical signs compared to the first study, however the immune response from pigs 
inoculated with Lena showed differences compared to PRRSV Type 1 subtype 1 viruses 
(Weesendorp et al., 2013). The third experimental infection study with a PRRSV Type 1 subtype 3 
virus SU1-bel (but distinct from Lena) was performed (Morgan et al., 2013), and the results 
indicated increased clinical and pathological effects of the SU1-bel strain caused by an enhanced 
inflammatory immune response (Morgan et al., 2013). 
From these studies it is evident that PRRSV Type 1 subtype 3 is able to induce severe disease in 
pigs (Karniychuk et al., 2010, Morgan et al., 2013, Weesendorp et al., 2013). 
 
1.19. Diagnostic tools  
Diagnostic tools for detection of PRRSV are very important since diagnosis of PRRSV on the 
basis of clinical signs in the field is very difficult due to variations in the signs of infection (Botner, 
1997). The most common diagnostic tools for the diagnosis of PRRSV are immunoperoxidase 
monolayer assay (IPMA) (Wensvoort et al., 1991, Botner et al., 1994), enzyme-linked 
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immunosorbent assay (ELSIA) (Sorensen et al., 1998), and real-time RT-polymerase chain reaction 
(real-time RT-PCR) (Kleiboeker et al., 2005, Balka et al., 2009, Wernike et al., 2012). 
The IPMA method relays on measuring the binding of PRRSV antibodies in the sample serum to 
control virus present on the cell surface. At the National Veterinary Institute, DTU, Denmark, the 
IPMA plates are prepared by inoculating Marc-145 cells with a control virus (Type 1 or Type 2 
PRRSV) for approximately 24 hours following fixation in absolute ethanol. The fixated cells then 
incubate with control and test serum in different dilutions. If the test serum contains antibodies 
against PRRSV it will bind to the viruses present on the cell surface of the fixated cells. Peroxidase 
conjugated rabbit anti-swine immunoglobulin (IgG) is then added to the cells and will if present 
bind to the PRRSV antibodies attached to the cell surface. The IPMA is developed by the addition 
of H2O2 in ethylcarbazole and the plates can be interpreted using a light microscope (Botner et al., 
1994, Wensvoort et al., 1991). 
The ELISA method also relies on the detection of antibodies against PRRSV. At the National 
Veterinary Institute, DTU, Denmark, an ‘in house’ blocking ELISA is used for the detection and 
discrimination of PRRSV antibodies in serum samples (Sorensen et al., 1998). Microplates coated 
with Type 1 or Type 2 PRRSV antigen (separate plates) are added sample serum. If the test serum 
contains antibodies against the PRRSV antigen it will bind to the coated wells. Then biotinylated 
anti-PRRSV immune serum IgG is added which will only bind to the PRRSV antigens if the test 
serum was negative for PRRSV antibodies, since the presence of antibodies in the test serum will 
saturate the antigen-coat and hence no anti-PRRSV immune serum IgGs will be able to bind. To 
monitor this, peroxidase conjugated Avidin is added which will also only bind if the test serum was 
negative. The results of the ELSIA are visualized by a colorimetric reaction and the optical density 
(OD) is measured. OD% values above 44 means that the test serum was negative for PRRSV 
antibodies. If the ELISA for Type 1 and Type 2 are run parallel, and the outcome was positive for 
PRRSV (OD% < 44) the EU/US ratio can determined the genotype of the virus. EU/US ratios 
above 1.9 indicate Type 2 PRRSV and EU/US ratios below 1.3 indicate Type 1 PRRSV (Sorensen 
et al., 1998). A disadvantage with PRRSV antibody serological tests are that they do not 
discriminates between seropositive animals which have cleared PRRSV infection and carrier 
animals or whether the pigs are still viraemic (Oleksiewicz et al., 2001). However, high IPMA titers 
generally may indicate an acute infection (Botner, 1997). 
A common method for the detection of virus is real-time PCR. Several versions and chemistries 
have been developed and utilized for the detection of PRRSV (Balka et al., 2009, Kleiboeker et al., 
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2005, Kubista et al., 2006, Oleksiewicz et al., 1998). The advantage using real-time PCR is that it is 
fast, sensitive, and can be performed in high throughput (Kubista et al., 2006). The real-time PCR is 
performed on DNA, single-stranded (ssDNA) or double-stranded (dsDNA), and uses two primers 
that flank the nucleotide sequence to be amplified, the four deoxynucleotide triphosphates (dNTP), 
and a heat-stable polymerase (Kubista et al., 2006). The real-time PCR is performed by temperature 
cycling; first step is carried out at a high temperature to separate/melt the ds-DNA, then the 
temperature is lowered to let the primers anneal to the template DNA, and finally the temperature is 
set to the preferred temperature of the polymerase used (Kubista et al., 2006). During the real-time 
PCR a florescence signal is generated, from the incorporation of fluorescence either from 
fluorescent dyes or reporter fluorescent molecules attached to the probes or in some chemistries also 
one of the primers. The level of the fluorescent signal is measured in real-time at each temperature 
cycle and reflects the amount of DNA copies generated during the PCR reaction (Kubista et al., 
2006). Since PRRSV has an RNA genome, an initial step of reverse transcription (RT) needs to be 
carried out for the generation of a DNA copy (cDNA) of the RNA. This reaction is typically carried 
out at 50-60 ºC for 30 minutes by a reverse transcriptase. The primer initiating the cDNA synthesis 
may be one of the PCR primers (reverse primer) or a specifically designed RT primer which could 
be gene specific, poly(dT) or a mix of short random primers. Hence, PCR and real-time PCR using 
an RNA template is referred to as RT-PCR or real-time RT-PCR. The RT step can be in a separate 
reaction or in the same tube as the PCR the latter is referred to as OneStep RT-PCR/real-time RT-
PCR. Practical problems with the real-time RT-PCR method for detection of PRRSV is the high 
diversity of PRRSV since the sensitivity of the assay rely on the nucleotide match between the 
template PRRSV RNA and the primers and probes used. Due to the high diversity of PRRSV, it is 
difficult to design conserved primers matching all PRRSV genomes. A solution to this key problem 
which more recently has become prevalent is the use of mixture of several primer pairs and probes 
to cover a broader range of variant templates. The strategy can also be exploited in the design of 
assays that can discriminate between the two PRRSV genotypes for the simultaneous detection and 
typing of PRRSV. Another strategy is simply to run more than one assay. The real-time RT-PCR 
assay presently used for detection of PRRSV at the National Veterinary Institute, DTU, Denmark, 
employs the Primer Probe Energy Transfer (PriProET) chemistry (Balka et al., 2009). This system 
relays on respectively flourophor labeled reverse primer and probe with sense orientation. The 
probe is a short oligo complementary to a part in the region flanked by the forward and reverse 
primers. The reverse primer is labeled at its 5’-end and the probe at its 3’end. When the sense probe 
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hybridizes to the revere strand fluorescence is emitted since the flourophor on the reverse strand 
excites the flourophor on the probe. A melting curve can be collected following the PCR reaction 
and represent the matching of the probe to the amplicon hence genotyping of PRRSV can be 
determined.  
Conventional PCR can also be used for the detection of PRRSV. It uses a forward and a reverse 
primer and the PCR product is visualized by agarose gel electrophoresis. The DNA products 
obtained from conventional PCR can be used for sequencing, where the nucleotide composition and 
order will be determined. 
PRRSV can be isolated following growth on either PAM or Marc-145 cells (Kim et al., 1993, 
Wensvoort et al., 1991). Propagation of Type 2 PRRSV cannot take place in PAMs so a common 
cell line for propagation of Type 2 PRRSV is the Marc-145 cells and Type 1 PRRSV prefers PAMs 
however adaption to Marc-145 cells is possible (Botner et al., 1994, Botner, 1997). Cytopathic 
effect (CPE) is visible 2-3 days following inoculation and indicates PRRSV propagation in the 
cells. The cells can be immunohistochemically stained with a monoclonal antibody (SDOW17) or 
similar to confirm the presence of PRRSV (Fig. 1.5). 
 
 
 
Fig. 1.5. Immunohistochemically stained PAM and Marc-145 cells. Panel A: PAM inoculated 
with Type 1 PRRSV. Panel B: Marc-145 cells inoculated with Type 2 PRRSV. Images are kindly 
provided by A. Botner and J. Nielsen. 
 
 
1.20. Vaccines 
Several vaccines have been produced to combat PRRSV (Murtaugh and Genzow, 2011). Both 
attenuated live vaccines (e.g. Ingelvac® PRRS MLV and Porcilis® PRRS) and inactivated vaccines 
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(e.g. Progressis® and PRRomiSe®) have been developed (Murtaugh and Genzow, 2011). 
Vaccination against PRRSV has generally not been very successful, partially because of the rapid 
mutation rate and evolution of the virus, lack of cross-protection, and weakness in inducing the 
‘correct’ immune response in the animal (Nauwynck et al., 2012). Nevertheless, protection provided 
by the attenuated live vaccines is better than that from inactivated vaccines, however the protection 
from the attenuated live vaccine still rely on homologous situations (Murtaugh et al., 2002, 
Labarque et al., 2003).  
A very serious problem with the use of attenuated live vaccines is the risk of reversion to high 
virulence.  This scenario was seen following a vaccination program with the Ingelvac PRRS MLV 
that led to an epidemic of Type 2 PRRSV in the previously PRRSV Type 2 free country, Denmark 
(Botner et al., 1997, Madsen et al., 1998, Nielsen et al., 2001). 
In 2010 the EU project: New tools and approaches to control Porcine Reproductive and 
Respiratory Syndrome in the EU and Asia (PoRRSCon) were started by the initiative of 14 partners 
from Europe and Asia. The final goal of the EU project is to develop new generation, efficacious 
and safe maker vaccines that can be adapted to temporary changes and geographical differences. 
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Abstract 
PRRSV is a positive-sense RNA virus with a high degree of genetic variability among isolates. 
For diagnostic sensitivity and vaccine design it is essential to monitor PRRSV genetic diversity.  
However, to date only a few full genome sequences of PRRSV isolates have been made publicly 
available. In the present study, fast and robust methods for long range RT-PCR amplification and 
subsequent next generation sequencing (NGS) were developed and validated on nine Type 1 and 
nine Type 2 PRRSV viruses. The methods generated robust and reliable sequences both on primary 
material and cell culture adapted viruses and the protocols performed well on all three NGS 
platforms tested (Roche 454 FLX, Illumina HiSeq2000, and Ion Torrent PGM™ Sequencer). These 
methods will greatly facilitate the generation of more full genome PRRSV sequences globally. 
 
Keywords 
PRRSV, full genome sequencing, next generation sequencing, Illumina HiSeq2000, Roche 454 
FLX, Ion Torrent PGM sequencer    
  
Manuscript I 
 
39 
 
1. Introduction 
Porcine Reproductive and Respiratory Syndrome (PRRS), a potent viral disease of pigs, has a 
major impact on the health and welfare of pigs throughout the world. PRRSV causes reproductive 
failures in sows and gilts and respiratory diseases in growing pigs (Collins et al., 1992; Terpstra et 
al., 1991; Wensvoort et al.; 1991). Different PRRSV strains have been claimed to differ in 
virulence, but the underlining molecular determinants are still unknown despite decades of research. 
PRRS virus belongs to the Arteriviridae family, within the order Nidovirales (Cavanagh, 1997). 
It is a small enveloped virus containing a positive-sense single-stranded RNA genome with a 5’ cap 
and a polyadenylated 3’-end (Benfield et al., 1992; Meulenberg et al., 1998). The genome is 15-
15.5 kb in length and encodes 10 ORFs including the recently discovered ORF5a (Firth et al., 2011; 
Johnson et al., 2011; Snijder and Meulenberg, 1998; Wu et al., 2001). Based on nucleotide 
sequence comparison of European and North American isolates, PRRSV is divided into two 
genotypes, Type 1 and Type 2 respectively, with only 50-60 % nucleotide identity (Allende et al., 
1999). Furthermore,  Type 1 PRRSV genotype has been found to be more diverse, and can be 
categorized into at least four subtypes, where the protogenotype 1, the Lelystad virus (Genbank: 
M96262), belongs to subtype 1 (Stadejek et al., 2002; Stadejek et al., 2006; Stadejek et al., 2008).   
Most of the molecular analyses of the PRRSV genome have been performed on the genes coding 
for the structural proteins (ORF2-7) only. Of the seven structural proteins, glycoprotein 5 (GP5) 
encoded by ORF5 and the nucleocapsid (N) protein encoded by ORF7 have been the most 
examined. GP5 has been shown to contain a B-cell neutralizing epitope and is regarded as the most 
immunogenic viral protein, whereas the N protein has shown size polymorphism (Ansari et al., 
2006; Oleksiewicz et al., 2002; Ostrowski et al., 2002; Stadejek et al., 2002). Previous reports 
suggested that the length of ORF7 could be used as a subtype maker since its length varied between 
Type 1 strains originating from Eastern Europe (Stadejek et al., 2002; Stadejek et al., 2006; 
Stadejek et al., 2008). However, recently a PRRSV isolate from Slovakia encoded a 132 amino acid 
N protein (compared to 128 amino acids N protein in the Lelystad virus), but otherwise resembled 
the subtype 1 PRRSV (Jackova et al., 2012). These findings emphasized that the diversity of 
PRRSV are more  complex than initially anticipated and that examination of small genetic regions 
is not sufficient for understanding PRRSV sequence heterogeneity. This is further supported by the 
emergence of a highly pathogenic strain of PRRSV in China in 2006, which was highly similar to 
other Type 2 PRRSV strains in ORF5 and ORF7, but had indeed unique feature differences in other 
genes (An et al., 2010; Tian et al., 2007). Until now, only few full genome sequences of European 
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PRRSV isolates have been characterized (Darwich et al., 2011) and similarly little is known on the 
diversity of European Type 2 strains circulating in Europe. To accelerate the generation of full 
genome sequences of PRRSV, application of next generation sequencing (NGS) technology is the 
method of choice. In recent years the cost of using this technology has been reduced substantially 
and hereby making it more accessible (Glenn, 2011). The aim of the present study was to develop 
and validate a method for robust and reliable full length sequencing of PRRSV Type 1 and 2 based 
on long range PCR performed on viral RNA extracted from both primary material and cell culture 
isolates.  
 
2. Material and methods  
 
2.1. Sample material 
Samples included in this study were collected in Danish pig farms during the years 1992 to 2012. 
Details on the viruses and their origin are listed in Table 1. Some of the viruses were proliferated in 
Marc-145 cells or porcine alveolar macrophages (PAM) following the general procedure (Kim et 
al., 1993; Wensvoort et al., 1991). The ESP-1991-Olot91 “third passage MA-104” isolate was 
obtained from Dr. Luis Enjuanes (Department of Molecular and Cell Biology, CSIC, Madrid, 
Spain). One further passage in Marc-145 was carried out prior to sequencing.  
 
2.2. Viral RNA purification 
Viral RNA was purified from serum, lung tissues or cell culture supernatants. Lung tissue was 
prepared as a 5 % homogenate in RLT buffer (RNeasy® Mini Kit, QIAGEN, cat. no. 74106) with 1 
% β-mercaptoethanol (Sigma-Aldrich, cat. no. M3148). One steel bead (QIAGEN, cat. no. 69989) 
was added to each sample and the samples were homogenized in a Tissuelyser II (QIAGEN, cat. no. 
85300) for three minutes at 30 Hz. The homogenate was centrifuged for three minutes at 12,000 x g 
600 µl lung tissue homogenate was mixed with an equal volume of 70 % ethanol by pipeting and 
then transferred to an RNeasy® Mini column. The rest of the purification procedure was performed 
as described by the manufacturer’s instructions for purification of total RNA from animal tissues 
with RNeasy Mini Kit (QIAGEN). RNA from serum and cell culture supernatant was purified using 
QIAamp® Viral RNA Mini Kit (QIAGEN, cat. no. 52906) using the conditions recommended by 
the manufacturer. The RNA was stored at -80°C until use. 
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2.3. Screening for PRRSV with real-time RT-PCR 
PRRSV positive samples we selected for sequencing by screening of purified RNA using a 
modification of the Primer Probe Energy Transfer RT-PCR (PriProET-RT-PCR) OneStep real-time 
RT-PCR assay previously described (Balka et al., 2009).  
 
2.4. cDNA synthesis 
Full-length cDNA synthesis was performed with SuperScript® III First-Strand Synthesis System 
(Invitrogen, cat. no. 18080-51) using 3’-end poly(dT) reverse transcription (RT)-primer: 5’CAG 
GAA ACA GCT ATG ACA CCT GAT CTC TAG AAA CGT T(T)383’ (Nielsen et al., 2003). The 
method for the synthesis of full-length cDNA was as previously described for pestiviruses 
(Rasmussen et al., 2008; Rasmussen et al., 2010). In short, 8 µl of purified RNA (approx. 0.7 µg) 
was mixed with 1 µl of 10 µM RT-primer and 1 µl of 10 nM dNTPs. The mixture was incubated for 
5 minutes at 65°C in a thermal cycler with heated lid and then placed on ice for at least 1 minute.  A 
second mixture containing 2 µl 10x RT buffer, 4 µl 25 mM MgCl2, 2 µl 0.1 M DTT, 1 µl 40 U/µl 
RNaseOUT™, and1 µl SuperScript III RT™ was prepared and mixed gently with  the RNA/primer 
mixture. The cDNA synthesis was performed in a thermal cycler with heated lid at 50°C for 90 
minutes followed by incubation for 5 minutes at 85°C to inactivate the reverse transcriptase. To 
collect the samples a brief centrifugation step was applied and the cDNA was treated with 1 µl of 2 
U/µl E. coli RNase H for 20 minutes at 37°C to remove the RNA template. The cDNA was stored 
at -20°C until use. 
 
2.5. Primers for long range PCR amplification 
All the primer sequences used for long range PCR amplification are listed in Table 2. Each 
primer sequence was aligned against the sequence of the two PRRSV proto-genotypes, Lelystad 
virus (M96262) or VR2332 (U87392.3) using CLC Main Workbench v.6.6.2 (CLC BIO, Aarhus, 
Denmark). The primer sequences were adjusted to match the sequence of the two proto- genotype 
strains. 
 
2.6. Long range PCR amplification for sequencing 
 PCR amplifications were performed with AccuPrime™ Taq DNA Polymerase High Fidelity 
(Invitrogen, Cat. no. 12346-086). For amplification of PCR products covering the PRRSV genome 
in 4 fragments, 2 µl of cDNA template was mixed with 5µl 10x AccuPrime™ PCR buffer I, 1µl 10 
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µM specific forward primer (Table 2), 1 µl 10 µM specific reverse primer (Table 2), 0.5 µl 
AccuPrime™ Taq DNA Polymerase High Fidelity, and nuclease free water (AMRESCO®, cat. no. 
E476) in a final reaction volume of 50 µl. For amplification of PCR products covering the PRRSV 
genome in 2 fragments, 1 µl of AccuPrime™ Taq DNA Polymerase High Fidelity was used. The 
PCR amplification was carried out in a  T3 Thermocycler (Biometra) under the following 
conditions: 94°C 15 seconds, [45 cycles: 94°C for 15 seconds, 55°C for 30 seconds, and 68°C for 
60 seconds per kb amplification], 68°C  for 2 minutes per kb amplification, hold at 4°C. The PCR 
products were analyzed by agarose gel electrophoresis using E-gel® 0.8 % agarose gels (Invitrogen, 
cat. no G501808). Five µl of PCR product mixed with 7 µl 1:40 TrackIt™ loading buffer 
(Invitrogen, cat no. 10482-028) were loaded onto the gel. 10 µl 1 kb Plus DNA ladder as marker 
(Invitrogen, cat. no. 10787-018) was used as size marker. To remove primers and buffers, the PCR 
products were purified using Roche’s High Pure PCR Product Purification kit (cat. no. 11 732 676 
001) following the manufacturers protocol, with the exception that elution was done in 30 µl 
nuclease free water (Amresco, cat. no. E476). 
 
2.7. Full genome sequencing 
Three different platforms were used for next generation sequencing. For the sequencing of PCR 
amplicons covering the full genome of PRRSV in two fragments, 2.7 µg in total of equimolar 
concentration were sent to LGC Genomics GmbH (Berlin, Germany) for sequencing on the 
platform Roche 454 FLX. The two samples were sequenced at separate occasions on a 1/16 
Roche/454 Pico Titer Plate pooled together with 10 and 11 other libraries prepared from PCR 
amplicons of another virus with approximately the same size. The sequencing of PCR amplicons 
covering the PRRSV genome in four fragments was performed on the Illumina® HiSeq2000 and Ion 
Torrent PGM™ sequencer platforms. The four PCR products representing one PRRSV genome 
were pooled in equimolar quantities to a final amount of 1 µg. The sequencing on the platform Ion 
Torrent PGM™ sequencer was carried out by the DTU in-house facility (DTU Multi-Assay Core 
(DMAC), Technical University of Denmark). An Ion Torrent PGM™ chip 316 was used for 32 
libraries of approximately the same size. Sequencing on Illumina® HiSeq2000, took place at ARK 
Genomics (The Roslin Institute, University of Edinburgh, Scotland, UK). A total of 22 libraries of 
the same genome size were pooled and sequenced on one channel flow cell. The preparation of 
these libraries was performed following the Illumina® TruSeq™ DNA Sample Preparation v2 Kit A 
and B with minor exceptions (Illumina®, cat. no. FC-121-2001-1 and FC-121-2002). Instead of 
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purifying the samples using Agencourt AMPure XP beads as stated in the manufactures protocol, 
column purifications was performed using MinElute PCR Purification Kit (QIAGEN, cat. no. 
28004). 
 
2.8. 5’-RACE   
For Type 2 viruses amplified using the forward primer ‘Fragment-A-US-FW’ (Table 2), the 5’ 
end nucleotides were not amplified and therefore 5’ Rapid Amplification of the cDNA Ends was 
performed to complete the sequences. This was performed using 5’ RACE System for Rapid 
Amplification of cDNA Ends, version 2.0 (Invitrogen, cat. no. 18374-058) according to instructions 
from the manufacturer. In short, one gene-specific RT-primer was designed for the cDNA synthesis, 
one for the first PCR amplification and one for the final nested PCR using Primer3Plus web utility 
(Untergasser et al., 2007). The nested PCR products of approximately 500 bp were purified directly 
from the reactions using Roche’s High Pure PCR Product Purification kit (Roche, cat. no. 11 732 
676 001) or they were excised from E-gel 0.8% agarose gels and extracted using MinElute Gel 
Extraction Kit (QIAGEN, cat. no. 28604). The final RACE products were cloned into pCR®4-
TOPO® vectors and transformed into E. coli One Shot® TOP10 competent cells following the 
protocol for TOPO® TA Cloning® Kit for Sequencing (Invitrogen, K4575-02). Sequences were 
obtained with cycle sequencing performed at LGC Genomics using M13 primers. 
 
2.9. Sequence data analysis 
After initial removal of adaptors and low quality sequences, the quality of the FastQC files was 
examined using the applicant FastQC (version 0.10.1). The reads were trimmed in regards to the 
FastQC report. Trimming was done by the Prinseq-lite tool and mapping of the reads was 
performed by the Burrows-Wheeler aligner (BWA) using the Aln algorithm for the Illumina® 
HiSeq2000 data and the bwasw algorithm for Roche 454 FLX and Ion Torrent PGM™ sequencer 
data. Coverage depth was calculated by a combination of Samtools and Bedtools.  
The full length nucleotide sequences were aligned using MUSCLE (MUltiple Sequence 
Comparison by Log- Expectation). Phylogenetic trees of nucleotide sequences were constructed 
using Maximum Likelihood Phylogeny with the following parameter settings: Starting tree: 
Neighbor Joining, Substitution model: HKY, Transition /transversion ratio = 2.0, Rate variation: 
none, Estimate substitution rate parameter(s) = yes, Estimate topology = yes. All the phylogenetic 
analyses were carried out using CLC Main Workbench v.6.6.2 (CLC BIO, Aarhus, Denmark). 
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3. Results 
 
3.1. Specificity of the PCR products 
The long range PCR amplicons generated in this study covered the complete PRRSV genome in 
two or four fragments, with sequence overlap of 270-677 bp between the fragments (Table 2). To 
confirm the size, the purified PCR products were run on a 0.8 % agarose gel (Fig. 1). Most of the 
PCRs produced a single amplicon with the expected size, however, in few cases an unspecific band 
was in excess (Fig. 1, panel A, lane 4). In other cases, the PCR product of interest appeared in equal 
amount as unspecific products (Fig. 1, panel B, lane 9). In those cases with ambiguous products, the 
PCR amplicon of interest was gel extracted prior to sequencing. 
 
3.2 Sequence quality and trimming 
To evaluate the quality of the NGS data, adaptors and low quality sequences were first removed 
prior to further analysis with the FastQC application. This application helped visualize the quality 
of the reads by examining different parameters such as the distribution of the nucleotides in each 
read, read lengths, and calculated the Phred Quality Score of each nucleotide in each read. The 
Phred Quality Score described the probability of incorrect base calls and allowed to compare the 
efficacy of the different sequencing platforms. A Phred Quality Score of 30 (Q30) is equivalent to 
the probability of an incorrect base call in 1 out of a 1,000 times, which gives the base-call accuracy 
of 99.9 % (http://www.illumina.com/Documents/%5Cproducts%5Ctechnotes%5Ctechnote_Q-
Scores.pdf). A box plot of the Phred Quality Score distribution is shown in Fig. 2 and in 
supplementary material Fig. 1. The FastQC report obtained for Roche 454 FLX sequencing showed 
a decline in 3’ end reads quality and thus the major read lengths were trimmed from 592 bp to 450 
bp. The box plot of the Phred Quality Score distribution is shown in Fig. 2A- B. The average Phred 
Quality Score of the HiSeq2000 Illumina data was Q36.5 and which was highly acceptable. 
Although, a small decrease in the Phred Quality Score was  observed at the 5’ end of the reads (Fig. 
2, panel C- D, and supplement Fig. 1A-B),  the mean Q values were still above Q30, thus there was 
no reason for further trimming of these data. The majority of the full genome sequences of PRRSV 
were generated using the Ion Torrent PGM sequencer. The analysis of these data by FastQC, 
showed “warnings” in both the 5’ and 3’ ends of the reads with regard to the distribution of the four 
nucleotides. Thus, the reads were trimmed to a major length distribution of 170 bp to reach a 
minimal Phred Quality Score of Q20 for both the 5’ and 3’ ends. This strategy resulted in a mean 
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Phred Quality Score of Q24 or Q25 (Fig. 2, panel E-F and supplement Fig. 1C-L), which gave an 
acceptable base call accuracy between 99-99.9 %. An overview of the average Phred Quality Scores 
and major read lengths is listed in Table 3. 
 
3.3 Sequence output and coverage 
The data output varied among the different NGS platforms used, with the highest yield for the 
Illumina HiSeq2000 platform. In Table 3, total reads and mapped reads are listed for all samples. 
The amount of mapped reads in percent ranged from 23.8 % to 99.2 %. The outcome of mapped 
reads below 40 % may be result of low purity of the PCR amplicons in the sample or low quality of 
the library preparation. The distribution of the mapped reads throughout the genomes is shown in 
Fig. 3 and supplementary material Fig. 2 as a depth-of-coverage graph. Peaks with a substantially 
larger depth of coverage are present in all graphs. These peaks correspond to the overlap in 
sequence of the PCR amplicons. Variations in the coverage depths were seen between the PCR 
amplicons from the same sample, which indicate different quality and purity of the PCR amplicons 
or imprecise preparation of equimolar pools. In some cases regions without coverage was observed 
(Fig. 3) by that indicating gaps compared to the reference sequence. The presence of gaps were 
either confirmed or rejected by cycle sequencing. 
The complete full genome sequences had the lengths of 14,876-15,098 and 15,342-15,408 
nucleotides, for the Type 1 and Type 2 viruses, respectively (excluding the poly(A)-tail). 
Phylogenetic trees of the obtained full length sequences are shown in Fig. 4. The clustering of the 
viruses in the trees based on the full genome sequences were as expected and resembled the 
clustering of the isolates when the tree was based on ORF5 sequences only (data not shown). 
 
4. Discussion 
 
The main focus of this study was to develop fast and robust methods for full length sequencing 
of PRRSV directly from infected tissues using next generation sequencing platforms. The protocols 
generated sequences with the expected lengths and quality as illustrated by the preliminary 
phylogenetic analysis which showed the expected clustering of the analyzed isolates. Further 
analyses of the full genome sequences are in progress. 
The protocols described in the present study were based on the generation of long range PCR 
products using a high fidelity polymerase which has a low error-rate. This high fidelity polymerase 
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is a mixture of recombinant Taq DNA polymerase, Pyrococcus species GB-D polymerase, and 
Platinum Taq Antibody which results in a nine-fold increase in fidelity. Furthermore, this enzyme 
blend is effective over a wide range of target sizes up to 20 kb with some optimization   
(http://tools.invitrogen.com/content/sfs/manuals/accuprimetaqhifi_man.pdf). The protocol describes 
the sequencing of PCR amplicons covering the PRRSV genome in 2 and 4 fragments. Sequencing 
from two fragments has the advantage, besides the reduced labor handling only two amplicons, that 
only one sequence overlap will occur and less mismatch/bias from the primer sequencing will be 
incorporated in the PCR amplicons as only two primer pairs are used in the production of two PCR 
amplicons. On the other hand, the disadvantage when amplifying the PRRSV genome in two PCR 
fragments was that the concentration of the specific PCR amplicons often were of low concentration 
as they often needed to be extracted from the gel instead of direct purification from the PCR mix 
due to the present of  unspecific products. The advantage of sequencing from PCR amplicons 
covering the PRRSV genome in four fragments was that the PCR products were of relatively high 
concentrations and specificity hence the amplicons could be purified directly from the PCR mix 
without the need for gel purification. The disadvantage of sequencing on four fragments is that two 
sites of overlapping sequences will occur. The sequence primer bias is not problematic when 
sequencing with the NGS technology is performed to obtain a consensus sequence for phylogenetic 
and amino acid analyses, but should be kept in mind if the PCR products are sequenced for 
quasispecies and de novo analyses. 
 The main advantage of this method is that it enables viral RNA extracted directly from the 
primary material to be used as template for the cDNA synthesis. Such an approach bypasses the 
needs for propagation of PRRSV in cell culture which can be tedious and time-consuming. The use 
of primary material for sequencing furthermore prevents the introduction of mutations caused by 
cell culture adaptation and maintains the original level of quasispecies distribution. This new, 
innovative method offers a tool for a faster and quicker production of full genome PRRSV 
sequences compared to previous published protocol (Darwich et al., 2011; Van Doorsselaere et al., 
2011).  
Since only one NGS platform is available on most institutions, the applicability of the methods 
described here is tempting because all three tested NGS platforms were shown to generate PRRSV 
sequences of satisfactory quality. The selection of the optimal platform should be based on a variety 
of considerations including price, run time, read lengths, depth of coverage (yield data output). In 
the present set-up, the coverage depth was considerably higher for the Illumina HiSeq2000 
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compared to Roche 454 FLX and Ion Torrent PGM sequencer. Since PRRSV has a relative short 
genome of 15 kb, the coverage depth obtained in this study from all three NGS platforms was 
satisfying. The run time for Illumina HiSeq2000 was 11 days compared to the run time for Roche 
454 FLX and Ion Torrent PGM sequencer of 10 and 2 hours respectively. The short run times gives 
these latter two platforms an advantage in applications where a fast result is crucial. For de novo 
assembly, read lengths should be a factor to consider. In this study, 37 bp read lengths were 
obtained from the Illumina and reads from the Roche 454 FLX and Ion Torrent PGM sequencer 
were trimmed to major read lengths of 450 and 170 bp, respectively. The reads were mapped using 
a reference sequence and therefore the short read length was not a problem. 
In conclusion, the long-range PCR protocols of the present study offers a robust, cheap and fast 
method for the generation of full length PRRSV sequences directly from serum, tissues and cell 
cultures. The results of this work will be an added value for the development of new diagnostics and 
vaccine designs. 
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Table 1. Overview of sample origin and material. 
Virus sample Year of isolation Genotype Material Origin 
DK-1992-PRRS-111_92 1992 Type 1 PAM isolate Denmark 
DK-2010-10-10-3 2010 Type 1 PAM isolate Denmark 
DK-2011-05-11-14 2011 Type 1 PAM isolate Denmark 
DK-2011-05-23-9 2011 Type 1 PAM isolate Denmark 
ESP-1991-Olot91 1991 Type 1 Marc-145 isolate Spain 
DK-2003-6-5 2003 Type 1 PAM isolate Denmark 
DK-2003-7-2 2003 Type 1 PAM isolate Denmark 
DK-2008-10-5-2 2008 Type 1 Lung homogenate Denmark 
DK-2012-01-05-2 2012 Type 1 Serum Denmark 
DK-2010-10-1-2 2010 Type 2 Lung homogenate Denmark 
DK-2003-2-3 2003 Type 2 Marc-145 isolate Denmark 
DK-2004-2-1 2004 Type 2 Marc-145 isolate Denmark 
DK-2008-10-1-3 2008 Type 2 Lung homogenate Denmark 
DK-2012-01-11-3 2012 Type 2 Lung homogenate Denmark 
DK-2010-10-4-1 2010 Type 2 Lung homogenate Denmark 
DK-1997-19407B 1997 Type 2 Marc-145 isolate Denmark 
DK-2004-1-7-Pl 2004 Type 2 Marc-145 isolate Denmark 
DK-2011-030311-1 2011 Type 2 Lung homogenate Denmark 
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Table 2. Primer sequences for long range PCR amplification and expected amplicon sizes 
Primer name Primer Sequence (5’-3’) Expected size (bp) 
   
Type 1 PRRSV:   
   
Fragment-1-EU:  7278 
5’-UTR-1-35-EU-Fw1 GGC GCG CCT AAT ACG ACT CAC TAT AGA TGA TGT 
GTA GGG TAT TCC CCC TAC ATA CAC GAC A 
 
ORF1-7278-EU-Rev2 CAG CTT CAA GGC AGT TGT CA  
Fragment-2-EU:  8178 
ORF1-6920-EU-Fw3 CCC CTC TTT TTG AGA ATG GT  
Poly(dT)-RT4 CAG GAA ACA GCT ATG ACA CCT GAT CTC TAG AAA 
CGT T(T)38 
 
Fragment A-EU:  3019 
5’-UTR-1-35-EU-Fw1 GGC GCG CCT AAT ACG ACT CAC TAT AGA TGA TGT 
GTA GGG TAT TCC CCC TAC ATA CAC GAC  
 
ORF1-3019-EU-Rev1 CGC GGG CGC TTG AGT TCG GCA AAT T  
Fragment B-EU:  4529 
ORF1-2749-EU-Fw5 CCT GGA CCA GCC TTT AAA TC  
ORF1-7278-EU-Rev2 CAG CTT CAA GGC AGT TGT CA  
Fragment C-EU:  5500 
ORF1-6920-EU-Fw3 CCC CTC TTT TTG AGA ATG GT  
ORF2-EU-Rev6 GCA CAC TGA TGA GCC ATT GT  
Fragment D-EU:   
ORF2-EU-Fw6 CTG GCA CAG AAT TGC AGG TA 3375 
Poly(dT)-RT4 CAG GAA ACA GCT ATG ACA CCT GAT CTC TAG AAA 
CGT T(T)38 
 
 
Type 2 PRRSV: 
  
   
Fragment-1-US:   
Fragment-A-US-Fw7 GGA GGG CCA AGT CTA CTG CAC ACG A 7588 
Fragment-B-US-Rev4 TGG TTG TGC TCA ACC GCG T  
Fragment-2-US:  7939 
Fragment-C-US-Fw4 TCT CAG  AGT  TGG  CGA  CCC T  
Poly(dT)-RT4 CAG GAA ACA GCT ATG ACA CCT GAT CTC TAG AAA 
CGT T(T)38 
 
Fragment-A-US:  4541/4811 
Fragment-A-1-35-US-Fw 
 
CTCGAGGGCGCGCCTAATACGACTCACTATAGGATGA 
CGTATAGGTGTTGGCTCTATGCCTTGGCATT 
 
Fragment-A-US-Fw7 GGA GGG CCA AGT CTA CTG CAC ACG A  
Fragment-A-US-Rev4 GTG TCA GGG TCA ACC ACG A  
Fragment-B-US:  3506 
Fragment-B-US-Fw4 ATC TTG GCT GGA GCT TAC GT  
Fragment-B-US-Rev4 TGG TTG TGC TCA ACC GCG T  
Fragment-C-US:  5500 
Fragment-C-US-Fw4 TCT CAG  AGT  TGG  CGA  CCC T  
Fragment-C-US-Rev4 ATC CTG CAC CAA AGA GAC CT  
Fragment-D-US:  2900 
Fragment-D-US-Fw4 TTT CAG CAT CTA GCC GCC A  
Poly(dT)-RT4 CAG GAA ACA GCT ATG ACA CCT GAT CTC TAG AAA 
CGT T(T)38 
 
1Modified from Fang et al. 2006; 2Fang et al. 2006; 3Darwich et al. 2011; 4Nielsen et al. 2003; 5Modified from Darwich 
et al. 2011; 6Díaz et al. 2006; 7Modified from Nielsen et al. 2003. Fw: forward primer, Rev: reverse primer. 
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Table 3. Read quality and output yield 
Virus sample Platform Avg. Phred 
Quality 
Score 
Major read 
length (bp) 
Total readsa Mapped reads Mapped reads 
% 
Bases mapped 
DK-PRRS-111_92 FLX 37 450 5,679 5,633 99.2 2,534,850 
DK-2010-10-1-2 FLX 29 450 13,696 13,504 98.6 6,076,800 
DK-2010-10-3 Illumina 36.5b 37 3,151,310c 2,691,058b 85.4 99,569,146 
DK-2011-05-11-14 Illumina 36.5b 37 5,560,952c 5,409,041b 97.3 200,134,517 
DK-2011-05-23-9 Illumina 36.5b 37 4,810,154c 1,145,373b 23.8 42,378,801 
ESP-1992-Olot91 Illumina 36.5b 37 3,792,606c 3,252,661b 85.8 120,348,457 
DK-2003-6-5 Ion Torrent 24 170 70,875 55,844 78.8 9,493,480 
DK-2003-7-2 Ion Torrent 24 170 63,656 32,276 50.7 5,486,920 
DK-2008-10-5-2 Ion Torrent 25 170 75,357 51,011 67.7 8,671,870 
DK-2012-01-05-2 Ion Torrent 24 170 55,378 50,193 90.61 8,532,810 
DK-2003-2-3 Ion Torrent 25 170 43,915 38,252 87.1 6,502,840 
DK-2004-2-1 Ion Torrent 24 170 41,549 36,998 89.0 6,289,660 
DK-2008-10-1-3 Ion Torrent 25 170 74,948 55,303 73.8 9,401,510 
DK-2012-01-11-3 Ion Torrent 24 170 77,893 30,033 38.5 5,105,610 
DK-2010-10-4-1 Ion Torrent 24 170 52,658 41,554 78.9 7,064,180 
DK-1997-19407B Ion Torrent 24 170 56,171 53,026 94.4 9,014,420 
DK-2004-1-7-Pl Ion Torrent 24 170 65,900 62,542 94.9 10,632,140 
DK-2011-030311-1 Ion Torrent 24 170 85,327 66,526 78.0 11,309,420 
aAfter removal of adaptor and low quality sequences and examination by FastQC,  bFor Illumina the average Phred 
quality score is a mean value of the Pred quality score of R1 and R2, cPaired end reads 
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Fig. 1. 0.8 % agarose gel electrophoreses analysis of long range PCR amplicons. 
A: PCR amplicons for Type 1 PRRSV. Lane 4 and 5: Frag-1-EU and Frag-2-EU, lane 7-10: Frag-
A-EU, Frag-B-EU, Frag-C-EU, and Frag-D-EU.  
B: PCR amplicons for Type 2 PRRSV. Lane 4 and 5: Frag-1-US and Frag-2-US, lane 7-10: Frag-A-
US, Frag-B-US, Frag-C-US, and Frag-D-US. 
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Fig. 2. Box plots of Phred quality scores generated by FastQC. 
The grey box plots (box: interquartile ranges 25-75 %, whiskers: 10-90 %, and dark bar inside box: 
median) show the nucleotide-calling Phred quality score across all reads. A: DK-PRRS-111_92 
(Roche 454 FLX), B: DK-2010-10-1-2 (Roche 454 FLX), C: DK-2011-05-11-14 (Illumina HiSeq 
2000), D: Olot91( Illumina HiSeq 2000), E: DK-2011-10-4-1, (Ion Torrent PGM™ Sequencer), and 
F: DK-2012-01-05-2 (Ion Torrent PGM™ Sequencer). 
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Fig. 3. Depth of coverage plot. The x-axes represent the coverage of every single nucleotide 
position in respect to the reference sequence and the y-axes represent the sequence depth of every 
single nucleotide. (A) DK-PRRS-111_92, Roche 454 FLX, (B) DK-2010-10-1-2, Roche 454 FLX, 
(C) DK-2011-05-11-14, Illumina HiSeq 2000, (D) Olot91, Illumina HiSeq 2000, (E) DK-2011-10-
4-1, Ion Torrent PGM™ Sequencer, and (F) DK-2012-01-05-2, Ion Torrent PGM™ Sequencer. 
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Fig. 4. Phylogenetic trees of full length genomes. Panel A: Type 1 PRRSV viruses, panel B: Type 2 
PRRSV viruses. Scale bar represents 3 nucleotide changes per hundred. 
 
 
                   
  
Manuscript I 
 
57 
 
Supplementary Fig. 1. Box plots of Phred quality scores generated by FastQC. The grey box plots 
(box: interquartile ranges 25-75 %, whiskers: 10-90 %, and dark bar inside box: median) show the 
nucleotide-calling Phred quality score across all reads. (A) DK-2011-05-23-9, (B) DK-2010-10-10-
3, (C) DK-2003-6-5, (D) DK-2003-7-2, (E) DK-2008-10-5-2, (F) DK-2003-2-3, (G) DK-2004-2-1, 
(H) DK-2008-10-1-3, (I) DK-2012-01-11-3, (J) DK-1997-19407B, (K) DK-2004-1-7, (L) DK-
2011-030311-1. Next generation sequence platforms: A and B: Illumina HiSeq2000, C to L: Ion 
Torrent PGM™ Sequencer. 
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Supplementary Fig. 2. Depth of coverage plot. The x-axes represent the coverage of every single 
nucleotide position in respect to the reference sequence and the y-axes represent the sequence depth 
of every single nucleotide. (A) DK-2011-05-23-9, (B) DK-2010-10-10-3, (C) DK-2003-6-5, (D) 
DK-2003-7-2, (E) DK-2008-10-5-2, (F) DK-2003-2-3, (G) DK-2004-2-1, (H) DK-2008-10-1-3, (I) 
DK-2012-01-11-3, (J) DK-1997-19407B, (K) DK-2004-1-7, (L) DK-2011-030311-1. Next 
generation sequence platforms: A and B: Illumina HiSeq2000, C to L: Ion Torrent PGM™ 
Sequencer. 
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Abstract 
Porcine Reproductive and Respiratory Syndrome (PRRS) caused by the PRRS virus (PRRSV) is 
considered one of the most devastating swine diseases worldwide. PRRS viruses are divided into 
two major genotypes, Type 1 and Type 2, with pronounced diversity between and within the 
genotypes. In Denmark more than 50% of the herds are infected with Type 1 and/or Type 2 
PRRSV. The main objective of this study was to examine the genetic diversity and drift of Type 1 
viruses in a population with limited introduction of new animals and semen. A total of 41 ORF5 
and 38 ORF7 nucleotide sequences were obtained from viruses collected from 2003 to February 
2013. Phylogenetic analysis of ORF5 nucleotide sequences showed that the Danish isolates formed 
two major clusters within the subtype 1. The nucleotide identity to the subtype 1 protogenotype 
Lelystad virus (LV) spanned 84.9-98.8 % for ORF5 and for 90.7-100 % for ORF7. Among the 
Danish viruses the pairwise nucleotide identities of ORF5 and ORF7 were 81.2-100 % and 89.4-
100 %, respectively. Sequencing of the complete genomes, including the 5’ and 3’-end nucleotides, 
of 8 Danish PRRSV Type 1 showed that the genome lengths differed from 14,876 to 15,098 
nucleotides and the pairwise nucleotide identity among the Danish viruses was 86.5-97.3 % and the 
identity to LV was 88.7-97.9 %. The study strongly indicated that there have been at least two 
independent introductions of Type 1 PRRSV in Denmark and analysis of the full genomes revealed 
a significant drift in several regions of the virus. 
 
Keywords: 
PRRSV, genotype 1/Type 1, complete genome, ORF5, NSP2 
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1. Introduction 
Porcine Reproductive and Respiratory Syndrome (PRRS) is considered one of the most 
devastating and economically challenging diseases to the swine industry worldwide (Neumann et 
al., 2005). The causative agent is the PRRS virus (PRRSV), a small, enveloped single-stranded 
positive-sense RNA virus belonging to the Arteriviridae family, within the order Nidovirales 
(Cavanagh, 1997; Conzelmann et al., 1993). The PRRSV genome is 15-15.5 kb in length with a 5’ 
cap and a 3’ polyadenylated tail and it encodes at least 10 open reading frames (ORFs) (Firth et al., 
2011; Johnson et al., 2011; Snijder and Meulenberg, 1998; Wu et al., 2001). ORF1a and ORF1b 
covers the first three quarters of the PRRSV genome and encodes two long non-structural 
polyproteins, pp1a and pp1ab, where the latter is expressed after a ribosomal frameshift (Snijder 
and Meulenberg, 1998). pp1a and pp1ab are proteolytically cleaved into at least 12 non-structural 
proteins (nsps) (Snijder and Meulenberg, 1998; Fang and Snijder, 2010). ORF2-5 encodes the 
membrane glycoproteins, GP2-GP5, and ORF6 and ORF7 encodes a non-glycosylated membrane 
protein (M) and the nucleocapsid (N) protein, respectively. Two small genes, ORF2b fully 
embedded in ORF2 and ORF5a partially overlapping ORF5 encodes the non-glycosylated proteins 
E and ORF5a protein (Wu et al., 2001; Johnson et al., 2011; Firth et al., 2011). The PRRS 
symptoms were first described in the late 1980s in pigs in North America and a few years later 
similar disease symptoms were reported in Europe (Keffaber, 1989; Wensvoort et al., 1991). 
Genetic nucleotide sequence comparisons of viruses isolated in Europe and North America 
respectively revealed only 50-60 % identity between viruses; hence PRRSV was divided into two 
major genotypes, Type 1 and Type 2 (Allende et al., 1999). Genetic diversity is also pronounced 
within the genotypes, and Type 1 has been divided into at least three subtypes based on the length 
of ORF7, where the protogenotype 1, the Lelystad virus (LV, Genbank: M96262), belongs to 
subtype 1 (Stadejek et al., 2002; Stadejek et al., 2006; Stadejek et al., 2008; Forsberg et al., 2002). 
While PRRSV Type 1, subtype 1 isolates are found in Central and Western Europe and globally, 
subtypes 2, 3 and the putative subtype 4 have only been found in Eastern European countries east of 
Poland (Stadejek et al., 2008).  
In Denmark, PRRS was first diagnosed in March 1992 in a region with a high-density swine 
population in the southern part of Jutland close to the border of Northern Germany (Botner et al., 
1994). Until 1996, only Type 1 PRRSV circulated in the Danish swine herds, but due to use of Type 
2 Ingelvac PRRS MLV attenuated live vaccine that reverted back to high virulence in the field, 
Type 2 PRRSV was introduced into the Danish pig population (Botner et al., 1997; Madsen et al., 
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1998). Today, both Type 1 and Type 2 PRRSV are endemic in Denmark with more than 50% of the 
herds being infected. Vaccination to control the disease caused by both PRRSV genotypes has since 
then been used in Denmark. The vaccine Porcilis PRRS (MSD Animal Health) is the only licensed 
modified live vaccine against Type 1 PRRSV in Denmark. This vaccine was first introduced in 
Denmark in the beginning of 2001; however, use of this vaccine against Type 1 PRRSV was not 
consolidated until at the end of the decade. This vaccine is only licensed for use in slaughter pigs, 
whereas in the rest of Europe it is also licensed for breeding animals. Extensive sequencing of 
circulating PRRSV isolates during the 1990s revealed that only subtype 1 of the Type 1 PRRSV 
strains was circulating in Denmark but only few Danish PRRSV isolates have been sequenced since 
then. The export of Danish pigs to Eastern and central Europe is significant i.e. in 2012 Denmark 
exported more than 9 million living pigs and more than ¼ of a million breeding animals whereas 
only few (less than 100) breeding animals were imported to Denmark. Despite this limited import of 
living pigs the possibility that foreign PRRSV isolates may be introduced into Denmark by 
contaminated transport carriers or persons cannot be excluded but this will probably be rare events. 
Nevertheless, the diversity of PRRSV circulating in Denmark is of mutual interest for a range of 
European pig producing countries. The main objective of this study was to close the gap in 
knowledge on the genetic diversity of currently circulating PRRS Type 1viruses in Danish pigs and 
to investigate the genetic drift of the virus in a population with limited possibility of new strains 
being introduced. Extensive analyses of ORF5 and ORF7 sequences obtained from viruses isolated 
between 2003 and primo 2013 were examined and compared to sequences obtained from viruses 
isolated from Danish pig herds in the 1990s. Furthermore, for the first time the complete genome 
analysis of Danish Type 1 viruses is presented and compared to other Type 1 complete genomes 
isolated in Europe, North America, and Asia. The results revealed that two viral clusters are 
circulating, one Lelystad -like and a unique ‘Danish’ cluster.  
 
2. Materials and methods 
 
2.1. Sample material  
Lung tissues, serum, and nasal swabs included in this study were obtained from 27 Danish swine 
herds in the years 2003 to 2013. A number of strains were proliferated in porcine alveolar 
macrophages (PAM) as previously described (Wensvoort et al., 1991).  
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2.2. RNA extraction  
Total RNA was extracted from serum, nasal swabs, cell culture supernatant, or lung tissue. Lung 
tissue was prepared as a 5 % homogenate in RLT buffer (QIAGEN) containing 1 % β-
mercaptoethanol (Sigma-Aldrich). RNA was extracted from lung homogenate and nasal swabs 
using RNeasy Minikit (QIAGEN) according to the manufacturer’s instructions. Total RNA from 
serum and cell culture supernatant was purified using QIAamp Viral RNA Mini Kit (QIAGEN). 
Elution volume for both extractions methods was 60 µl. The RNA was stored at -80°C until use. 
 
2.3. Real time RT-PCR  
Purified RNA was initially screened for PRRSV using a modification of the Primer Probe 
Energy Transfer RT-PCR (PriProET-RT-PCR) assay described by Balka et al. 2009 (Balka et al., 
2009).  
 
2.4. cDNA synthesis and PCR amplification  
Full-genome length cDNA synthesis was performed by SuperScript® III First-Strand Synthesis 
System (Invitrogen) following the recommendations by the manufacturer except that the cDNA 
synthesis step was extended to 90 minutes. A poly(dT) RT-primer was used (5’-CAG GAA ACA 
GCT ATG ACA CCT GAT CTC TAG AAA CGT T(T)38-3’ as cDNA primer (Nielsen et al., 2003). 
PCR amplification of ORF2 to ORF7 was carried out using AccuPrime™ Taq DNA Polymerase 
High Fidelity Kit (Invitrogen). The PCR mixture was prepared as recommended by the supplier 
except that the amount of AccuPrime™ Taq High Fidelity was increased to 0.5 µl. The PCR cycling 
was as follows: [94°C for 15 seconds], 45 cycles: [94°C 15 seconds, 55°C for 30 seconds, 68°C for 
60 seconds] then finalized with 68°C for 5 minutes and cool down to 4°C. PCR cycling was 
performed on a T3 Thermocycler (Biometra). PCR primers for amplifying ORF2 to ORF7 were 
from Diaz, 2006 (Diaz et al., 2006). The PCR products were analyzed by agarose gel 
electrophoresis using E-gel 2 % agarose gels (Invitrogen) and purified with High Pure PCR Product 
Purification kit (Roche). 
Long range PCR amplification for full genome sequencing was performed using full-genome 
length cDNA as template with AccuPrime™ Taq High Fidelity kit as described by Kvisgaard et al. 
2013. 
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2.5. Cycle sequencing and next generation sequencing  
PCR products of ORF2 to ORF7 were sequenced by cycling sequencing using the Sanger 
method (Sanger et al., 1977). In total, 30 ORF5 sequences (accession no. KC862504-33) and 27 
ORF7 sequences (KC862534-60) were obtained. Three (3) sequences each covering ORF2 to ORF7 
(KC862562-64) were assembled from 7 overlapping PCR products. Eight (8) full genome 
sequences (KC862566-69; KC862571-74, Table 1) were produced from long range PCR amplicons 
covering the full genome of PRRSV in two or four fragments and sequenced by next generation 
sequencing technologies. For a detailed description of the procedure and next generation 
sequencing see Kvisgaard et al. 2013. In short, equimolar concentrations of the PCR amplicons 
covering the full genome of PRRSV were prepared for sequencing on Roche/454 Genome 
Sequencer FLX + Titanium (LGC Genomics GmbH, Berlin, Germany), Illumina HiSeq2000 (ARK 
genomics The Roslin Institute, University of Edinburgh), or Ion Torrent GPM sequencer (DTU 
Multi-Assay Core (DMAC), Kgs. Lyngby, Denmark). 
 
2.6. Data analyses  
The contigs of ORF2 to ORF7 were produced from assembling the raw data obtained by cycle 
sequencing against the PRRSV Type 1 reference sequence Lelystad (LV) (Genbank: M96262) 
using the commercial software CLC Main Workbench v. 6.6.2 (CLC BIO, Aarhus, Denmark). 
Mapping of the reads obtained from the full genome sequencing was performed by the Burrows-
Wheeler aligner (BWA) using the Aln algorithm for the Illumina HiSeq2000 data and the bwasw 
algorithm for Roche 454 FLX and Ion Torrent PGM sequencer data (Kvisgaard et al., 2013). Amino 
acid sequences were predicted from the nucleotide sequences using CLC Main Workbench v. 6.6.2. 
Nucleotide and amino acid sequences were aligned using MUSCLE (MUltiple Sequence 
Comparison by Log- Expectation). Phylogenetic trees were constructed from Neighbor Joining 
Algorithm with Bootstrap: 1,000 replicates (CLC Main Workbench v. 6.6.2, CLC BIO, Arhus, 
Denmark).  
The rate of Synonymous (dS) and non-synonymous (dNS) substitutions in each ORF of the 8 full 
genome sequences were calculated by Synonymous Non-synonymous Analysis Program (SNAP) 
(http://hcv.lanl.gov/content/sequence/SNAP/SNAP.html) (Körber, 2000). Estimates of amino acid 
substitutions were determined by the method of dS-dNS rates: dS-dNS > 0, dS-dNS < 0, and dS-
dNS = 0 representing tendencies for synonymous and non-synonymous variations, and neutral 
mutations, respectively.  
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Potential N-glycosylation sites were determined for GP2, GP3, GP4, and GP5 using NetNGlyc 
1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/). A potential glycosylation site was accepted 
when the potential score was above the minimum threshold of 0.5 and the agreement between nine 
neural networks (‘the jury’) was 9/9 with minimum ++ (- = potential < 0.5 (threshold), + = potential 
> 0.5, ++ = potential > 0.5 and Jury agreement (9/9), +++ = potential > 0.75 and Jury agreement) 
(http://www.cbs.dtu.dk/services/NetNGlyc/output.php).  
 
3. Results 
 
3.1. Genetic diversity of ORF5 and ORF7  
A total of 41 ORF5 and 38 ORF7 nucleotide sequence data were obtained from 44 viruses 
collected from 2003 to February 2013. The nucleotide lengths of the ORF5 and ORF7 sequences 
were 606 and 387 nucleotides, respectively. A single virus (DK-2012-10-01-27/KC862521) had an 
ORF5 nucleotide length of 603. The nucleotide identity to the subgroup 1 genotype Lelystad virus 
(LV) (M96262) spanned for ORF5 84.9-98.8 % and for ORF7 90.7-100 % and among the Danish 
viruses the pairwise nucleotide identities of ORF5 and ORF7 were 81.2-100 % and 89.4-100 %, 
respectively.  
 
3.2. Phylogenetic analysis  
The nucleotide sequences from this study were aligned with previously sequenced Danish 
viruses (Forsberg et al., 2002) obtained from Genbank and representative viruses from Europe, 
Asia, and North America. Phylogenetic trees based on the nucleotide sequences of ORF5 and ORF7 
are shown in Fig. 1. The phylogenetic analysis of ORF5 nucleotide sequences showed that the 
Danish viruses formed two major clusters. The majority of the Danish viruses isolated in the period 
2008-2013 clustered together with the LV and the Porcilis vaccine viruses with a pairwise 
nucleotide identity of 95.2-98.8 % and 95.7-99.8 %, respectively (I, Fig. 1A). The other Danish 
cluster (II, Fig. 1A) constituted Danish viruses collected prior to 2008 but also a few viruses from 
2011-2012 with nucleotide identity to LV of 84.9-93.6 %. One virus with a 3 nucleotide deletion in 
ORF5 belonged to this cluster. Interestingly, this cluster contained only Danish viruses and a single 
virus from China isolated in 2009. The Danish ORF7 sequences also clustered into 2 major clusters 
(I-II, Fig. 1B), with a pairwise identity to LV of 95.6-100 % and 90.7-96.1 %, respectively.  
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3.3. Amino acid analysis of GP5 and N proteins  
Examination of the deduced amino acid sequences from ORF5 showed that 105 of the 201 
positions in GP5 were conserved in all of the 58 Danish isolates (52.0 % conserved sites). Forty-
nine positions varied in more than one isolate, and 19 positions varied in more than 10 isolates. At 
position aa122 and aa172, the amino acid residues leucine/phenylalanine and glycine/aspartic acid, 
respectively were equally distributed, hence a consensus amino acid at these two positions was not 
possible to determine. Three potential N-glycosylations sites, N37, N46, and N53, were conserved 
in 90 %, 100 %, and 100 % of the viruses, respectively. The glycosylation site N37 was not present 
in 6 Danish viruses isolated between 1992 and 2007 which is in accordance with this glycosylation 
site not being present in the Type 1 reference strain LV. The cysteine residue thought to be involved 
in heterodimer formation with the M protein at position 50 (Verheije et al., 2002) was conserved in 
all the Danish sequences. The previously predicted (Plagemann, 2004; Oleksiewicz et al., 2002) 
major neutralizing epitope (aa38-54) and epitope site ES13 (aa178-200) were conserved in the 
consensus sequence of Danish GP5 sequences. One of the highly variable positions (aa122) was 
located in a putative T-cell epitope (Diaz et al., 2009) (Fig. 2A). A histogram illustrating the 
variability among the 58 Danish viruses is shown in Fig. 2B. The major neutralizing epitope located 
at the amino acid position aa38-54 was highly conserved in all the Danish viruses, which was also 
the case for the ES13 epitope (Oleksiewicz et al., 2002).  
The examination of the deduced nucleocapsid protein revealed less variation between the Danish 
viruses compared to the GP5 protein (Fig. 3). Eighty-nine out of 128 amino acid positions in the N 
protein were conserved (69.5 % conserved sites). Twenty positions varied in more than one isolates, 
and only 4 positions varied in more than 10 isolates. The two cysteine residues at position 27 and 76 
thought to be crucial for homodimer formation of the N protein were conserved throughout all the 
Danish isolates as was the putative linear B-cell epitope at position 80-88 described previously (An 
et al., 2005). The four predicted T-cell epitopes (Diaz et al., 2009) where highly conserved, with a 
minor variation at position aa64 where 8 isolates harbored an amino acid substitution. The most 
variable position in the N protein among the Danish viruses was at aa13, with 26 viruses harboring 
substitution (Fig. 3). 
 
3.4. Genetic analysis of complete genomes 
Complete genomes, including the very 5’ and 3’-end nucleotides, of 8 Danish PRRSV Type 1 
isolated in the years 1992 to 2012 were determined and the sequences analyzed and compared to 
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published reference sequences. The genome lengths differed from 14,876 to 15,098 nucleotides 
(excluding the Poly(A) tail) and the pairwise nucleotide identity among the Danish viruses was 
86.5-97.3 % and the isolates were 88.7-97.9 % identical to the LV strain (Table 1). The analysis of 
synonymous - non-synonymous (dS-dNS) mutations among the 8 Danish genomes showed a 
substantial higher amino acid substitution rate in ORF1a than in ORF1b (Fig. 4). The dNS 
mutations in the genes encoding the structural proteins were scattered throughout the genomes, with 
the highest rates in ORF3 and ORF5 (Fig. 4).  
A global phylogenetic analysis of PRRSV Type 1 ORFs 1-7 (Fig.5) showed that the Danish 
viruses divided into two clusters as seen for the ORF5 and ORF7 phylogenetic analyses (Fig. 1). 
Five of the Danish isolates clustered with LV, Porcilis PRRS, and two viruses isolated in Germany 
1992 and Thailand 2006. The three remaining Danish viruses grouped separately with a Chinese 
isolate from 2009. 
 
3.5. The non-structural proteins 
In Table 2 the pairwise nucleotide and amino acid identity of the non-structural proteins (nsp) of 
the Danish viruses are listed. The lowest average amino acid variation was found in nsp6, nsp11, 
nsp8, and nsp12, respectively. The highest variation was found in nsp1α/β and nsp2 with the amino 
acid identity range of 86.2-97.9 % and 77.0-97.7 % respectively. The predicted epitope site ES1 in 
nsp1α/β at position aa236-252 showed high variation with a substitution rate of 41 % among the 
Danish viruses. A comparison of the predicted amino acid sequences of the nsp2 of the Danish 
isolates with 19 previous published sequences of Type 1 PRRSV viruses is shown in Fig. 6. The 
lengths of nsp2 for the Danish viruses varied from 1004 to 1078 amino acids. Interestingly, DK-
2008-10-5-2 and DK-2012-01-05-2 had a 74 amino acid deletion also seen in the Porcilis PRRS 
strain (Darwich et al., 2011). These deletions spanned the predicted ES3 (Oleksiewicz et al., 2001) 
and T-cell epitope (Fang et al., 2004). Furthermore, a three amino acid deletion was discovered in 
DK-2003-6-5 located in ES7. The B cell epitope sites ES3, ES4, and ES7 together with the T-cell 
epitope were all located in highly variable regions, with substitution rates of 66%, 74 %, 74 % and 
87%, respectively.  
 
3.6. The structural proteins  
Comparisons of the deduced amino acid sequences of the structural proteins of the Danish 
isolates revealed that the highest variation among the 8 Danish viruses was in GP3 and GP4 with an 
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average similarity of 88.3 ± 4.3 and 90.4 ± 3.6, respectively (Table 2). Both GP3 and GP4 induce 
neutralizing antibodies (Oleksiewicz et al., 2001; Oleksiewicz et al., 2002) and encode the B cell 
epitopes ES11 and ES12 at position aa60-87 and aa59-70 relative to GP3 and GP4 of LV, 
respectively. The amino acid sequences of GP3 of the eight isolates were aligned with the GP3 of 
additional 27 Danish viruses isolated in 2010 and in the 1990s (Forsberg et al., 2001) (Fig 7A). The 
ES11 showed a substitution rate of 46 % among the 35 Danish viruses (Fig. 7A). In comparison to 
the LV strain, DK-2003-7-2 had a deletion in GP3 of 8 amino acids at the position aa240-247 (Fig. 
7B). This deletion has previously been detected in three Asian viruses (GU047344, GU047345, and 
EU076704) and eight Danish viruses isolated in the 1990s also had 1 to 8 amino acids deletions in 
this area (Fig. 7B). This region has previously been found to contain a B-cell epitope 
(243RKASLSTS250) (Oleksiewicz et al., 2000) but this antigenic motif is not present in any of the 
viruses examined in the present study (Fig. 7B). The ORF3 and the ORF4 coding regions overlap 
and hence any deletion in this shared coding region is likely to affect both protein products, which 
also was the case for DK-2003-7-2 which with an 8 amino acid deletion in GP4 at the position 
aa58-65 in LV (Fig. 8). The ES12 of GP4 is located in a region prone for deletions and besides that, 
it is also a highly variable region with a 100 % substitution rate among the Danish viruses (Fig. 8).  
Examination of potential N-glycosylation sites revealed 2 putative N-glycosylation sites in GP2, 
7 putative N-glycosylation sites in GP3 and 4 putative N-glycosylation sites in GP4 (Table 3). The 
result of nine neural networks predicted that both putative N-glycosylation sites in GP2 (N173 and 
N179) were glycosylated, although one virus (DK-2010-10-12-1) did not score an unanimous vote 
from the jury network. For GP3 only N27, N50, N130, and N194 were potentially N-glycosylated. 
For N27, three Danish viruses were not predicted to harbor N-glycosylation at this site. For GP4 
only N88 and N124 were predicted to be N-glycosylated (Table 3).  
Cysteine residues important for protein folding and function were 100 % conserved in all the 
Danish viruses examined. 
 
4. Discussion 
There has been a gap in knowledge regarding the diversity of PRRSV Type 1 circulating in 
Denmark since the latest available information was obtained on viruses isolated in the late 1990s.  
Most work on the diversity of European PRRS Type 1 viruses has focused on the structural 
proteins encoding genes, mainly ORF5, and ORF7 (Oleksiewicz et al., 2000; Forsberg et al., 2002). 
Here we report an extensive analysis of ORF5 and ORF7 of 48 viruses and full genome sequences 
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of 8 Type 1 PRRS viruses isolated over almost two decades which to our knowledge make this 
study the most extensive Type 1 study published globally. The phylogenetic analyses of ORF5 and 
ORF7 revealed that the viruses isolated in Danish herds between 2003 and primo 2013 were highly 
diverse and clustered into two distinct phylogenetic groups. Most of the viruses grouped with the 
Type 1 reference strain LV which is highly identical to the Porcilis vaccine strain, however a few 
recent viruses clustered into a phylogenetic group that contained only the Danish viruses and these 
isolates were genetically different from the LV strain. Interestingly, only viruses isolated after the 
Porcilis vaccine were introduced in Denmark grouped in the LV cluster which may indicate that the 
Porcilis strain may be circulating in Danish herds. That the Danish PRRSV Type 1 viruses divide 
into two phylogenetic groups was also shown in the study by Forsberg et. al, 2002 (Forsberg et al., 
2002). That study also indicated the existence of two Danish clusters in that two viruses isolated in 
1993 and 1995 grouped with LV and were therefore called ‘LV-like, although they only shared 93.6 
% pairwise identity to LV. LV was the first European PRRSV Type 1 isolated, and the sequence of 
this virus has been used as reference sequence in genetic comparisons, however based on the 
grouping in the phylogenetic tree not all the Type 1 viruses in Denmark may be progenies of LV 
(Shi et al., 2010). Accordingly, one of the first sequenced Danish PRRS viruses, DK111-92 
(AJ223078) isolated in 1992, showed a pairwise nucleotide identity to LV of only 93.1 % in ORF5. 
These analyses of early Danish PRRSV viruses suggested that more than one PRRSV Type 1 strain 
circulated in Europe and that Type 1 PRRSV was introduced into Denmark upon at least two 
different occasions. The presence of diverse Type 1 isolates in Europe at such an early time point 
indicates that Type 1 viruses have undergone a pronounced genetic drift or that the virus has been 
circulating a long time before clinical signs became evident. These findings are in agreement with 
the observation that Type 1 PRRSV isolated in Italy and United Kingdom clustered in two groups, 
one LV like and one Italian-/British-like (Forsberg et al., 2002; Frossard et al., 2013; Shi et al., 
2010). Despite the high level of diversity among the Danish ORF5 nucleotide sequences, the 
deduced amino acid sequence of GP5, showed high level of conservation at the positions of putative 
N-glycosylation sites, cysteine residues important for heterodimer formation with M protein, and 
also the putative neutralizing epitope was well conserved throughout all the Danish viruses.  
In conclusion, the analysis of the ORF5 and ORF7 sequences indicated the presence of two 
circulating virus clusters, one dominating vaccine/LV like and one resembling an early introduced 
strain. Importantly, the analysis also confirmed that all the Danish isolates fall within genotype 1, 
and are distinct from the recently described Eastern European subgroups (Stadejek et al., 2008). 
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The sequencing of the complete genomes of Danish PRRS field viruses confirmed that there is a 
high overall diversity among Type 1 viruses in Europe. Thus, the pairwise nucleotide variation over 
the complete genome was 2.7-5.8 %. Even among the most recently isolated viruses (2010-2012). 
The variation within the viral genome showed to be unequally distributed as NSP1α/β, NSP2, 
ORF3, and ORF4 showed the highest level of variation with 9.2 %, 12.4 %, 9.2 %, and 9.7 % 
average variation, respectively. The genomic regions with the lowest variation were ORF6 and 
ORF7 with 5.1 % and 4.6 % average variation, respectively. ORF1b showed a relatively high 
average nucleotide variation of 7.7 %, however, most of the variations were synonymous, and 
consequently the average amino acid variation was only 3.1 %. This level of amino acid 
conservation correlates well with the fact that this part of the viral genome encodes the key 
enzymes; RNA dependent RNA polymerase (nsp9) and helicase (nsp10) important for the RNA 
replication and unwinding of RNA duplexes, respectively (Fang and Snijder, 2010). The overall 
diversity of the Danish viruses fits very well with the global picture of Type 1 PRRSV diversity 
recently published by Darwich et.al (Darwich et al., 2011). 
The nsp2 protein is the largest of the mature PRRSV proteins and has been shown to be critical 
in proteolytic processing of proteins active in virus replication and modulation of the immune 
response (Fang and Snijder, 2010; Han et al., 2009). The N-terminal of nsp2 possesses a putative 
cysteine protease domain of about 100 amino acids (aa36-aa140, Fig. 6). This cysteine domain is 
likely to be required for nsp2/3 proteolysis (Han et al., 2007). Nsp2 is the viral protein containing 
most B-cell epitopes (Oleksiewicz et al., 2001) and the antibody response to nsp2 is greater than 
towards any other PRRSV protein, however the antibodies raised against this protein is non-
neutralizing (Johnson et al., 2007; Brown et al., 2009). One epitope, ES2, located in the putative 
cysteine protease domain, showed high level of conservation among the Danish viruses and 
globally, which agrees with the earlier findings that this domain is important for viral survival, as 
deletion of the domain is lethal to the virus (Han et al., 2007).The length of the nsp2 protein has 
been reported to be highly variable (Fang et al., 2004; Han et al., 2006) which also was the case for 
the Danish viruses in this study (1004-1078aa). DK-2008-10-5-2 and DK-2012-01-05-2 contained a 
74 amino acid deletion at the exact same position as the Porcilis PRRS vaccine; however the 
pairwise nucleotide identity of the two Danish viruses and the vaccine strain was only 95.8 % and 
97.4 % indicating that this deletion cannot be used as a marker for the vaccine strain. Interestingly, 
this region span the epitope sites ES3 and the putative T-cell epitope and may therefore be prone to 
changes which are supported by the findings that other PRRSV Type 1viruses also harbored 
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deletions in the same region (Fig. 6). One Danish virus harbored a 3 amino acid deletion in ES7 
which has not previously been reported. The significance of these epitope sites in nsp2 was 
confirmed by a study by Chen et. al (Chen et al., 2010) showing that deletion of ES3 actually 
increased the cytolytic activity and showed more vigorous growth kinetics in vitro and produced a 
higher vial peak load in pigs. The opposite was seen for deletions of ES4 and ES7. The impact of 
the ES3deletion in nsp2 of the vaccine strains should be investigated more thoroughly since it may 
suggest that the Porcilis PRRS vaccine strain has the ability to replicate more efficiently.   
Of the structural proteins, the highest degree of variation was seen in GP3 and GP4 (Table 2). 
Especially the areas predicted to contain epitopes underwent higher mutation rates and harbored 
more deletions than those motifs crucial for protein folding and functions, such as cysteine and 
glycosylation sites. From the deduced amino acid sequences of GP2, GP3, and GP4, 2, 7 and 4 
putative N-glycosylation motifs were present in all the Danish sequences, thus only four sites in 
GP3 and two sites in GP4 were predicted to be N-glycosylated by a neural network. Both putative 
N-glycosylation sites predicted for GP2were conserved in all the Danish viruses examined, however 
one virus failed the neural network jury prediction at N173. The finding that not all putative N-
glycosylations sites were predicted to be glycosylated even though the N-glycosylation motif (N-X-
S/T-X, X ≠ P) was fulfilled can be explained by protein folding leading to steric hindrance for the 
glycans or simply because glycosylations at these positions is of no advantage for the virus 
survival/function. The results can also be due to misinterpretation of the neural network in regards 
to the parameters to be fulfilled for accepting an N-glycosylation site. Accordingly, a previous study 
of the role of N-glycosylation of GP2 showed that lack of glycosylation at either one or both sites 
did not affect the formation or infectivity of virions (Wissink et al., 2004). The role of N-
glycosylation of GP3 and GP4 of Type 1 PRRSV has not yet been examined in vitro, but such 
studies have been performed for Type 2 PRRSV (Das et al., 2011). They showed that N-
glycosylation of N42, N50, N131 in GP3 (corresponds to N42, N50, N130 in GP3 PRRSV Type 1) 
was required for infectious virus production, where as any three of the four putative N-
glycosylation sites (N37, N84, N120, and N130 in GP4 PRRSV Type 2) were necessary for 
recovery of infectious virus. From the analysis of N-glycosylation sites in GP4 in this study, only 
N88 and N124 (equals N84 and N120 in Type 2 PRRSV) were predicted to be N-glycosylated. 
In conclusion, this study presents for the first time the examination of complete genomes 
obtained from PRRS Type 1viruses isolated in a country with very limited import of living animals 
and semen. Only 18 complete genomes (or nearly complete) of PRRSV genotype 1 sequences were 
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as of date available for comparison in public databases, where 10 of the genomes were obtained 
from viruses isolated in Europe in the years 1991 to 2007 (Darwich et al., 2011; Van Doorsselaere 
et al., 2011; Van Doorsselaere et al., 2012; Meulenberg et al., 1993). Thus, the present work adds 
valuable data on the PRRSV Type 1 viruses circulating in Europe. Characterization of the genetic 
and antigenic diversity of PRRSV is mandatory for the development and maintenance of diagnostic 
tools and for development of new vaccine entities. 
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Table 1. Overview of the 8 Danish Type 1 PRRSV complete genomes 
aExcluding the Poly(A) tail; bPairwise nucleotide identity to Lelystad (M96262) 
 
Table 2. Pairwise nucleotide and amino acid identity range among the 8 Danish PRRSV Type 1 
field viruses and the range of identity to LV. The predicted pp1a and pp1ab protein cleavage sites 
are from Fang and Snijder, 2010. 
 
ORFs Length (nt) % identity 
range(nt) 
Avg. nt 
identity % 
(mean ± sd) 
% identity 
rangeto LV 
(nt) 
Proteins Length 
(aa) 
% identity 
range(aa) 
Avg. aa 
identity % 
(mean ± sd) 
% identity 
range 
to LV (aa) 
ORF1a 6969, 7182, 
7191 
83.3-98.0 90.2 ± 4.5 86.8-97.9 pp1a 2276, 2347, 
2350 
84.8-97.9 90.5 ± 3.7 87.9-98.1 
NSP1α/β 1155 84.9-97.4 90.8 ± 4.3 86.7-98.3 nsp1α/β 385 86.2-97.9 91.3 ± 3.3 88.1-98.4 
NSP2 3012, 3225, 
3234 
79.1-97.8 87.6 ± 5.1 85.3-98.0 nsp2 1004, 1075, 
1078 
77.0-97.7 86.1 ± 6.1 82.4-97.7 
NSP3 690 87.1-99.3 91.8 ± 3.9 87.7-99.4 nsp3 230 93.5-99.6 95.8 ± 1.9 94.8-100.0 
NSP4 609 85.4-100.0 91.9 ± 4.7 86.5-99.3 nsp4 203 91.1-100.0 95.7 ± 2.6 92.6-99.5 
NSP5 510 85.7-99.0 92.3 ± 4.5 87.7-99.8 nsp5 170 89.4-100.0 94.7 ± 3.1 91.2-100.0 
NSP6 48 85.4-100.0 92.3 ± 5.0 85.4-100.0 nsp6 16 100.0 100.0 100.0 
NSP7α/β 807 87.5-98.3 92.2 ± 3.4 89.5-98.6 nsp7α/β 269 91.8-98.88 95.5 ± 2.2 92.9-98.9 
NSP8 135 88.4-99.3 93.9 ± 3.0 89.9-99.3 nsp8 45 95.6-100.0 97.9 ± 2.0 95.6-100.0 
ORF1b 4509a 88.1-97.4 92.3 ± 3.2 89.1-98.2 pp1b 1502 94.9-99.2 96.9 ± 1.5  95.4-99.1 
NSP9 2052 88.8-98.0 92.8 ± 3.1 89.7-98.4 nsp9 684 95.3-99.6 97.5 ± 1.4 95.3-99.6 
NSP10 1326 86.6-97.2 91.8 ± 3.9 87.8-98.1 nsp10 442 92.1-99.1 95.6 ± 2.2 93.4-99.1 
NSP11 672 87.8-97.6 92.1 ± 3.2 89.3-97.9 nsp11 224 96.9-99.6 98.3 ± 0.8 97.3-99.6 
NSP12 456 87.4-96.7 92.1 ± 2.8 89.8-98.3 nsp12 152 92.8-99.3 96.1 ± 2.0 93.4-100.0 
ORF2 750 89.9-97.3 93.3 ± 2.3 91.1-98.0 GP2 249 91.6-97.6 94.0 ± 1.8 93.2-98.4 
ORF2b 213 93.4-99.1 96.1 ± 1.3 94.8-99.1 E 70 97.1-100.0 96.1 ± 1.3 97.1-98.6 
ORF3 798, 774 85.8-96.7 90.8 ± 3.4 87.7-97-7 GP3 265, 257 81.1-94.7 88.3 ± 4.3 82.6-96.9 
ORF4 528,552 84.2-96.6 90.3 ± 4.2 85.9-96.7 GP4 175, 183 84.7-97.3 90.4 ± 3.6 87.4-97.3 
ORF5 606 88.5-98.4 93.0 ± 3.1 89.8-98.0 GP5 201 89.6-99.0 92.9 ± 2.5 92.0-97.5 
ORF5a 132 95.5-98.5 96.4 ± 0.9 97.0-99.2 ORF5a 
protein 
43 90.7-100.0 94.8 ± 1.9 93.0-100.0 
ORF6 522 91.8-98.5 94.9 ± 1.9 93.5-99.4 M 173 93.6-99.4 96.2 ± 1.6 95.4-99.4 
ORF7 387 92.5-99.2 95.4 ± 1.9 94.1-99.7 N 128 93.8-99.2 96.5 ± 1.5 96.9-100.0 
aLength calculated from NSP9 coding region in ORF1a minus the ribosomal frameshift 
 
 
Table 3. Putative N-glycosylation sites in GP2, GP3, and GP4 of the Danish Type 1 PRRSV 
Virus GP2 GP3 GP4 
 N173 N179 N27 N42 N50 N130 N151 N159 N194 N37 N88 N124 N134 
              
DK-1992-PRRS-111_92 9/9 ++ 9/9 ++ 8/9 + 5/9 + 9/9 ++ 9/9 +++ 8/9 + 6/9 + 9/9 ++ 7/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2003-6-5 9/9 ++ 9/9 ++ 7/9 + 5/9 + 9/9 ++ 9/9 +++ 8/9 + 7/9 + 9/9 ++ 8/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2007-7-2 9/9 ++ 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 8/9 + 9/9 ++ 7/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2008-10-5-2 9/9 ++ 9/9 ++ 8/9 + 5/9 + 9/9 ++ 9/9 +++ 8/9 + 8/9 + 9/9 ++ 8/9 + 9/9 ++ 9/9 ++ 7/9 + 
DK-2010-10-10-3 9/9 ++ 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 7/9 - 9/9 ++ 7/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2011-05-11-14 9/9 ++ 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 7/9 - 9/9 ++ 8/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2011-05-23-9 9/9 ++ 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 7/9 - 9/9 ++ 7/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2012-01-05-2 9/9 ++ 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 4/9 + 9/9 ++ 7/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2010-30-11-11 9/9 ++ 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 4/9 + 9/9 ++ 7/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2010-30-11-14 9/9 ++ 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 4/9 + 9/9 ++ 7/9 + 9/9 ++ 9/9 ++ 8/9 + 
DK-2010-10-12-1 8/9 + 9/9 ++ 9/9 ++ 5/9 + 9/9 ++ 9/9 +++ 8/9 + 7/9 - 9/9 ++ 8/9 + 9/9 ++ 9/9 ++ 8/9 + 
              
 91 % 100 % 73 % - 100 % 100 % - - 100 % - 100 % 100 % - 
 
  
Virus Accession no. Collection year Genome lengtha Nt identityb (%) 
DK-1992-PRRS-111_92 KC862566 1992 15,098 92.0 
DK-2003-6-5 KC862571 2003 15,089 88.9 
DK-2003-7-2 KC862572 2003 15,074 88.7 
DK-2008-10-5-2 KC862573 2008 14,876 94.8 
DK-2010-10-10-3 KC862568 2010 15,098 97.5 
DK-2011-05-11-14 KC862567 2011 15,098 97.9 
DK-2011-05-23-9 KC862569 2011 15,098 97.2 
DK-2012-01-05-2 KC862574 2012 14,876 96.0 
Manuscript II 
 
77 
 
Fig. 1. Phylogenetic analyses of PRRSV Type 1 ORF5 (A) and ORF7 (B) nucleotide sequences. 
Alignment of the sequences was performed with the MUSCLE algorithm, and phylogenetic 
analyses (neighbor-joining method with bootstrap 1.000) were conducted using CLC Main 
Workbench v. 6.6.2 (CLC BIO, Arhus, Denmark). The ORF5 and ORF7nuclotide sequences of 
protogenotype for PRRSV Type 2 VR2332 were used as outgroups (‘set root above node’). The 
scale bar represents 4 nucleotide changes per hundred. All the Danish isolates are marked in red. 
The two major groups, I and II, formed by the Danish isolates are identified by black bars.  
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Fig. 2. (A) Consensus amino acid sequence obtained from an alignment of 58 Danish GP5 
sequences. Epitope sites are highlighted with black boxes and the three putative N-glycosylation 
sites are marked with an asterix (*)(NetNGlyc 1.0). (B) A histogram showing the number of 
substitutions found at each amino acid position in the GP5 of 58 Danish isolates. ‘Empty’ positions 
represent conserved amino acids. The three potential N-glycosylation sites at aa37, aa46, aa53 are 
marked with *. At the amino acid positions aa122 and aa172, the amino acid residues 
leucine/phenylalanine and glycine/aspartic acid, respectively were equally distributed, hence a 
consensus amino acid at these two positions was not possible to determine. 
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Fig 3. (A) Consensus amino acid sequence obtained from the alignment of 55 Danish PRRSV N 
protein sequences. Epitope sites are highlighted with black boxes. (B) A histogram showing the 
number of substitutions found at each amino acid position in N protein of 55 Danish viruses. 
‘Empty’ positions represent conserved amino acids.  
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Fig. 4. Topology of synonymous (dS) and non-synonymous (dNS) substitutions in 8 Danish Type 1 
viruses. Estimates of amino acid substitutions were represented by the method of dS-dNS rates: dS-
dNS > 0, dS-dNS < 0, and dS-dNS = 0 representing tendencies for synonymous and non-
synonymous variations, and neutral mutations, respectively. The numbering on the x-axis represents 
selected amino acid position in polyprotein 1a and polyprotein 1ab. aa386, aa1464, and aa3037 
represent the putative cleaving sites between nsp1α/β and nsp2, nsp2 and nsp3, and nsp9 and nsp10, 
respectively in regards to the pp1ab sequence of LV. 
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Fig. 5. Phylogenetic analysis of PRRSV Type 1 ORF1-7 nucleotide sequences. Bootstrap values are 
shown on branches. The scale bar represents 18 nucleotide changes per hundred. BEL = Belgium, 
CHN = China, DK = Denmark, ESP = Spain, GER = Germany, HKG = Hong Kong, KOR = South 
Korea, POR = Portugal, THA = Thailand. 
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Fig. 6. Alignment of the putative amino acid sequence of nsp2 for PRRSV Type 1. Epitope sites 
(ES) described by Oleksiewicz (2001) are highlighted in black boxes. Grey squares represents 
deletions. 
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Fig. 7. Partial amino acid alignment of GP3. (A). N-terminal of GP3. Epitope site ES11 is 
highlighted with a black box. (B) C-terminal of GP3. Deletions in GP3 are represented with gray 
rectangles and the putative antigenic site (RKASLSTS) of GP3 is highlighted with a black box. 
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Fig. 8. Amino acid alignment of the N-terminal part of GP4. Deletions in GP4 is represented with 
gray rectangles and the predicted epitope site 12 (ES12) of GP4 is highlighted with a black box. 
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Abstract 
Type 2 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) was first detected in 
Europe in 1996 co-incident with the introduction of a live attenuated vaccine that reverted back to 
virulence. Since then, only limited ORF5 and ORF7 sequences of  Type 2 PRRS  viruses have been 
reported throughout Europe, and these sequences are very similar to the vaccine strain (>98 %). 
Until now, no complete genomes of Type 2 PRRSV isolated in Europe have been made public. In 
the present study, the genetic and antigenic diversity of  11 complete genomes  and 49  full-length 
ORF 5 sequences of  Type 2 PRRS viruses isolated in Denmark from 2003-2012 were examined. 
The genetic identity of the 11 complete genomes to the vaccine strain ranged between 93.6 - 99.6 % 
while the 49 ORF5 sequences examined were 94.0-99.8 % identical to the VR2332 strain. 
Phylogenetic analysis in a global Type 2 PRRSV framework classified all Danish isolates to a 
single cluster (sub-lineage 5.1) which comprised strains closely-related to the Type 2 prototype 
isolate VR2332 and a commercially available modified live vaccine.  
 
 
 
Keywords: 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) 
Genotype 2/Type 2 
Full genome/complete genome 
Non-structural protein 2 (nsp2) 
Amino acid variations 
ORF5 
  
Manuscript III 
 
89 
 
1. Introduction 
A mystery swine disease causing reproductive failure in sows and severe pneumonia in piglets 
was first described in North America in the late 1980s and was a few years later also observed in 
Europe (Keffaber. 1989; Wensvoort et al. 1991). The etiological agent of the disease was found to 
be viral and finally named Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) based 
on the clinical signs (Terpstra et al. 1991; Wensvoort et al. 1991; Collins et al. 1992).  Isolation and 
characterization of viruses obtained from the two continents indicated a pronounced degree of 
genetic heterogeneity with only 50-60 % nucleotide identity (Wensvoort et al. 1991; Collins et al. 
1992; Allende et al. 1999). Subsequently, PRRS viruses were divided into two major genotypes 
named Type 1 for the genotype initially described in Europe and Type 2 for the North American 
genotype (Allende et al. 1999). Nowadays, both genotypes circulate worldwide and therefore the 
nomenclature has been changed to Type 1 for the European genotype and Type 2 for the genotype 
initially found in North America (Fang et al. 2004; Ropp et al. 2004; An et al. 2010; Chen et al. 
2011).     
PRRSV is an enveloped single-stranded positive-sense RNA virus, belonging to the 
Arteriviridae family within the order Nidovirales (Cavanagh. 1997). The genome is 15-15.5 kb long 
and encodes 10 ORFs (Meulenberg et al. 1993; Wu et al. 2001; Firth et al. 2011; Johnson et al. 
2011). ORF5, encoding the glycoprotein GP5, is one of the most variable genes  and is therefore 
often used in phylogenetic analysis (Conzelmann et al. 1993; Key et al. 2001; Shi et al. 2010). A 
serological survey performed in 1996 documented that Denmark was free of antibodies against 
Type 2 PRRSV prior to the introduction of a modified live vaccine (Botner et al. 1997; Madsen et 
al. 1998).  Since then, Type 2 PRRSV infections have been sporadically reported throughout 
Europe, however, ORF5 and ORF7 sequences of European Type 2 PRRSVs are scarce.  Apart from 
a Hungarian Type 2 PRRSV strain very different from all published sequences (Balka et al. 2008), 
all published European Type 2 viruses shared a high degree of identity to the PRRSV MLV vaccine 
strain (>98%) which is based on the VR2332 isolate . In 2006, China experienced the emergence of 
a highly pathogenic strain of PRRSV which had a unique genomic structure (Tian et al. 2007; An et 
al. 2010). The PRRSV epidemic in China affected more than 2,000,000 pigs with about 400,000 
fatal cases. This abrupt occurrence of highly pathogenic PRRSV strains emphasizes the significance 
of monitoring the diversity of circulating strains around the world both in respect to the sensitivity 
and specificity of diagnostic tests as well as efficacy of available vaccines. 
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 Today - more than 15 years after the initial introduction - Type 2 PRRSV still causes significant 
clinical problems in Danish herds. Previously sequenced Danish Type 2 PRRSV isolates were 
reported to have a high level of identity to the vaccine strain (Madsen et al. 1998; Storgaard et al. 
1999). However, since only a few Danish PRRS viruses have been sequenced during the last 15 
years, the diversity of circulating Type 2 viruses in Denmark and Europe is unknown. This 
represents an important void especially since the export of Danish pigs to Eastern and central 
Europe is significant. For example, in 2012 Denmark exported more than 9 million live pigs 
whereas the import of breeding animals was much less (n < 100). Despite this limited import of live 
pigs, it is still possible that foreign PRRSV isolates may be introduced into Denmark by 
contaminated transport carriers or persons as recently seen in Sweden (Carlsson et al. 2009). 
Similarly, insight into PRRSV diversity in Denmark is of mutual interest for a range of countries. 
Accordingly, the main objective of the present study was to close the knowledge gap on the 
temporal diversity of circulating Type 2 PRRS viruses in Danish pigs. A comprehensive sequence 
analysis of ORF5 and its gene product, GP5, of Danish Type 2 PRRSV viruses isolated in the years 
2003-2012 was performed and compared to the early introduced Danish Type 2 viruses and globally 
isolated Type 2 viruses. Additionally, for the first time, a thorough genetic and antigenic analysis of 
11 complete genome sequences of Type 2 PRRSV isolated in Europe was conducted.  
 
2. Material and methods 
 
2.1. Sample material 
Lung tissue, serum, oral fluid, and nasal swabs were obtained from 35 Danish swine herds in the 
years 2003 to 2012. A number of strains were propagated for one passage in Marc-145 cells using 
the general cell culture procedure (Kim et al. 1993). 
 
2.2. RNA extraction 
Total RNA was extracted from serum, nasal swabs, cell culture supernatant, and lung tissue. 
Lung tissue was prepared as a 5 % homogenate in RLT buffer (QIAGEN) containing 1 % β-
mercaptoethanol (Sigma-Aldrich). RNA was extracted from lung homogenate and nasal swabs 
using RNeasy Minikit (QIAGEN) according to the manufacturer’s instructions. Total RNA from 
serum and cell culture supernatant was purified using QIAamp Viral RNA Mini Kit (QIAGEN). 
Elution volume for both extractions methods was 60 µl. The RNA was stored at -80°C until use. 
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2.3. Real time RT-PCR 
Purified RNA was screened for PRRSV using a modification of the Primer Probe Energy 
Transfer RT-PCR (PriProET-RT-PCR) assay described by Balka et al. (Balka et al. 2009).  
 
2.4. cDNA synthesis and PCR amplification 
Full-genome cDNA synthesis was performed by SuperScript® III First-Strand Synthesis System 
(Invitrogen) following the recommendations by the manufacturer except that the cDNA synthesis 
step was extended to 90 minutes. A poly(dT) RT-primer was used as cDNA primer  (5’-CAG GAA 
ACA GCT ATG ACA CCT GAT CTC TAG AAA CGT T(T)38-3’ (Nielsen et al. 2003). PCR 
amplification of ORF5 and ORF7 was carried out using the AccuPrime™ Taq DNA Polymerase 
High Fidelity Kit (Invitrogen). The PCR mixture was prepared as recommended by the supplier 
except that the amount of AccuPrime™ Taq High Fidelity was increased to 0.5 µl. The PCR 
amplification was conducted on a T3 thermo cycler (Biometra) with the following conditions: 
[94°C for 15 seconds], 45 cycles: [94°C 15 seconds, 55°C for 30 seconds, 68°C for 60 seconds] 
then finalize with 68°C for 5 minutes and cool down to 4°C. PCR primers for amplifying ORF5 and 
ORF7 were from Oleksiewicz, 1998 (Oleksiewicz et al. 1998). PCR products were analyzed on 2 % 
agarose gels (E-gels, Invitrogen). 
Long range PCR amplification was performed using the full-genome cDNA as template with 
AccuPrime™ Taq High Fidelity kit as described by Kvisgaard et al. 2013. 
 
2.5. Cycle sequencing and next generation sequencing 
PCR products of the ORF5 and ORF7 amplifications were sequenced by cycling sequencing 
using the Sanger method (Sanger et al. 1977) with the ORF5 and ORF7 primers used as sequencing 
primers (Sanger et al. 1977). In total, 39 ORF5 sequences (accession no. KC506625; KC506628-30; 
KC506632-35; KC506637-41; KC506643-59; KC506661-662; KC506665; KC506667-69; 
KC506671-72; KC577601) and 45 ORF7 sequences (accession no. KC506674; KC506677-79; 
KC506681-84; KC506686-90; KC506692-712; KC506714-15; KC506718; KC506720-22; 
KC506724-26; KC577602-3) were generated.    
Full genome sequences were generated by next generation sequencing technologies (NGS) using 
long range PCR amplicons covering the full genome of PRRSV in two or four fragments as 
templates. For a detailed description of the procedure and next generation sequencing see Kvisgaard 
et al. 2013. In short, equimolar concentration of the PCR amplicons covering the full genome of 
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PRRSV were prepared for sequencing on Roche/454 Genome Sequencer FLX + Titanium (LGC 
Genomics GmbH, Berlin, Germany and Ion Torrent GPM sequencer (DTU Multi-Assay Core 
(DMAC), Kgs. Lyngby, Denmark). Additionally, full length sequences of two Danish viruses (DK-
2010-10-2-1 and DK-2010-10-7-1) were obtained using the 454 GS Jr. platform. DNA template for 
these two isolates was generated using a random PCR method previously described (Van 
Doorsselaere et al. 2011). 
 
2.6. Sequence analysis 
 Data analysis of ORF5 and ORF7 sequences obtained from the cycle sequencing was carried out 
using the commercial software CLC Main Workbench v. 6.6.2 (CLC BIO, Arhus, Denmark). 
Contigs of ORF5 and ORF7 were produced from assembling the raw data obtained from cycle 
sequencing against the reference sequence VR2332 (PRU87392). Nucleotide and amino acid 
sequences were aligned using MUSCLE (MUltiple Sequence Comparison by Log- Expectation) 
(Edgar. 2004). The ORF5 sequences were classified based on a globally representative ORF5 
phylogenetic framework (Shi et al. 2010). The ORF5 phylogenetic tree of the newly sequenced 
Danish isolates and reference sequences was constructed using a Bayesian Markov chain Monte 
Carlo (BMCMC) method implemented in MrBayes v3.2 (Ronquist et al. 2012) under settings 
previously described (Shi et al. 2010). 
 Mapping of  reads obtained from full genome sequencing was performed by the Burrows-
Wheeler aligner (BWA) using the Aln algorithm for the Illumina HiSeq2000 data and the bwasw 
algorithm for Roche 454 FLX and Ion Torrent PGM sequencer data (Kvisgaard et al. 2013). Amino 
acid sequences were predicted from the nucleotide sequences using CLC Main Workbench v. 6.6.2. 
Nucleotide and amino acid sequences were aligned using MUSCLE (MUltiple Sequence 
Comparison by Log- Expectation). The phylogenetic tree constituting the complete genomes were 
constructed from Neighbor Joining Algorithm with Bootstrap: 1,000 replicates (CLC Main 
Workbench v. 6.6.2, CLC BIO, Arhus, Denmark).  
Potential N-glycosylation sites were determined for GP2, GP3, GP4, and GP5 using NetNGlyc 
1.0 Server (http://www.cbs.dtu.dk/services/NetNGlyc/). Using a neural network, N-glycosylation 
sites were selected when potential above the threshold 0.5 was reached 
(http://www.cbs.dtu.dk/services/NetNGlyc/output.php). 
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3. Results 
 
3.1. Analysis of ORF5 and ORF7 sequences 
A total of 49 ORF5 and 55 ORF7 nucleotide sequences were obtained from 57 viruses collected 
in the years 2003-2012. The lengths of the ORF5 and ORF7 sequences were 603 and 372 
nucleotides, respectively. The viruses DK-2011-30-3-13, DK-2011-30-3-15, and DK-2011-30-3-20 
collected simultaneously from the same pig herd, were almost identical and had a 3 nucleotide 
deletion in ORF5 (corresponding to residues114-116 in Ingelvac PRRS MLV). This deletion was 
also present in two non-European viruses, one from Thailand and one from the USA (THA-2002-
02SP3 and US-ISU3927) however, these isolates shared only 86.8% and 92.3 % identity in ORF5 
to these three Danish sequences. Among the Danish sequences, the pairwise nucleotide identity was 
90.9-100% and 93.0-100.0 % for ORF5 and ORF7, respectively. The pairwise nucleotide identity of 
the Danish sequences to the Ingelvac PRRS MLV vaccine strain was in the range 94.0-99.8 % and 
94.6-100 % in ORF5 and ORF7, respectively. Phylogenetic analysis of ORF5 in a globally 
representative context (Shi et al. 2010) showed all the Danish viruses to be closely related to the 
cluster of VR2332-like or vaccine-like strains i.e. sub-lineage 5.1 (Fig. 1). Similar comparisons 
solely between Danish isolates indicated a maximum nucleotide non-identity of 9.1 %.(Fig. 1). 
Pairwise nucleotide comparisons based on a partial ORF5 region (nt91-522) between Danish Type 
2 PRRS viruses and two Hungarian Type 2 PRRS viruses from 2005 and 2006 (Balka et al. 2008) 
showed only 84.2-88.2 % identity (data not shown).  
 
3.2. Antigenic analysis of the deduced amino acid sequence of the major glycoprotein 5, GP5 
Examination of the deduced amino acid sequences of ORF5, GP5, showed that 144 positions out 
of 200 were conserved in all 49 Danish sequences (72 % conserved sites). Twenty-four positions 
varied in more than one virus, and 7 positions varied in more than 10 viruses. The most variable 
position was at aa34 where 34 viruses varied. Six different amino acid residues were seen at this 
site. Interestingly, position aa34 is a putative N-glycosylation site in Type 2 PRRS viruses. The 
cysteine residue at position aa48 thought to be involved in heterodimer formation with the M 
protein (Mardassi et al. 1996) was conserved in all the Danish sequences. The decoy epitope 
(A/VLA/VN motif) at position aa27-30 (Ostrowski et al. 2002) is located in a hypervariable region 
of GP5 and this motif was conserved in the majority of the Danish viruses (Fig. 2). The neutralizing 
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epitope of GP5 located in the region aa37-45 (SHL/FQLIYNL) is known to be highly conserved, 
which also was seen for the Danish viruses (Fig. 2) (Ostrowski et al. 2002).  
Potential N-glycosylation sites were observed at seven different positions: N30, N32, N33, N34, 
N35, N44, and N51 (Table 1). Using a neural network, N-glycosylation sites were predicted to be 
utilized if the threshold was above 0.5. The result of these network predictions, revealed 8-9 
different putative glycosylation patterns among the Danish viruses (Table 1). N-glycosylation sites 
variations were located mainly between aa30-35 near the highly variable region, including the 
highly variable site at position aa34 as mention previously. The N44 and N51 N-glycosylation sites 
were conserved in all but one sequence, where N44->D44 but the N51 glycosylation site was 
conserved in this virus (DK-2012-10-1-5). The most common N-glycosylation pattern was N30, 
N33, N44, and N51 which 34 viruses harbored, however, in 14 of these sequences N30 did not 
reach the potential threshold of 0.5 and therefore was not predicted to be N-glycosylated by the 
neural network (glycosylation pattern 2, Table 1). 
 
3.3. Genetic analysis of 11 complete Danish PRRSV Type 2 genomes 
Eleven complete genomes of Type 2 PRRSV (Kvisgaard et al. 2013) isolated from Danish pig 
herds in the years 1997 to 2012 were aligned and analyzed. The genome lengths varied from 
15,396-15,408 nucleotides (excluding the Poly(A) tail) and the pairwise nucleotide identity among 
the Danish viruses was 90.6-99.3 % and they  were 93.6-99.6  % identical to the vaccine strain 
Ingelvac PRRS MLV (Table 2). DK-2008-10-1-3 and DK-2010-10-1-2 were clearly different from 
the majority of Danish isolates in that the pairwise nucleotide identities to the other Danish 
sequences were 92.8-95.3 % and 91.1-93.6 %, respectively.  These two isolates were only 90.6 % 
identical. Furthermore, DK-2010-10-1-2 (sub-lineage 5.2) shared only 93.6 % nucleotide identity to 
Ingelvac PRRS MLV vaccine (sub-lineage 5.1) making it the most diverse of the Danish viruses at 
the genetic level which was supported by phylogenetic classification as well. A phylogenetic tree 
was constructed with the complete Danish sequences and Type 2 sequences isolated in North 
America and China (Fig. 3). Despite the fact that the Danish isolates varied up to 10% of genomic 
sites, they all grouped together in a cluster which also included the vaccine strain, VR-2332 and 
three other US strains isolated in the mid-1990s. This grouping largely mirrored the phylogenetic 
clustering (lineage 5) described earlier using ORF5 only.  
Table 3 lists the pairwise nucleotide and deduced amino acid identity of the non-structural 
proteins (nsp) and structural proteins of the Danish viruses. The average similarity of the different 
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ORFs ranged from 94.9 ± 2.9 % for ORF1a to 97.8 ±1.5 % for ORF6. The low average similarity of 
ORF1a was mainly due to the low similarity in the coding regions of NSP1β and NSP2 among the 
Danish sequences which were in the range of 85.1-99.3 % and 86.6-98.9 %, respectively. The 
similarity of the protein products, nsp1β and nsp2, was also low (80.8-99.5 % and 94.0-98.2 %), 
thus indicating that most mutations in this region are non-synonymous.  
 
3.4. Examination of the non-structural protein 2 (nsp2) of the Danish PRRSV Type 2 viruses 
Fig. 4 shows an alignment of the deduced nsp2 amino acid sequences of 11 Danish viruses 
together with three North American isolated Type 2 PRRS viruses reported to be highly virulent 
(Han et al. 2006; Gauger et al. 2012) and three Chinese PRRSV Type 2 viruses, one high 
pathogenic (GDBY1), one low pathogenic (GDQJ), and one (BJ-4) very similar to Ingelvac PRRS 
MLV (99.7 % nucleotide identity) (Yan et al. 2007; Li et al. 2010). The virus, BJ-4, has also been 
used for B-cell epitope identifications in nsp2 (Yan et al. 2007). Alignment of the predicted amino 
acid sequence of nsp2 of the Danish viruses with the vaccine strain revealed that several of the 
Danish viruses harbored deletions resulting in variation of the length of nsp2 from 1174 to 1096 
amino acids residues. One virus harbored a 4 amino acid deletion following the amino acid at 
position 793 and five other viruses harbored a 3 amino acid deletion at the position corresponding to 
aa593-595 in nsp2 of Ingelvac PRRS MLV. One of the viruses harboring the 3 amino acid deletion 
was the virus DK-2010-10-1-2 and this virus also had a 19 amino acid deletion corresponding to the 
position aa498-516 in Ingelvac PRRS MLV nsp2. Thus, this virus encoded the shortest nsp2 of the 
Danish viruses with an amino acid length of 1174 residues. All the deletions observed in the Danish 
viruses were located at the hyper variable region between aa150-850 of nsp2. The nsp2 protein is 
known to be the most diverse protein of all the proteins encoded by PRRSV, nevertheless, the 
cysteine protease domain (PL2) located in the region aa46-146 of nsp2 is known to be conserved 
within the same genotype. Indeed, this region was also highly conserved in the Danish viruses with 
only 17 substitution sites out of 101positions while the North American and Chinese viruses had 
only 16 and 9 substitution sites, respectively, in comparison to the Ingelvac PRRS MLV nsp2 
sequence. The amino acid residues forming the putative catalytic triad C54, D88, and H123 (Han et 
al. 2009), were conserved in all the Danish viruses as well as in the American and Chinese viruses. 
All 6 putative B-cell epitopes identified by Yan et al. (2007) are highlighted in Fig. 4. Epitope sites 
SP1, SP2, and SP4 were highly conserved among the Danish viruses, whereas epitope sites SP5, 
SP6, and SP8 showed a high proportion of variable sites (60 %, 64 %, and 69 %, respectively).  
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Comparison of the Danish nsp2 sequences to the vaccine strain showed high similarity for 7 of 
the viruses (DK-1997-19407B, DK-2004-1-7-Pl, DK-2010-10-2-1, DK-2010-10-4-1, DK-2010-10-
7-1, DK-2011-030311-1, and DK-2012-01-11-3) with 96.2-99.3 % amino acid identity and lower 
similarity for 4 viruses (DK-2003-2-3, DK-2004-2-1, DK-2008-2-1, and DK-2010-10-1-2) with 
amino acid identity in the range of 89.0-92.5 %.  
 
3.5. Antigenic analysis of the minor glycoproteins, GP2, GP3, and GP4 
The pairwise amino acid identities of the minor glycoproteins, GP2, GP3, and GP4 among the 
Danish sequences are listed in Table 3. GP3 was shown to be the most diverse structural protein 
among the Danish Type 2 viruses with amino acid identity of 90.9-99.2 %. Linear B-cell epitopes 
have been identified in all 3 minor glycoproteins using Pepscan technologies using the sequence of 
the virus strain NVSL 97-7895 (de Lima et al. 2006). The GP2 comprised two putative linear B-cell 
epitopes at amino acid positions aa41-55 and 121-135, respectively (Fig. 5). These regions were 
highly conserved among the Danish viruses; however, the epitope located at the region aa41-55 
harbored 4 substitutions sites compared to the NVSL 97-7895 strain. For GP3, 4 overlapping 
consecutive linear B-cell epitopes have been identified (aa61-75, aa71-85, aa81-95, and aa91-105) 
(de Lima et al. 2006). Even though GP3 was the most diverse structural protein among the Danish 
Type 2 viruses, the 4 epitope sites were all highly conserved with only 8 substitution sites 
distributed throughout all 4 epitope regions (aa61-105) when compared to the NVSL 97-7895 strain 
GP3 sequence (Fig. 6). The putative epitope site in GP4 at position aa51-65 was not conserved 
among the Danish viruses with 10 substitution sites out of a possible of 15 (Fig. 7).  
Examination of potential N-glycosylation sites revealed 2 putative N-glycosylation sites at N178 
and N184 in GP2 (Fig. 5), 7 putative N-glycosylation sites (N29, N42, N50, N131, N152, N160, 
and N195) in GP3 (Fig. 6), and 4 putative N-glycosylation sites (N37, N84, N120, and N130) in 
GP4 (Fig. 7). The result of nine neural networks predicted all putative N-glycosylation sites in GP2 
and GP4 to be N-glycosylated however N37 in GP4 did not score a unanimous vote from the jury 
network to be N-glycosylated. For GP3 all 7 putative N-glycosylation sites were predicted to be N-
glycosylated in all the Danish viruses except for virus DK-2008-10-1-3 where the potential at this 
position did not reach the threshold of 0.5. A unanimous vote from the jury predicted N-
glycosylation at N195 however this position is believed to be located in the transmembrane region 
of GP3, hence unlikely to be glycosylated (Dokland. 2010). 
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The cysteine residues important for protein folding and function was 100 % conserved in all the 
minor structural proteins of the examined Danish viruses. 
 
4. Discussion 
We report here for the first time the sequences of complete genomes obtained from Type 2 
PRRS viruses isolated in Europe. With the 11 complete genomes sequenced from viruses isolated in 
the years 1997-2012 (Kvisgaard et al. 2013), the evolution of Type 2 PRRSV since its introduction 
15 years ago in Denmark is now well described. The virus DK-1997-19407B was isolated about 6 
months after the Danish PRRSV Type 2 vaccination program first started in the fall of 1996.  The 
virus was obtained from a herd that had not been vaccinating against PRRSV Thus, since it is 
regarded as very unlikely that another VR2332-like virus was introduced into Denmark in the fall of 
1996 coincidentally with the start of the vaccination program, this virus must incorporate the 
genetic changes incurred by the PRRS vaccine virus while spreading between herds and can be 
regarded as the historical European Type 2 PRRSV reference strain (Nielsen et al. 2001). In the 
present study, we sequenced the complete genome of this reference strain and showed that it was 
99.4 % identical to the vaccine strain and to two other Type 2 viruses isolated in the US in 1995 and 
1997, respectively. These findings support epidemiological data indicating that Type 2 PRRSV was 
likely introduced into Denmark by the MLV vaccine. This view is further sustained by the negative 
outcome of a serological testing of 2159 sows performed prior to the introduction of the vaccine in 
the autumn of 1996 using a type specific immunoperoxidase monolayer assay (IPMA) (Botner et al. 
1994; Sorensen et al. 1997). 
The sudden emergence of more pathogenic PRRS viruses in North America (Han et al. 2006; 
Gauger et al. 2012), Asia (Tian et al. 2007; An et al. 2010) and Eastern Europe (Karniychuk et al. 
2010; Weesendorp et al. 2013; Morgan et al. 2013) emphasize the importance of monitoring the 
genetic diversity of PRRSV.  Despite this obvious need, there has been only a limited focus on the 
genetic diversity of Type 2 PRRSV in Europe, perhaps because the few viruses that were analyzed 
were found to be very similar  (> 98 %) to the Ingelvac PRRS MLV vaccine in ORF5 and ORF7 
(Stadejek et al. 2013). This has led to the perception that all Type 2 viruses in Europe are closely 
related to the attenuated vaccine strain and are only minor contributors to clinical PRRS in Europe. 
In Hungary, however, where the Ingelvac PRRS MLV vaccine has not been used (Balka et al. 
2008), two Type 2 PRRS viruses were isolated in 2005 and 2006. First it was believed that these 
viruses was introduced through infected breeding animals imported from Denmark, however, later it 
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was shown that they shared 91 % identity to a Canadian strain indicating that they may have been 
introduced by other sources (Balka et al. 2008). Pairwise nucleotide comparison of the partial ORF5 
sequences of the Hungarian viruses to the 49 Danish viruses examined in our study revealed that 
they only shared 84.2-88.2 % nucleotide identity and therefore support that these isolates did not 
originated from Denmark. 
The majority of the 11 complete genomes showed high level of similarity to the vaccine strain 
with pairwise nucleotide identity of 98.1-99.6 %. This similarity correlated well with the diversity 
in ORF5 of the Danish viruses where all the ORF5 sequences clustered along with the vaccine 
strain in lineage 5 (Shi et al. 2010). Interestingly, four viruses isolated in 2003, 2004, 2008, and 
2010 showed a higher level of diversity to the vaccine strain with 93.6-96.1 % complete genome 
similarity, however, they still clustered within the lineage 5 in the phylogenetic analysis. Based on 
the ORF5 nucleotide sequences obtained from all Danish viruses isolated between 2003-2012, the 
diversity of the Danish viruses to the vaccine strain was in the range of 94.0-99.8 %, which is a 
larger range than the diversity of most European Type 2 viruses (> 98 % similarity to the vaccine 
strain) (Greiser-Wilke et al. 2010; Stadejek et al. 2013).  
 Notwithstanding insights based on ORF5, the examination of limited genomic regions may not 
be sufficient for a more complete understanding of PRRSV sequence heterogeneity, as illustrated by 
the non-structural protein coding regions NSP1β and NSP2 of the Danish viruses that showed a 
very broad identity range to the vaccine strain in the range of 85.1-99.3 % and 86.6-98.9 %, 
respectively.  
 At the genomic level, the isolates DK-2008-10-1-3 and DK-2010-10-1-2 exhibited the greatest 
divergence with pairwise nucleotide identity to the other Danish genome sequences in the range of 
92.8-95.3 % and 91.1-93.6 %, respectively and shared only 90.6 % nucleotide similarity between 
each other. DK-2010-10-1-2 was the virus with the shortest genome constituting 15,342 nucleotides 
with a discontinuous deletion in the coding region of NSP2 of 57 plus 9 nucleotides (corresponding 
to 19 plus 3 amino acids in the deduced amino acid sequence of nsp2, Fig. 4). The consecutive 9 
nucleotide deletion was also seen in 4 other viruses examined in this study. Although some of these 
viruses were sequenced from RNA extracted from cell culture supernatant, the deletion is naturally 
occurring since it was also found in partial NSP2 sequences obtained from the corresponding 
primary material (data not shown).  During screening of partial NSP2 sequences, several viruses 
(from 2003, 2010 and 2011) were found to harbor the same deletion (data not shown). Deletions are 
often seen in the NSP2 coding part of the PRRSV genome (Ropp et al. 2004; Han et al. 2006), and 
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also in high virulent strains such as the MN184A and MN184B viruses and all the high pathogenic 
viruses isolated in China during the outbreak in 2006-2009 (An et al. 2010). Based on these 
findings, one might presume that deletions in NSP2 were linked to high virulence of the virus. 
However, a low pathogenic virus, GDQJ (GQ374441), isolated in 2008 was shown to harbor the 
exact same deletion as the high pathogenic Chinese viruses (Li et al. 2010). Additionally, using 
chimeric viruses, the NSP2 deletion in the 2006 Chinese outbreak of PRRS was shown not to be 
linked to virulence (Zhou et al. 2009).  In this sense, the deletions found in NSP2 of the Danish 
viruses can be regarded as an ‘epidemiological marker’ and not as a marker of virulence.  
The nsp2 is the viral protein containing the highest frequency of B-cell epitopes (Oleksiewicz et 
al. 2001; de Lima et al. 2006; Yan et al. 2007) and the humoral antibody response to nsp2 is more 
pronounced than towards any other PRRSV protein. However, most of the antibodies are non-
neutralizing (Han et al. 2007; Johnson et al. 2007; Brown et al. 2009). Analysis of the Danish 
viruses showed that epitope sites SP1, SP2, and SP4 identified by Yan et al. (2007) were highly 
conserved among the Danish viruses, whereas epitope sites SP5, SP6, and SP8 showed a high 
proportion of variable sites of 60 %, 64 %, and 69 %, respectively (Fig. 4). De Lima et al. (2006), 
identified 18 B-cell epitopes in nsp2 of a North American virus (NVSL 97-7895, acc. no. 
AY545985), but none of these epitopes were conserved in the Danish nsp2 sequences probably as a 
consequence of the high level of amino acid variation of nsp2 (amino acid comparison of the North 
American nsp2 sequence to the Danish nsp2 sequences were 77.5-82.7 % identity). The North 
American virus, NVSL 97-7895 was also used for screening of linear B-cell epitopes in the 
structural proteins and the epitopes identified in GP2 and GP3 was highly conserved among the 
Danish viruses and to the North American strain although the overall amino acid variation was high 
in all three minor glycoproteins compared to the Danish viruses. The B-cell epitope identified in 
GP4 at position aa51-65 were highly variable with 10 substitutions out of 15 possible. This fit well 
with previous findings that this protein only reacted with a small fraction of tested post-infection 
sera (de Lima et al. 2006).  Taken together these results indicated that some - but not all - epitopes 
present in the nonstructural and structural proteins of Type 2 PRRSV are prone for changes – which 
again indicate that antibodies generated against some epitopes may have no impact on virus 
survival. In general, comparisons of full-length genomes provide valuable information on conserved 
and variable regions and thereby can reveal new targets for immune intervention, the design of new 
vaccines and for the development of diagnostic tests.  
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The N-glycosylation of GP5 may be critical for proper functioning of the protein as N-
glycosylation, in general, is important for correct folding, targeting, and biological activity of 
proteins (Ansari et al. 2006). In this study, potential N-glycosylation sites (N-X-S/T-X, X ≠ P) were 
observed at seven different positions in GP5: N30, N32, N33, N34, N35, N44, and N51. The result 
of a neural networks predictions, lead to 8-9 different putative glycosylation patterns among the 
Danish viruses, with the N-glycosylation of  N30, N33, N44, and N55 the most abundant pattern. 
However, even though the N-glycosylation motif at N30 was present in 14 sequences the potential 
for glycosylation did not reach the threshold of 0.5, hence not predicted to be N-glycosylated. The 
position N30 is located in the C-terminal part of the putative signal peptide and glycosylation at this 
position may not have any influence on the mature protein, but may contribute to other biological 
functions such as immune evasion. The N-glycosylation at position N44 has previously been shown 
to be important for infectious virus production (Ansari et al. 2006) and only one of the 
glycosylation patterns found among the Danish GP5 sequences failed to predict this site to be 
glycosylated because the N44 was substituted to a D44 and the N-glycosylation motif was lost. 
Of the 11 complete genomes examined in this study, all of the putative N-glycosylation motifs in 
the minor glycoproteins GP2, GP3, and GP4 were present and predicted to be N-glycosylated which 
strongly indicates that the glycosylation of these motifs are important for the functioning of 
respective proteins.  
In conclusion, this study presents for the first time the examination of complete genomes 
obtained from Type 2 PRRS viruses isolated in Europe. From the complete genomes it was revealed 
that there was an overall high diversity between the Danish viruses (90.6-99.3 %) and one virus 
harbored only 93.6 % similarity to the vaccine strain. These results indicate that there has been a 
pronounced genetic divergence among the Danish Type 2 PRRSVs (sub-lineages 5.1 and 5.2) but 
the data do not support multiple introductions of different Type 2 strains into Denmark which fits 
well with the limited import of living animals and semen into Denmark. Lastly, Type 2 viruses in 
Denmark seem to induce more severe clinical signs compared to other European countries but share 
relatively close evolutionary relationship in ORF 5 to Type 2 viruses found in other European 
countries. .  This could indicate that the genetic determinants of viral virulence lie outside ORF5 
and emphasize that the generation of more complete genome sequences of European Type 2 isolates 
should be prioritized. 
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Table 1.  
Glycosylation pattern in GP5 of the Danish PRRSV Type 2 viruses isolated in the years 2003-2012 
(n = 49) 
 
N-
glycosylation 
pattern 
N-glycosylation sites in GP5 
No. of 
sequences 
% 
of 
total 
 N30 N32 N33 N34 N35 N44* N51   
          
1 +  +   + + 20 41 
1 +**  +   + + 14 29 
2 +    + + + 6 12 
3   +   + + 2 4 
4  +    + + 2 4 
5    + + + + 2 4 
6      + + 1 2 
7 +  + +  + + 1 2 
8 +  + +   + 1 2 
*When this N-glycosylation site was present, all viruses scored a 9/9 jury agreement from the neural network. 
**The N-glycosylation site is present in the sequence, but the potential for glycosylation did not reach the threshold of 
0.5. 
 
 
Table 2. 
Overview of the 11 Danish Type 2 PRRSV complete genomes 
 
Virus 
Accession 
no. 
Collection 
year Clinical signs (herd) 
Sequencing 
material 
Genome 
length* 
Nt 
identity%** 
DK-1997-19407B KC862576 1997 Stillborn piglet*** Marc-145 isolate 15,396 99.4 
DK-2003-2-3 KC862584 2003 - Marc-145 isolate 15,408 96.1 
DK-2004-2-1 KC862585 2004 - Marc-145 isolate 15,408 96.0 
DK-2004-1-7-Pl KC862578 2004 - Marc-145 isolate 15,408 99.4 
DK-2008-10-1-3 KC862582 2008 Reproductive failure Lung homogenate 15,408 95.4 
DK-2010-10-1-2 KC862579 2010 Respiratory Lung homogenate 15,342 93.6 
DK-2010-10-7-1 KC862580 2010 Respiratory Marc-145 isolate 15,399 98.8 
DK-2010-10-2-1 KC862581 2010 Respiratory Marc-145 isolate 15,399 99.6 
DK-2010-10-4-1 KC862583 2010 Respiratory Lung homogenate 15,399 98.1 
DK-2011-030311-1 KC862577 2011 High fever Lung homogenate 15,408 99.3 
DK-2012-01-11-3 KC862575 2012 
Respiratory/ 
reproductive failure Lung homogenate 15,399 98.3 
*Excluding the Poly(A) tail, **Pairwise nucleotide identity to Ingelvac PRRS MLV (EF484033), *** This virus was 
obtained from a non-vaccinated herd about 6 months after the Danish vaccination program had started in the fall 1996.  
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Table 3.  
Pairwise nucleotide and amino acid identity range of the 11 Danish PRRSV Type 2 field strains and 
identity range to Ingelvac PRRS MLV (EF484033). The predicted pp1a and pp1ab protein cleavage 
sites are from Fang and Snijder, 2010. 
 
ORFs Length (nt) % identity 
range (nt) 
Avg. nt 
identity % 
(mean ± 
sd) 
% identity 
range to 
Ingelvac (nt) 
Proteins Length (aa) % identity 
range (aa) 
Avg. aa 
identity % 
(mean ± sd) 
% identity 
range to 
Ingelvac (aa) 
          
ORF1a 7446, 7500, 
7503, 7512 
88.8-99.2 94.9 ± 2.9 92.2-99.6 pp1a 2481, 2499, 
2500, 2203 
89.2-99.2 94.6 ± 2.8 92.4-99.6 
NSP1α 540 92.8-99.6 96.9 ± 1.8 95.0-99.8 nsp1α 180 96.1-100.0 97.9 ± 1.0 97.2-100.0 
NSP1β 609 85.1-99.3 93.8 ±3.6 91.0-99.5 nsp1β 203 80.8-99.5 90.8 ± 4.7 87.2-99.5 
NSP2 3522, 3576, 
3579, 3588 
86.6-98.9 94.1 ± 3.4 90.6-99.4 nsp2 1174,1192, 
1193, 1196 
84.0-98.2 92.4 ± 4.0 89.0-99.3 
NSP3 690 90.7-99.6 95.8 ± 2.4 94.5-99.9 nsp3 230 94.8-100.0 97.9 ± 1.3 97.0-100.0 
NSP4 612 90.9-100.0 95.9 ± 2.6 93.8-100.0 nsp4 204 94.1-100.0 97.6 ± 1.7 95.6-100.0 
NSP5 510 88.6-99.0 95.4 ± 2.6 92.6-99.4 nsp5 170 94.1-100.0 97.1 ± 1.6 95.9-100.0 
NSP6 48 83.3-100.0 95.7 ± 4.6 87.5-100.0 nsp6 16 93.8-100.0 98.9 ± 2.4 93.8-100.0 
NSP7α/β 777 90.9-99.5 96.2 ± 2.3 94.2-99.9 nsp7α/β 259 95.4-100.0 98.0 ± 1.4 96.9-100.0 
NSP8 138 93.5-100.0 97.2 ± 1.9 95.7-100.0 nsp8 45 95.6-100.0 98.9 ± 1.3 97.8-100.0 
ORF1b 4506 92.5-99.6 96.7 ± 1.9 94.8-99.7 pp1b 1501 97.4-99.8 98.7 ± 0.6 98.1-99.9 
NSP9 2052 92.6-99.7 96.8 ± 1.8 95.3-99.8 nsp9 684 97.4-99.9 98.7 ± 0.7 98.0-100.0 
NSP10 1323 92.5-99.6 96.6 ± 2.0 94.9-99.6 nsp10 441 96.6-100.0 98.8 ± 0.9 97.3-99.8 
NSP11 669 90.6-99.9 96.4 ± 2.4 93.1-99.7 nsp11 223 97.3-100.0 99.1 ± 0.8 98.2-100.0 
NSP12 462 92.2-99.8 96.1 ± 1.9 94.6-99.8 nsp12 153 94.8-99.4 97.4 ± 1.2 96.7-100.0 
ORF2 771 91.1-99.7 96.3 ± 2.2 93.8-99.6 GP2 256 91.0-99.6 96.3 ± 2.3 92.2-99.2 
ORF2b 222 93.7-100.0 97.4 ± 1.9 95.1-99.6 E 73 91.8-100.0 96.9 ± 2.0 93.2-98.6 
ORF3 765 92.3-99.5 96.4 ± 1.9 94.0-99.6 GP3 254 90.9-99.2 95.9 ± 2.2 92.1-98.8 
ORF4 537 93.7-99.6 97.1 ± 1.6 95.0-99.1 GP4 178 92.1-100.0 96.4 ± 2.3 94.4-99.4 
ORF5 603 91.0-99.2 96.0 ± 2.0 94.4-99.3 GP5 200 91.5-98.5 95.2 ± 1.8 93.5-99.0 
ORF5a 156 91.7-98.7 95.7 ± 1.6 95.5-99.4 ORF5a 
protein 
51 88.2-100.0 95.9 ± 2.5 94.1-100.0 
ORF6 525 94.3-100.0 97.8 ± 1.5 96.0-99.6 M 174 97.7-100.0 98.9 ± 0.6 98.3-99.4 
ORF7 372 93.0-100.0 97.7 ± 1.9 94.6-100.0 N 123 95.9-100.0 98.9 ± 1.3 97.6-100.0 
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Fig. 1. Phylogenetic analysis of the Danish ORF5 sequences in a globally representative context. 
All the Danish sequences are marked with a red dot, all European sequences are marked with a blue 
dot, and the vaccine strain and the Type 2 protogenotype VR2332 are marked with green triangles. 
All the Danish ORF5 sequences were closely related to the cluster of VR2332-like or vaccine-like 
strains i.e. sub-lineage 5.1. The tree was constructed using a BMCMC method implemented in 
MrBayes v3.2. 
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Fig. 2. A histogram showing the number of substitutions found at each amino acid position in GP5 
of 49 Danish isolates. ‘Empty’ positions represent conserved amino acids. The seven potential N-
glycosylation sites at aa30, aa32, aa33, aa34, aa35, aa44, and aa51 are marked with *. Decoy 
epitope at position aa27-30 and the Neutralizing epitope at position aa37-45 are marked with black 
bars.  
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Fig. 3. Phylogenetic analysis of 11 Danish complete PRRSV Type 2 genomes and 10 complete 
genomes of viruses isolated in China and North America. The tree was constructed by the neighbor-
joining method using CLC Main workbench (v. 6.6.2). Bootstrap values were calculated from 1,000 
replicates and shown on branches. The scale bar represents 15% nucleotide change. PRRSV Type 1 
Lelystad is used as outgroup (set root above node). CHN = China, DK = Denmark, US = United 
States of America. 
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Fig. 4. Amino acid alignment of nsp2. Putative B-cell epitopes (Yan et. al 2007) are highlighted in 
black boxes. The amino acid residues forming the putative catalytic triad C54, D88, and H123 (Han 
et al., 2009) are marked with black stars. Deletion sites are marked with grey rectangles. 
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Fig. 5. Amino acid alignment of GP2.  The 11 Danish GP2 amino acid sequences were aligned 
against the North American virus, US-1997-97-7895 used for detection of B-cell epitopes (de Lima 
et. al 2006). The two putative B-cell epitopes (No. 102 and 110) are highlighted with a black box. 
The putative N-glycosylations sites (N178 and N184) are marked with *. 
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Fig. 6. Amino acid alignment of GP3. The 11 Danish GP3 amino acid sequences was aligned 
against the North American virus, US-1997-97-7895, used in detection of B-cell epitopes (de Lima 
et. al 2006). The four overlapping putative B-cell epitopes (no. 129-132) are highlighted with black 
boxes. The seven putative N-glycosylations sites (N29, N42, N50, N131, N152, N160, and N195) 
are marked with *. 
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Fig. 7. Amino acid alignment of GP4. The 11 Danish GP4 amino acid sequences was aligned 
against the North American virus, US-1997-97-7895, used in detection of B-cell epitopes (de Lima 
et. al 2006). The one putative B-cell epitope (no. 153) is highlighted with a black box. The four 
putative N-glycosylations sites (N37, N84, N120; and N13) are marked with *. 
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Abstract 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is the cause of significant 
reproductive and respiratory disease in swine worldwide. In Denmark approximately 50 % of the 
herds are seropositive for PRRSV of either or both genotypes. 
In November 2010, a pig herd in the Northern part of Denmark experienced an infection with 
Type 2 PRRSV where the clinical impact appeared to be much more severe than normal reported 
from Danish Type 2 PRRSV affected herds. Due to the clinical observations of reproductive 
failures in sows and high mortality in piglets, it was speculated that a new, more pathogenic 
PRRSV strain had evolved in Denmark. The overall aim of the present study was to make a genetic 
and biological characterization of the virus isolated from the herd. Complete genome sequencing of 
isolates from the case herd revealed that although the case strain had some unique genetic features it 
was in overall very similar to the vaccine strain and to older Danish isolates. In an experimental 
trial, the virus induced no overt clinical signs in pigs following intranasal inoculation of the case 
strain or an older Danish strain. Virus shedding, acute phase responses and, serological responses 
were also comparable. Vaccination with a commercial MLV Type 2 vaccine had significant effect 
on virus shedding, together with magnitude and duration of viraemia. Combining the genetic and 
biological achieved data indicates that the severe disease seen in the field are influenced by other 
factors than the virus and emphasize that research aimed at identifying virulence maker of PRRSV 
are highly needed. 
 
Keywords: 
 PRRSV, Type 2, Europe, Pigs, experimental infection 
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1. Introduction 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) belongs to the Arteriviridae 
family within the order Nidovirales (Cavanagh. 1997) and is the cause of significant respiratory and 
reproductive disease in swine worldwide (Han et al. 2006; Tian et al. 2007; Karniychuk et al. 2010). 
PRRSV is an enveloped single-stranded positive-sense RNA virus with a genome size of 15.0- 15.5 
kb and contains a 5’-end cap and 3’-end polyadenylated tail (Meulenberg et al. 1998). The genome 
encodes at least 10 open reading frames (ORFs), including the recently discovered ORF5a 
(Meulenberg et al. 1993; Wu et al. 2001; Firth et al. 2011; Johnson et al. 2011).  Based on 
nucleotide sequence comparison of early isolates of European and North American PRRSV it was 
found that they only shared 50-60 % nucleotide identity, hence PRRSV was divided into two major 
genotypes; Type 1 for the European isolated viruses and Type 2 for the North American isolated 
(Allende et al. 1999). Today both genotypes circulate worldwide (Shi et al. 2010). In Denmark, 
Type 1 PRRSV was first recognized in 1992, and in connection to an extensive vaccination program 
in 1996, Type 2 PRRSV was introduce (Botner et al. 1997; Madsen et al. 1998). Approximately 50 
% of the Danish herds are seropositive for PRRSV antibodies against either or both types of 
PRRSV. 
From time to time highly virulent PRRSV strains evolve, which results in impaired animal 
welfare and huge economical losses for the swine industry (Neumann et al. 2005; Han et al. 2006; 
Tian et al. 2007; Karniychuk et al. 2010). In 2006, China experienced the emergence of a highly 
pathogenic strain of PRRSV, which was similar to other Chinese Type 2 PRRSV strains in ORF5, 
but had indeed unique feature differences in other genes (Tian et al. 2007; An et al. 2010). The 
PRRSV epidemic in China affected more than 2 million pigs with about 400,000 fatal cases. This 
abrupt occurrence of high pathogenic PRRSV strains emphasizes the significance of monitoring the 
diversity of circulating PRRSV strains around the world both in respect to the sensitivity and 
specificity of diagnostic tests as well as efficacy of available vaccines. 
In November 2010, a severe case of PRRSV with high mortality rate in piglets occurred in a 
farrow-to-finisher herd in the northern part of Denmark. By real-time RT-PCR, Type 2 PRRSV was 
detected in lung tissue samples from 10 days old piglets submitted to the National Veterinary 
Institute for routine diagnostics. The samples were negative for swine influenza virus, Porcine 
circovirus type 2 (PCV2) and Mycoplasma hyopneumoniae. The infection was subsequently 
attempted to be controlled by extensive vaccination with Ingelvac® PRRS MLV and tightened of 
management procedures. From week 6 until week 14 after the initial infection, up to 75 % of the 
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fetuses were born as mummified. In February 2011 (12 weeks after the initial infection were 
recognized in piglets), pleura and lung tissue from mummified fetuses and stillborn piglets were 
found positive for PRRSV by real-time RT-PCR. The fetuses were negative for porcine parvovirus 
(PPV), PCV2 and Leptospira spp. Approximately15 weeks following the initial infection the 
number of liveborn piglets and the mortality until weaning was back to normal (33 weaned piglets 
per sow per year). Total losses of piglets until weaning for the 15-week period were about 30 %. 
The average loss in the nursery was 9.3 % until 18 weeks post the initial infection. Nineteen (19) 
weeks after the initial infection, post wean mortality were back to normal (2.2%).  
Since the clinical impact appeared to be much more severe than normal reported from Danish 
Type 2 PRRSV affected herds, it was speculated that a new, more pathogenic PRRSV strain had 
evolved in Denmark similar to the strains that have previously evoked in Minnesota, China and 
Eastern Europe. However, the severity could also be due to a variety of other factors related to 
management and/or other infections. The overall aim of the present study was to make a genetic and 
biological characterization of the virus isolated from the herd by full-genome sequence analysis of 
the isolate and by comparing the infection dynamic of the virus isolated from the herd with an older 
Danish Type 2 isolate by experimental infection in young pigs. An additional aim was to assess the 
protective effect of a MLV Type 2 vaccine against this recent Danish Type 2 PRRSV isolate. 
 
2. Materials and methods 
 
2.1. Case samples 
Samples from the case herd were collected in November 2010, February 2011 and March 2011.  
In November 2010, lung samples from nine 10-day-old piglets were obtained. In February 2011, 
seven (7) lungs from mummified fetuses and 13 lungs and 11 pleura samples from stillborn piglets 
were obtained from the same pig herd. In March 2011, lungs and livers from three stillborn piglets 
and lungs and/or hearts and livers from 11 mummified fetuses were obtained.  
From the samples submitted in November 2010, one virus, designated DK-2010-10-13-1, was 
isolated in Marc-145 cells using general cell culture procedure (Kim et al. 1993). 
 
2.2. RNA extraction from field samples 
Lung tissue was initially prepared as a 5 % homogenate in RLT buffer (QIAGEN) containing 1 
% β-mercaptoethanol (Sigma-Aldrich). RNA was extracted from lung homogenate and pleura using 
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RNeasy Minikit (QIAGEN) according to the manufacturer’s instructions. Total RNA from cell 
culture supernatant for full genome sequencing was purified using QIAamp Viral RNA Mini Kit 
(QIAGEN). The elution volume for both extractions methods was 60 µl. The RNA was stored at -
80°C until use. 
  
2.3. Real-time RT-PCR 
The extracted RNA was screened for PRRSV using a modification of the Primer Probe Energy 
Transfer RT-PCR (PriProET-RT-PCR) assay described by Balka, 2009 (Balka et al. 2009). 
 
2.4. cDNA and conventional PCR 
Full-genome cDNA synthesis was performed by SuperScript® III First-Strand Synthesis System 
(Invitrogen) as described elsewhere (Kvisgaard et al. 2013b). PCR amplification of partial-NSP2 
(Zhou et al. 2009), ORF5 and ORF7 (Oleksiewicz et al. 1998) was carried out using the 
AccuPrime™ Taq DNA Polymerase High Fidelity Kit (Invitrogen). The PCR mixture was prepared 
as recommended by the supplier except that the amount of AccuPrime™ Taq High Fidelity was 
increased to 0.5 µl and 2 µl cDNA was used as template. The PCR amplification was conducted on 
a T3 thermo cycler (Biometra) with the following conditions: [94°C for 15 seconds], 45 cycles: 
[94°C 15 seconds, 55°C for 30 seconds, 68°C for 60 seconds] then finalize with 68°C for 5 minutes 
and cool down to 4°C. PCR primers for amplifying ORF5 and ORF7 were from Oleksiewicz, 1998 
(Oleksiewicz et al. 1998). 
Long range PCR amplification was performed using the full-genome cDNA as template with 
AccuPrime™ Taq High Fidelity kit as described by Kvisgaard et al. 2013. 
 
2.5. Cycle sequencing and next generation sequencing 
PCR products of partial-NSP2, ORF5 and ORF7 were sequenced by cycling sequencing using 
the Sanger method using the PCR primers as sequencing primers (Sanger et al. 1977). The complete 
genome of DK-2010-10-13-1 was obtained using the 454 GS Jr sequencer from the laboratory of 
Fred Leung, The University of Hong Kong, Hong Kong, China. DNA templates for the isolate was 
generated using a random PCR method previously described (Van Doorsselaere et al. 2011). The 
complete genome of DK-2011-88005-A8-Pl was obtained using the Ion Torrent GPM sequencer 
(DTU Multi-Assay Core (MAX), Kgs. Lyngby, Denmark) as described elsewhere (Kvisgaard et al. 
2013).  
Manuscript IV 
 
120 
 
2.6. Data analysis 
 Data analysis of sequences obtained from cycle sequencing was carried out using the 
commercial software CLC Main Workbench v. 6.6.2 (CLC BIO, Arhus, Denmark). Contigs of 
ORF5 and ORF7 were produced from assembling the raw data obtained for cycle sequencing 
against the reference sequence VR2332 (PRU87392). The complete genome of DK-2011-88005-
A8-Pl was achieved by the mapping of reads using the Burrows-Wheeler aligner (BWA) 
(Kvisgaard et al. 2013b). Amino acid sequences were predicted from the nucleotide sequences 
using CLC Main Workbench v. 6.6.2. Nucleotide and amino acid sequences were aligned using 
MUSCLE (MUltiple Sequence Comparison by Log- Expectation). 
 
2.7. Inoculation material for experimental infection 
The viruses were propagated in Marc-145 cells using the general cell culture procedure (Kim et 
al. 1993). For both viruses, a second passage of cell culture supernatant was used as the inoculation 
material. The DK-1997-19407B isolate, an older Danish PRRS Type 2 virus, had a titer of 5.4log10 
TCID50/ ml. The DK-2010-10-13-1 isolate had a titer of 5.9log10 TCID50/ ml. One milliliter of cell 
culture supernatant was diluted to a total volume of 4 ml and administered intranasally to each pig 
with 2 ml per nostril.  
 
2.8. Experimental set-up 
Twenty-eight 4-week-old pigs (Landrace X Yorkshire X Duroc cross-breeds) were purchased 
from a commercial pig production herd seropositive for Actinobacillus pleuropneumoniae (AP) 
serotypes 6 and 12, but declared free from a range of important swine pathogens including 
Mycoplasma hyopneumoniae, PRRSV and AP serotypes 1, 2, 3, 4, 5, 7, 8, 9 and 10 according to the 
Danish Specific Pathogen Free (SPF) system. The pigs were randomly divided into one control 
group with four pigs (group 1) and three experimental groups (groups 2-4) each with 8 pigs. The 
individual groups were housed in separate sections of the BSL3 animal isolation facilities at the 
National Veterinary Institute, Lindholm. After an acclimatization period of 5 days, the pigs in group 
4 (pig no. 21 – 28) were vaccinated (2 ml intramuscularly (i.m)) with the Ingelvac® PRRS MLV 
vaccine (Boehringer Ingelheim Animal Health; Ingelheim, Germany). Four weeks later, at post 
inoculation day 0 (DPI 0), the pigs in group 1 (pig no. 1-4) were sham- inoculated intranasally (i.n.) 
with Eagle’s MEM. The pigs in group 2 (pig no. 5-12) and group 3 (pig no. 13-20) were inoculated 
i.n. with the DK-1997-19407B and the case DK-2010-10-13-1 isolate, respectively.  Pigs in group 4 
Manuscript IV 
 
121 
 
(pig no. 21 -28) were challenged with the DK-2010-10-13-1 case isolate. The group 1 and group 4 
pigs were euthanized on DPI 29 and the other two groups on DPI 30. Euthanasia was performed by 
intravenous injection of pentobarbiturate (50 mg/kg) followed by exsanguination by cutting the 
arteria axillaris. The study was carried out in accordance with the Danish legislation on animal 
experiments (LBK nr 1306 – 23/11/2007) and EU regulations on the use of laboratory animals for 
research. 
 
2.9. Clinical examination  
Individual pigs were subjected to daily clinical examination and body rectal temperatures were 
recorded. To avoid influence of handling on the body temperature recordings, these were usually 
carried out while pigs were eating. On a few occasions, restrainment of pigs was necessary to 
measure the temperatures. In order to obtain a semi-quantitative measure for comparison of clinical 
disease between the 4 groups, all pigs were scored using the clinical scoring (CS) system developed 
for swine fever infections by Mittelholzer et al. (2000) and modified for PRRSV experiments 
focusing on PRRS typical clinical signs in growing pigs, - evaluating parameters like common well-
being, appetite, respiration, and eye-disorders. 
 
2.10. Sampling 
Blood samples were collected from all pigs on post inoculation days (DPI) -28, 0, 3, 7, 10, 14, 
21, 28, and 29/30 (days of euthanasia) for clinical, virological, haematological and immunological 
examination. Samples obtained on DPI -28 and 0 were collected prior to vaccination and 
inoculation, respectively. Blood samples were collected in 5 or 10 ml vacutainers (Venoject; 
Terumo Europe, Leuven, Belgium) from the anterior vena cava. Non-stabilized whole-blood 
samples were left on ice to coagulate for 15 minutes and centrifuged at 3500 rpm for 10 minutes at 
4°C. Serum was separated and stored at -80°C for subsequent analysis. In parallel to the blood 
samplings, nasal swab samples were collected on the same days except on day -28, 29/30 PI from 
the right nostril. The swabs were placed in 1 ml PBS (pH 7.5) and stored at -80°C until further 
analysis. 
 
2.11. Tissue sampling  
At post mortem, two identical samples from the following tissues were collected: nasal mucous 
membrane, tonsil, trachea (the middle part), tracheobronchial lymph node, liver, spleen, and lung 
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tissue from the right apical- and diaphragmatic lobes, the intermediate lobe and from lesions, if 
present. One of each sample was fixed in 10% neutral buffered formalin. The other tissue samples 
were stored at -80°C.  
 
2.12. Total WBC counts 
Total WBC counts were carried out on freshly collected EDTA-stabilised blood samples using a 
semi-automated animal blood cell counter (Vet abcTM, ABX, Montpellier, France). All samples 
were counted twice, and the mean value was used.  
 
2.13. Flow cytometry analyses  
Phenotyping of leukocytes in peripheral blood was carried out by flow cytometry, using single as 
well as triple labeling methods to define different sub-populations. Single-colour analysis was 
applied to differentiate leukocyte populations and for B-cell detection, as previously described 
(Nielsen et al. 2003b). Phenotyping of peripheral blood T-cell subpopulations was performed by 
triple-color flow cytometry using CD3/CD8/CD4 labelling, as previously described (Nielsen et al. 
2003b). Selection of gates was as described elsewhere (Summerfield et al. 2001). This permitted the 
identification of the T-cell subpopulations as CD3+CD4+CD8- naïve Th cells, CD3+CD4+CD8+ as 
memory/activated Th cells, CD3+CD4-CD8+ as Tc cells, CD3+CD4-CD8low//-.as  T cells. NK cells 
were defined as CD3-CD4-CD8+ cells.  
 
2.14. Quantification of viral load in experimentally infected pigs  
Total RNA was extracted from 100 µl serum and nasal swab samples with QIAsymphony® SP 
robot using QIAsymphony® RNA Kit with protocol RNA CT 400 v.5 and elution volume 100 µl 
according to instructions from the supplier (QIAGEN). Known PRRSV positive samples and 
negative controls were included in each 24-sample batch of RNA purifications. Extracted RNA was 
stored at -80˚C. 
For real-time RT-PCR, the previously published “Kleiboeker mod-1” primers and probe 
targeting Type 2 PRRSV ORF7, 3’UTR (Wernike et al. 2012) were used. The PCR mix contained 2 
µl template RNA, or nuclease free water (Amresco, Medinova, Denmark) for no template controls 
together with 10 µl nuclease free water (Amresco, Medinova, Denmark), 5 µl 5x QIAGEN OneStep 
RT-PCR buffer (QIAGEN®, Cat. No. 210215), 1 µl dNTP mix [10 mM each], 0.75 µl primer 
NAfw 5’-ATRATGRGCTGGCATTC-3’ [10 pmol/µl], 0.75 µl primer NArev 5’-
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ACACGGTCGCCCTAATTG-3’, 0.5 µl dual labeled probe 5’-TEX-
TGTGGTGAATGGCACTGATTGACA-BHQ2 [10 pmol/µl] and 1 µl QIAGEN OneStep RT-PCR 
Enzyme Mix. Amplifications were performed on RotorgeneQ (QIAGEN®) with temperature 
profile: 30 min at 50˚C for reverse transcription followed by 15 min at 95˚C, and 45 cycles of 15 
sec at 94˚C, 60 sec at 60˚C and 10 sec of 72˚C.  Fluorescence signals were collected during the 
extension step of each cycle in the Yellow channel and analyzed with Rotor-Gene Q software 
version 2.0.2 (QIAGEN) setting NTC threshold at 10 % and the normalised fluorescence threshold 
limit at 0.01 for cycle threshold (Ct) value determination starting normalising from cycle 2. Samples 
were tested in duplicates, and determined positive when both replicates were positive with a Ct less 
than 37. 
Quantifications of viral load in experimental samples were performed against standard curves 
matching each of the inoculation virus isolates and imported into each RT-PCR run with adjustment 
according to a PRRSV RNA calibrator sample included in triplicate in each real-time RT-PCR run. 
Standard curves for quantification of DK-2010-10-13-1 virus were obtained using a five-fold 
dilution series of 5.9 log10 TCID50/ml of DK-2010-10-13-1 inoculum virus isolate spiked 1:100 
into PRRSV negative swine serum and nasal swab material, respectively. RNA was extracted from 
each spiked dilution and tested in triplicate by real-time RT-PCR in at least two independent PCR 
experiments. The serum and nasal swab standard curves had respectively a PCR efficiency of 97 % 
(R2 = 0.99, slope = -3.398) and 91 % (R2 = 0.99; slope = -3.547) and their range of quantification 
covered 7 and 6 log5 dilution steps corresponding to concentrations 0.5 - 8.0E+03 and 0.52 – 
8.1E+03 TCID50/ml equivalents. Similarly, standard curves for quantification of DK-1997-19407B 
virus in serum and nasal swabs were produced by spiking of 5.4 log10 TCID50/ml DK-1997-
19407B inoculum virus isolate in PRRSV negative serum and nasal swab material. They had PCR 
efficiencies 98 % (R2 = 0.98; slope = -3.374) and 93 % (R2 = 0.99; slope = -3.909), respectively, 
and both covered 6 log5 dilution steps corresponding to concentrations 0.5 - 1.4E+03 and 0.14 – 
2.3E+03 TCID50/ml equivalents, respectively. 
 
2.15. Serology 
Antibodies in sera from experimentally infected pigs were analyzed using a PRRSV genotype 
discriminating IPMA (Sorensen et al. 1997) and a genotype discriminating blocking ELISA 
(Sorensen et al. 1998). For IPMA, the serum was initially diluted 1:50 and then tested using a 
fivefold dilution series (1:50-1:6250). The results were expressed as the highest dilution generating 
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a positive signal (titer). In ELISA, the serum were tested diluted 1:2 and the results expressed as 
blocking percentage (OD %). A sample was considered positive if the OD percentage was below 
44. 
 
2.16. Acute phase proteins 
Plasma levels of haptoglobin was determined by a sandwich ELISA using an in-house mouse 
anti-porcine haptoglobin monoclonal antibody as catching antibody and a commercial rabbit anti-
human haptoglobin detection antibody (DAKO A0030, DAKO, Glostrup, Denmark) as previously 
described [REF1] . CRP was analyzed by a sandwich type ELISA using dendrimer-coupled cytidine 
diphosphocholine (a CRP-binding ligand) in the coating layer as described in [REF4] employing 
polyclonal rabbit anti-human antibodies with cross-reactivity towards porcine CRP followed by 
peroxidase-conjugated goat anti rabbit antibody for detection (both antibodies from DAKO, 
Glostrup, Denmark).  
 
2.17. Statistics 
Unpaired t-tests with 95 % confidence interval were performed for the comparisons of responses 
between groups using GraphPad Prism version 5.00 for Windows, GraphPad Software, San Diego 
California USA, www.graphpad.com. 
 
3. Results 
 
3.1. Screening of case samples for PRRSV by real-time RT-PCR 
All nine lungs from 10 days old piglets collected in connection to the initial clinical signs in 
November 2010 were found positive for Type 2 PRRSV by real-time RT-PCR screening. Two 
lungs from mummified fetuses and three lungs and one pleura sample from stillborn piglets in 
February 2011were positive for Type 2 PRRSV by real-time RT-PCR.  One lung from stillborn 
piglets and 9 lungs from mummified fetuses collected in March 2011 were also positive for PRRSV 
Type 2.  
 
3.2. Genetic and antigenic analysis of NSP2 (partial), ORF5, and ORF7 
ORF5 and ORF7 were sequenced from all nine lungs obtained from the 10 days old piglets in 
November 2010. These case viruses were almost (>99.2%) identical both genes. The pairwise 
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nucleotide sequence identity between ORF5 and ORF7 of these viruses to Ingelvac PRRS MLV 
was 97.2-97.4 % and 98.6 %, respectively. Alignment of the deduced amino acid sequence of ORF5 
revealed some amino acid variations in the glycoprotein 5 (GP5) of the case viruses compared to the 
vaccine strain and other Danish PRRSV Type 2 viruses (fig. 1). Some of the variations in GP5 of 
the case viruses were also present in the high pathogenic (HP) PRRSV strains from China. The HP-
PRRSV strains from China had also showed to harbor a discontinuous deletion of 1 plus 29 amino 
acids in the non-structural protein 2 (nsp2), encoded in ORF1a of the PRRSV genome (Tian et al. 
2007). The variations in GP5 of the case viruses led to the sequencing of a partial part of the coding 
region of NSP2 including the region where the Chinese HP-PRRSV strain had deletions. The amino 
acid alignment of partial nsp2 encoded by the case viruses and three Chinese HP-PRRSVs are 
shown in fig. 2. The case viruses did not harbor the same deletions as the HP-PRRSV strains, but 
instead a 3 amino acid deletion was detected. Blast searches did not reveal any published viruses 
harbouring this 3 amino acid deletion in nsp2 of Type 2 PRRSV. Besides the 3 amino acid deletion 
in nsp2 several amino acid variations were detected compared to the vaccine strain (fig. 2). The 
pairwise nucleotide sequence similarity of partial NSP2 to the vaccine strain was 94.3-95.0 %. 
Comparison of ORF5, ORF7, and partial NSP2 sequences obtained from viruses from the initial 
infection in November 2010 to the sequences obtained from mummified fetuses and stillborn piglets 
approximately 12 weeks later confirmed that it was the same virus strain still circulating in the pig 
herd. Thus, the pairwise nucleotide sequence identities between the two viruses were for ORF5, 
ORF7, and partial NSP2 99.3-99.8 %, 99.7-100 %, and 99.2-100 %, respectively. The amino acid 
alignments shown in fig. 1 and fig. 2 further confirmed the similarity of these viruses with 98.5-100 
%, 100 %, and 98.8-100 % pairwise amino acid identities in GP5, N, and partial nsp2 respectively. 
 
3.3. Complete genome sequence comparison 
Complete genome sequences were obtained from PRRSV extracted from lung tissue and pleura 
submitted in November 2010 (DK-2010-10-13-1) and February 2011 (DK-2011-88005-A8-Pl). The 
complete genomes were 15,402 nucleotides long (excluding the poly(A)-tail) and the pairwise 
nucleotide identity between the two genomes was 99.7 %. The identity to the vaccine strain was 
97.8 - 97.9 %. Apart from the 9 nucleotides in NSP2 no further deletions was observed.  
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3.4. Clinical signs and body temperature 
Generally, all pigs remained healthy throughout the experimental period, and only very few 
deviations from normal health was seen (data not shown). Pig no 7, which was slightly lethargic, 
had increased respiratory rate at eating and showed increased body temperature (40.2°C) on DPI 18, 
only. Short (1-3 days) episodes with semi-liquid feces were observed occasionally in all groups. 
Increased body temperatures (fig. 3) could be related to restraint of pigs or to the episodes with 
semi-liquid feces for some of the pigs in group 4. 
 
3.5. Gross pathology  
At necropsy, no lesions were seen in the control pigs (no. 1-4) and only minor lesions were 
revealed among the remaining pigs.  
In group 2, three pigs (nos. 5, 6, 8) were without lesions. Observed lesions were focal lobular 
condensation in the cranial lung lobe (no. 9) and mild enlargement of the tracheobronchial lymph 
nodes (nos. 7, 9, 10, 11). Pig no. 7 was pale and had chronic adhesive pleuritis and pericarditis. In 
three pigs (nos. 7, 10, 12), the spleen was mottled and/or the margins of the spleen were slightly 
depleted.  
In group 3, pigs nos. 15, 19 and 20 had no lesions. Findings were mild enlargement of the 
tracheobronchial lymph nodes (nos. 13, 14) and a mottled spleen with slightly depleted margins 
(nos. 16, 17). Pig no. 18 had a renal cyst.   
Two of the vaccinated pigs (group 4) were without lesions (nos. 22 and 26). Findings in the 
cranial lung lobes were focal- (no. 21) or multifocal (no. 25) areas of condensation, and in the 
dorsal lung lobes ecchymotic hemorrhages (no. 24) and areas of collapsed lung tissue (atelectasis) 
(no. 27) was seen. In two pigs the margins of the spleen were slightly depleted (no. 23, 28). 
 
3.6. Total WBC counts and blood leukocyte phenotyping 
Total WBC counts were decreased at DPI 3 in pigs in groups 2 and 3 (fig. 4).  This decrease was 
reflected by a reduction in absolute lymphocyte counts, caused by significantly reduced levels of B 
cells in both groups together with decreased numbers of CD8+ cells (TC and NK cells) in group 2 
pigs. At DPI 14, all values have returned to levels approximately corresponding to DPI 0 levels. For 
the remaining blood leukocyte subtypes, no significant differences were observed among the groups 
(data not shown). 
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3. 7. Real time RT-PCR on PRRSV 
PRRSV was detected by real-time RT-PCR in all pigs inoculated with virus (groups 2-4). The 
viremia peaked at DPI 7 (fig. 5), but the viral load was significantly lower and of much shorter 
duration in the vaccinated group (gr. 4) compared to the unvaccinated animals (p= 0.04). In groups 
2 and 3, the mean viral load reached approximately 3 log10 TCID50 equivalents and PRRSV 
remained detectable until the end of the experiment at DPI 28. The mean viral load was, however, 
higher the group of pigs inoculated with DK-2010-10-13-1 than with DK-1997-19407B at DPI 10 
and 14 although not statistically different. Low levels of PRRSV were detected at DPI 0 in serum 
from 4 out of the 8 pigs in the vaccinated group and these results were reproduced from a second 
RNA extraction from the same serum samples. Contrary, none of the pigs in the other groups were 
positive by real-time RT-PCR at DPI 0.  
 Virus excretion in nasal swabs peaked with approximately 1 log10 TCID50/ml equivalents at 
DPI 7 for the virus inoculated and unvaccinated groups of pigs and rapidly declined (fig. 6). Virus 
was detected in nasal swab samples from all pigs in the virus inoculated non-vaccinated groups 
starting at DPI 3. In the group of pigs inoculated with DK-1997-19407B, virus was detected until 
DPI 7 in 3 pigs, until DPI 10 in 4 pigs, and until DPI 14 in one pig. The DK-2010-10-13-1 
inoculated pigs were positive for virus in their nasal swab samples until DPI 10 for 6 pigs, one pig 
was positive until DPI 14 and the last pig in that group only had detectable levels of virus at DPI 21. 
In the vaccinated group, only two out of the eight pigs showed detectable levels of virus in nasal 
swabs, and only at DPI 10.  
 
3.8. Serology  
In ELISA, all animals were clearly negative at day -28 and only vaccinated animals (group 4) 
were positive at DPI 0 (fig. 7). Following the inoculation at DPI 0, all animals in groups 2-4 
seroconverted at DPI 7 followed by a steady increase in level of antibodies that remained high until 
the end of the study at DPI 28. A similar development in IPMA titers were observed (fig. 8), 
however the animals in group 2-4 seroconverted at DPI 14 in IPMA compared to DPI 7 in ELISA. 
 
3.9. Acute phase protein measurements 
The acute phase responses were included as an objective measure of the severity of infection. 
Results from measurements of the acute phase proteins C - Reactive Protein (CRP), and 
haptoglobin are shown in fig. 9 and 10, respectively. The unvaccinated and PRRSV inoculated 
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groups of pigs (groups 2-3) showed a clear CRP response following inoculations at DPI 0, peaking 
on DPIs 7 and with a second peak at DPI 21 (group 2 only). Similarly, haptoglobin peaked at 
around DPI 10 in both groups. The CRP and haptoglobin responses of the pigs in the vaccinated 
group were similar to the responses of the pigs in the sham inoculated control group and showed 
some random increases and decreases throughout the observations period. 
 There was a significant difference in haptoglobin concentration between group 1 (controls) and 
group 2 when using an unpaired t-test with 95 % confidence interval (p=0.04) (fig. 10).  No other 
significant differences were seen between the groups. 
 
4. Discussion 
The aim of the study was to perform a genetic characterisation of a PRRS virus isolated from a 
herd with severe reproductive and respiratory symptoms and to compare the “virulence” of the virus 
with an older Danish Type 2 isolate in vivo. Although the case strain DK-2010-10-13-1 had some 
unique genetic features it was overall very similar to the vaccine strain and to older Danish Type 2 
isolates. Furthermore, the virus induced no overt clinical signs in pigs following intranasal 
inoculation.  
Terms such as “high and low pathogenicity”, “high and low virulence”, and “hot strains” are 
often interchangeable used to allocate PRRSV isolates into pathotypes, but efforts to link specific 
genetic motifs to different biological and immunological features has so far been unsuccessful. 
Thus, until now no clearly defined molecular marker of virulence have been established for PRRSV 
(Opriessnig et al. 2002; Wu et al. 2009) . The 1 + 29 amino acid deletions seen in the nsp2 of High 
pathogenic PRRSV stains in China were at first believed to be a virulence marker, however, 
experimental infections performed with chimeric infectious clones and the finding of a low 
pathogenic field virus also harboring deletion at the same positions has subsequently shown that 
this unique discontinuous deletion was not directly related to virulence (Zhou et al. 2009; Li et al. 
2010). The nucleotide sequences revealed that the DK-2010-10-13-1 strain was 96.9-97.4 % and 
94.3-95.0 % identical to the vaccine strain in ORF5 and partial NSP2, respectively. The pairwise 
nucleotide identity between the sequences obtained from the viruses from the initial infection and 
those obtained approximately 12 weeks after were 99.3-99.8 %, 99.7-100 %, and 99.2-100 % 
identical in ORF5, ORF7, and partial NSP2, respectively. Taken together, these results documented 
that it was the same strain that was isolated 3 months apart, that this strain was different from the 
vaccine strain and that the strain belonged to the same group of Type 2 PRRS viruses found 
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elsewhere in Denmark (Kvisgaard et al. 2013a). The DK-2010-10-13-1 strain had a deletion of three 
amino acids in nsp2 not previously described for any Type 2 strains (Kvisgaard et al. 2013a). This 
unique 3 amino acid deletion was also present in viruses collected from 6 of 14 Danish pig herds 
(accession no. KF311033-57) (unpublished data).  Five of these where isolated in 2010 and 2012 
and one was collected in 2003. It is not known if these herds experienced very severe clinical signs 
so the use of this 3 amino acid deletion as a predictor/marker of virulence is not sustained by the 
available data.  
Results of previous studies supported the concept that the magnitude and duration of viraemia is 
the best indicator of the “virulence” of a given PRRSV strain, however, a direct quantitative 
relationship between virulence and viral load has not been established (Haynes et al. 1997; Johnson 
et al. 2004; Weesendorp et al. 2013). In the present study, the level of virus were higher from DPI 3 
and onwards in pigs infected with the DK-2010-10-13-1 virus in comparison to the older Danish 
DK-1997-19407B strain, however, the differences were not significant. Furthermore, the viraemia 
were of shorter duration and lees pronounced than described for other strains of PRRSV causing 
significant clinical disease and mortality in experimental trials (Johnson et al. 2004; Weesendorp et 
al. 2013). Thus, it is doubtful if these differences in duration and magnitude of viraemia between 
the case strain and an older Danish Type 2 strain can explain the severe clinical signs and 
mortalities seen in the herd from which this strain was isolated. On the contrary, the more 
pronounced reduction of B and CD8+ cells in animals inoculated with the older Danish isolate, 
indicated that the older Danish strain were more virulent than the case strain. 
Neither overt clinical signs nor mortalities were seen in the present study albeit the pigs were 
indeed infected as documented by the significant acute phase protein responses and the 
development of antibodies against PRRSV.  There are many possible explanations for differences in 
clinical impact in the field and in experimental set up`s. The virus used for the experimental 
infection was initially recovered from a foetus thus it is possible that more severe signs could 
evolve if a transplacental infection model had been used. Furthermore, others have previously failed 
to provoke severe clinical disease under experimental conditions with PRRSV isolated from 
severely affected herds (Halbur et al. 1996) probably because the clinical impact are influenced by 
other factors in the herd such as co-infections with swine influenza virus, PCV2, Mycoplasma and 
secondary bacterial infections (Harms et al. 2001; Schmitt et al. 2001). Indeed, the temporary 
decrease of total lymphocytes and B cell numbers in both unvaccinated groups of pigs indicated a 
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state of immunosuppressant following infection which may prone the animals for secondary 
infections. 
The unchanged blood parameters and the lack of acute phase responses observed after infection 
of the vaccinated pigs indicated a protective effect of the vaccine against infection with the case 
strain despite the nucleotide difference between the vaccine isolate and the case strain was ranged 
from 3 to almost 6 % in some genes. Indeed, the viral load in serum was significantly higher and of 
longer duration in the groups of non-vaccinated virus inoculated pigs than in the group of 
vaccinated pigs. Similarly, the vaccinated group of pigs had significantly reduced virus excretion in 
nasal swabs, and only 2 out of 8 pigs had virus at detectable albeit low levels of virus at DPI 10, the 
remaining pigs were negative throughout the experiment. These results documented that vaccination 
with the Ingelvac® PRRS MLV vaccine (Boehringer Ingelheim Animal Health; Ingelheim, 
Germany) reduced viremia and excretion of the virus, thus being effective of limiting the impact of  
the DK-2010-10-13-1 case virus and would be expected to be effective in the control of an outbreak 
with this and related viruses. These findings are in accordance with the finding that the vaccine was 
used effectively in the control of the  infected herd but contradicts the perception that a variability 
of more than 2% among field strain and vaccine strains results impair the of efficacy of the vaccine. 
In conclusion, under the condition of the present study, a PRRS virus isolated from a herd 
experiencing very severe clinical signs and significant mortalities, failed to induce comparable signs 
in an experimental set-up. Full genome sequencing of the isolate revealed that the isolate was very 
similar to other Danish Type 2 isolates. Combining these data indicate that the severe disease seen 
in the field are influenced by other factors than the virus and emphasize that research aimed at 
identifying virulence maker of PRRSV are highly needed. 
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Fig. 1. Amino acid alignment of GP5  
 
 
Fig. 2. Amino acid alignment of partial nsp2. Gray squares represents deletions 
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Fig. 3. Diagram of the mean body temperature measurements  
 
 
Fig. 4. Diagram of mean white blood cell (WBC) count 
 
 
Fig. 5. Mean viral load in serum quantified by real-time RT-PCR  
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Fig. 6. Diagram of mean viral load quantified by real-time RT-PCR  
 
 
Fig. 7. Results of the PRRSV blocking ELISA. A sample was considered positive when the blocking 
percentage was below 44% 
 
 
Fig. 8. Results of the IPMA analysis. The serum samples were tested in five dilutions (1:50-1:6250) and the 
results are expressed as the highest dilution given a positive signal 
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Fig. 9. Results of the CRP analysis (group means) expressed as ng/ML 
 
 
Fig. 10. Results (groups means) of the haptoglobin analysis expressed as µg/ML 
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DISCUSSION, CONCLUSION, AND PERSPECTIVES 
 
The main focus of this PhD project has been on the genetic diversity of the Porcine Reproductive 
and Respiratory Syndrome Viruses circulating in the Danish pig population. To accomplish this, 
optimization of the amplification method of smaller genes for cycle sequencing was performed and 
a method for sequencing the complete PRRSV genome from long range PCR fragments using next 
generation sequencing technologies was developed. Furthermore, an experimental study of a Type 2 
PRRS virus causing significant clinical disease in the field was carried out. The method for 
complete genome sequencing was used to sequence the case virus.  
In this project, traditional cycle sequencing based on the Sanger method (Sanger et al., 1977) 
was used for the sequencing of shorter regions of the PRRSV genome. For this purpose cycle 
sequencing was an obvious choice as it is fast and obtainable for most laboratories. However, cycle 
sequencing has its limitations when it comes to sequencing length and sequencing depths. To 
sequence the complete genome of PRRSV using cycle sequencing the genome has to be covered by 
PCR fragments of length adequate for this sequencing method (~900 bp). Due to the high diversity 
between PRRS viruses it is difficult to design conserved primers matching all PRRSV genomes, 
hence longer PCR fragments are preferred. When using next generation sequencing technologies 
the lengths of the PCR fragments are of no concern and long amplicons are applicable. So it was 
with the use of NGS technologies for sequencing in mind the method for long range PCR 
amplification was developed. First, the four-fragment amplification strategy was developed and 
then the idea came of using some of the primers from the four-fragment amplification to cover the 
PRRSV genome in only two PCR fragments. However, the amplification of PRRSV in two 
fragments does not work on all samples and the output may be lower than when amplifying the 
genome in 4 fragments and therefore are the majority of the complete genomes obtained during this 
PhD project from sequencing on four PCR fragments. The two fragment strategy may still be a 
good choice for some applications (cloning of the virus, quasispecies experiments, test for 
recombination etc.) however individual optimization for each virus to be sequenced may be 
necessary to gain a higher concentration of the PCR amplicons.  
The data output or depth of coverage obtained from next generation sequencing is the most 
pronounced improvement when comparing to cycle sequencing. From the three NGS platforms 
used during this project the average time a single nucleotide was read during the sequencing process 
were ~10,000 times for the Illumina HiSeq2000 and ~250 times for Roche 454 FLX and Ion 
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Torrent PGM™ Sequencer. The obtained sequencing depth can be increased for Roche and Ion 
Torrent by reducing the number of isolates pooled prior to sequencing although this will increase 
the cost per virus. The sequencing depth can be used to study genetic variation in relation to a 
reference sequence or the existence of quasispecies, however, precautions should be taken when 
determining this as the variations seen may have originated from errors induced during the RT and 
PCR steps and not during replication of the virus in the host. New quasispecies may also be 
introduced when propagating PRRSV in vitro. Protocols exist that generate complete genomes 
using NGS performed directly on RNA without an amplification step. In most cases this procedure 
requires, however, that the virus have been propagated. The method described here allows full 
length sequences to be generated directly from tissue or serum and do not require a large virus load 
to be present. 
From the study of Type 1 PRRS viruses circulating in the Danish pigs, it was confirmed that 
only subtype 1 is present in Denmark. However, the diversity between the Type 1 PRRS viruses 
was relatively high and phylogenetic analysis of ORF5 and complete genomes showed that the 
Danish Type 1 PRRS viruses divided into two clusters, one LV/vaccine-like strain and one 
resembling an early introduced strain. The vaccine-like strain was the dominating type of Type 1 
PRRSV following the introduction of Porcilis PRRS in the beginning of 2001. 
The study of Type 2 PRRS viruses was a priority as Denmark was the first country in Europe to 
be infected with this genotype in relation to a vaccination program with a live attenuated vaccine 
(Botner et al., 1997, Madsen et al., 1998). Furthermore, it was interesting to study the evolution of 
the vaccine strain in a country with minimal import of living pigs. Only a scarce number of Type 2 
PRRSV ORF5 sequences obtained from viruses isolated in Europe have been published (Stadejek et 
al., 2013) and no complete sequences have been sequenced and published before the present PhD 
project started. From the diversity study of Danish isolated Type 2 PRRS viruses it was found that 
they all were classified to a single cluster (sub-lineage 5.1 (Shi et al., 2010b)) which comprised 
strains closely-related to the Type 2 protogenotype isolate VR2332 and the modified live vaccine 
strain. However, the diversity between the Danish viruses was as high as 9.1 % indicating 
pronounced genetic drift of Danish Type 2 PRRS viruses. 
From the results obtained from both diversity studies there were no indications of new 
introductions of PRRSV strains into the Danish pig population and on the basis of these finding the 
currently used diagnostic tools should be able to detect the PRRS viruses infecting the Danish pigs. 
However, an important point that has to be considered is that currently the only method used for 
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virus detection is real-time RT-PCR. If a diverse PRRSV stain is introduced, the standard primer 
and probes may not detect the new virus. Before implementing real-time RT-PCR as a diagnostic 
tool for detection of PRRSV, virus detection was carried out by inoculation on cell cultures 
followed by immunohistochemical staining. However this method has disadvantages as well, 
besides being slow and time-consuming, not all PRRS viruses are able to proliferate in vitro either 
due to incorrect handling of the sample material from the herd to the laboratory or because the virus 
is not adaptable to cell cultures. To overcome both scenarios, both methods could be implemented 
in the diagnosis of PRRSV. Another solution could be to develop a multiplex PCR assay where 
several primer pairs and probes that were able to cover a broader range of variant templates where 
used. To design primer and probes that fulfills this, it is very important to be aware of which viruses 
circulating in other countries as well and also participation in ring tails are indispensable. This 
further signifies the importance of continuing surveillance of the diversity of PRRSV also after this 
PhD study and the end of the EU project in 2014. Hopefully the industry is willing to support this 
activity. 
 PRRS is a notifiable disease in Denmark in case the virus has been detected by real-time RT-
PCR, culturing or detection of antibodies against PRRSV in serum or pleura obtained from stillborn 
fetuses or piglets before ingestion of colostrum. As a consequence, the herd cannot deliver pigs to 
normal slaughterhouses for six months which leads to significant economical losses. These 
regulations do not apply for detection of antibodies in adult pigs. These regulations causes the field 
veterinarians and pig producers to hesitate submitting samples for virus detection, hence the 
numbers of acute infected herds in Denmark may be higher than what is believed on the background 
of positive cases determined from virus detection by real-time RT-PCR. Since most Danish herds 
use serology even for diagnosis of acute cases of PRRSV further characterization of the virus 
isolates by sequencing are not possible. Thus, a new variant of PRRSV could easily escape 
detection in Denmark, emphasizing that some degree of active surveillance is needed.  
During the course of the PhD project a natural infection with Type 2 PRRSV occurred in the 
Northern part of Denmark. This herd experienced significant clinical signs including reproductive 
failures in sows and high mortality rates for weak born piglet. On the basis of the clinical signs, it 
was feared that a new and more virulent strain of PRRSV was introduced into Denmark. In 
connection to this infection, the newly developed methods showed its importance and practical 
applicability. Sequence analysis on samples from this herd revealed that the strain was similar to 
other Danish viruses but also that it had some special genetic features in some minor genes. 
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Subsequently an experimental infection with this strain revealed that the infection dynamic was 
similar to circulating classical Danish Type 2 strains. This case underlined perfectly that methods 
for fast and reliable sequencing of PRRSV isolates are important tools for the elucidation of unusual 
events that in turn could treating the important export of living pigs and pork product to PRRSV 
“sensitive” countries such as Brazil and China.     
In conclusion, the results obtained during this project showed homology between viruses within 
the same genotype. On this background there is no reason to question the ability of the currently 
used diagnostic tools to detect PRRSV and the available vaccines should also be protective against 
present day Danish PRRS viruses. However, the genetic heterogeneity between the two genotypes, 
Type 1 and Type 2, are so distinct that perhaps PRRSV Type 1 and PRRSV Type 2 should be 
regarded as two different viruses. This heterogeneity is also very pronounced in an antigenic 
manner, as amino acid compositions at neutralizing epitopes greatly differs. Recombination 
between PRRS viruses have been documented on several occasions (Chen et al., 2013, Forsberg et 
al., 2002, Frossard et al., 2013). However, proof of recombination between Type 1 and Type 2 
PRRSV strains has of this date never been published and since recombination preferentially occurs 
between genomes with high similarity it further demonstrate the differences between the PRRSV 
genotype 1 and 2.  
A future study regarding PRRSV could be to pursue the thought of dividing Type 1 and Type 2 
into two distinct PRRS viruses. Recombination studies should be performed in vivo and in vitro, 
using co-infection with both genotypes followed by analysis of recombination between the two 
viruses using the described methods for complete genome sequencing. A resembling in vitro study 
has been carried, however only a small region was sequenced and no indication of recombination 
between Type 1 and Type 2 was detected (van Vugt et al., 2001). 
A further optimization of complete genome sequencing directly from RNA preferable extracted 
from primary infected material offer a new and unique tool to study the genetic variation and 
quasispecies even without cDNA steps.  
One of the milestones in understanding PRRS would be to identify virulence marker(s). From the 
complete genome analysis and experimental infection with a case virus given severe clinical disease 
in the field, failed to identify a virulent marker. This further underlines the difficulties in predicting 
the outcome of PRRS and more than one field incident of significant clinical disease are needed to 
be able to compare viruses. To investigate potential virulent markers it is of great importance that 
the clinical signs of the virus in the field are known together with information on co-infections in 
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the herd. Luckily, the National Veterinary Institute already have a splendid collaboration with the 
Danish field veterinarians and information of the clinical signs incurred from recently infected 
herds should be obtainable.  
Reverse genetics could also be a very interesting field to further investigate the virulence of 
PRRSV by testing specific motifs identified in hot field strains. 
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APPENDIX I 
 
Introduction to own work 
In the following sections thorough descriptions of the laboratory methods used during the PhD 
project are presented. All the described methods, together leads to the main objective of the study: 
to investigate the genetic diversity of PRRSV circulating in Danish pigs.  
 Methods 
Marc-145 cells 
One ampule of frozen Marc-145 cells (1.6 x106 cells/ml) was thawed on a 37°C water bath. 
Immediately after, the thawed cell suspension was transferred to a 15 ml Nunc tube added 10 ml 
wash medium (app. I. table 1). The cell suspensions were centrifuged at 700 x g for 15 minutes. The 
supernatant was discarded and the cell pellet was resuspended in 40 ml initial growth medium and 
transferred to 160 ml cell culture flask. The cells incubated in a cell incubator at 37°C and 5 % CO2. 
It took 1-2 days for the cells adhere. The 10 % FCS maintenance medium (app. I. table 1) was 
changed every second day.  
When confluent the cells were trypsinized. First the cell culture medium was discarded and the 
cells were rinsed 3 x 3 ml 100µg/ml Trypsin. Following the third rinse, 1 ml of Trypsin was left in 
the cell culture flask and the cells incubated at 37°C until they had loosened. The cells were added 5 
ml of maintenance medium and 1 ml cell suspension (1:6 split) was transferred to a new cell culture 
flask containing 40 ml of 10 % FCS maintenance medium. The cells were incubated in a cell 
incubator at 37°C and 5 % CO2. The cells adhered within 24 hours. Cells of a 1:6 split usually takes 
5 days to grow to confluence. 
Freezing Marc-145 cells for back-up/storage was done by transferring trypsinized cells to a 50 
ml tube added 40 ml wash medium. The cell suspension was mixed by roughly pipeting up and 
down. The cells in suspension were counted using a hemocytometer and the rest of the cell 
suspension was centrifuged at 700 x g for 15 minutes. The cell pellet was resuspended in freezing 
medium (app. I. table 1) to a final cell concentration of approximately 1.5 x 106 cells/ml. The cell 
suspension was divided in 1 ml aliquots to cryotubes. The cell aliquots were stored at -80°C for 24 
hours following transfer to N2-tank for storage. 
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App. I. table 1. Cell culture media for continuous cell lines 
MEM cell medium 
FCS final 
conc. (%) 
L-glutamine 
final conc. 
(mM) 
NEAA 
final conc. 
(%) 
Pen/strep 
final conc. 
(mg/ml) 
DMSO 
final conc. 
(%) 
Wash medium 2 - - - - 
Initial growth medium 20 2 1 0.1 - 
Maintenance medium 5/10 2 1 0.1 - 
Freezing medium 20 - - - 10 
 
Porcine alveolar macrophages 
The PAM ampules were transported on dry ice from the N2-tank to the cell laboratory. The 
frozen PAM ampules were quickly thawed on a pre-heated 37°C water bath. Immediately following 
thawing the PAMs were divided between two 50 ml tubes containing 30 ml wash medium (app. I. 
table 1) and centrifuged at 1000 x g for 10 minutes, 4°C. Following centrifugation the supernatant 
was discarded and the cell pellet was resuspended in 5 % FCS maintenance medium (app. I. table 1) 
to the cell concentration needed. For propagation of PRRSV, the cell suspension was prepared as a 
2.0 x 106 cells/ml. After adding the PAM suspension to e.g. 24-well cell culture plates, the cells 
were incubated in a cell incubator at 37°C and 5 % CO2 for 1 hour where after the cells had settle 
and ready for inoculation with PRRSV. 
Propagation of PRRSV on PAM and Marc-145 cells 
For inoculation on PAMs, cells were seeded at the concentration of 2.0 x 106 PAMs/ml. For 
inoculation on Marc-145 cells, the cells had to be confluent or close to. 
 
Inoculation material: 
Pleura: dilute 1:5 in MEM supplemented with 10 x pen/strep. 
Lung: homogenize tissue in 1:10 MEM supplemented with 10 x pen/strep. 
Serum: use as it is, although serum is not the best inoculation material for propagation of 
PRRSV. 
All inoculation materials were sterile filtrated through a 0.45 µM sterile filter. 
For inoculation in 24-well plates lung and pleura was added in 200µl/well and serum was added 
in 50µl/well. 
Following inoculation with the sample material, cells incubated in a cell incubator at 37°C and 5 
% CO2. CPE could be seen 3-5 day after inoculation. When CPE was observed the propagation of 
virus was terminated by transferring the cell medium supernatant to storage tubes and stored at -
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80°C. A second passage could be carried out by transferring 50 µl of cell medium supernatant to 
new cells. 
To confirm propagation of PRRSV, RNA was extracted from the cell medium supernatant and 
screened by PriProET RT-PCR. 
Extraction of RNA 
Total RNA was extracted from lung tissue, pleura, nasal swabs, serum, and cell culture 
supernatant using commercial RNA purification kits from QIAGEN. 
 
Lung tissue was homogenized as follows: 
1. RLT buffer (included in RNeasy Minikit, QIAGEN) was added β-mercaptoethanol to a 1 % 
concentration. 
2. 2 ml tubes were prepared with one 5 mm steal beads per tube and 1400 µl RLT- β-
mercaptoethanol buffer. 
3. 70 mg lung tissue was cut into small bits and added the 2 ml tubes 
4. The lung tissue was homogenized using Tissuelyser II (QIAGEN) for 3 minutes at 30 Hz. If 
needed, the procedure was repeated. 
5. The tubes were centrifuged at 12,000 x g for 3 minutes. 
6. Carefully the supernatant was pipette in two aliquots of 600 µl to new 1.5 ml eppendorf tubes. 
One tube was saved as back-up at -20°C. 
 
Total RNA extraction from lung homogenate, nasal swabs, and pleura using RNeasy Minikit 
(QIAGEN): 
Positive controls were prepared from 200 µl PRRSV cell culture supernatant added 400 µl RLT- 
β-mercaptoethanol buffer. 
Negative controls were prepared from 200 µl RNAse free water added 400 µl RLT- β-
mercaptoethanol buffer. 
Nasal swabs and pleura samples were prepared from 200 µl material added 400 µl RLT- β-
mercaptoethanol buffer. 
1. Each sample (600 µl) was added 1 vol. 70 % EtOH and mixed by pipeting. 
2. 700 µl sample was added the RNeasy mini column and centrifuged at 8,000 x g for 15 
seconds. The flow-through was discarded and the rest of the sample material was added the column 
and the centrifugation was repeated. 
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3. 700 ml RW1 buffer was added to the column. The samples were centrifuged at 8,000 x g for 
15 seconds. The flow-through was discarded. 
4. 500 µl RPE buffer was added the column and centrifuged at 8,000 x g for 15 seconds. The 
flow-through was discarded. 
5. An additional 500 µl RPE buffer was added the column and centrifuged at 8,000 x g for 2 
minutes. The flow-through was discarded. 
6. Centrifuged the column at 12,000 x g for 1 minute followed by transfer of the column to a new 
1.5 ml eppendorf tube. 
7. 60 µl RNAse free water was carefully added to the center of the column and incubated for 1 
minute at RT. The RNA was eluted by centrifugation at 8,000 x g for 1 minute. 
8. The purified RNA was stored at -80°C or evaluated by PriProET RT-PCR. 
 
Total RNA extraction from serum and cell culture supernatant using QIAamp Viral Minikit 
(QIAGEN): 
1. 140 µl serum or cell culture supernatant were added to 1.5 ml eppendorf tube. 
2. 310 µg carrier RNA was dissolved in 310 µl AVE buffer (1 µg/µl). 
3. The volume of AVL buffer needed for the RNA extraction and how much carrier RNA to add 
was calculated using the following equations: 
 
 n x 0.56 ml = y ml 
 y ml x 10 µg/ml = z µl 
n = number of samples to purify + 2 
Y = total volume of AVL buffer 
z = volume of 1 µg/µl carrier RNA to add to the AVL buffer 
 
4. 560 µl AVL-carrier RNA buffer was added to the tubes containing the sample material and 
incubated for 10 minutes at RT. 
5. The samples were centrifuged shortly. 
6. 560 ml EtOH was added the samples and mix by pulse-vortex for 15 seconds. 
7. 630 µl sample material was transferred to the QIAamp Viral RNA mini column and 
centrifuged at 6,000 x g for 1 minute. The flow-through was discarded. 
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8. The rest of the sample material was added to the column and the centrifugation step was 
repeated. 
9. 500 µl AW1 buffer was added to the column and centrifuged at 6,000 x g for 1 minute. The 
flow-through was discarded. 
10. 500 ml AW2 buffer was added to the column and centrifuged at full speed for 3 minutes. The 
flow-through was discarded. 
11. The column was centrifuged at full speed for 1 minute following transfer of the column to a 
new 1.5 ml eppendorf tube. 
12. 60 µl RNAse free water was carefully added to the center of the column and incubated at RT 
for 1 minute. The RNA was eluted by centrifugation at 6,000 x g for 1 minute. 
13. The purified RNA was stored at -80°C or evaluated by PriProET RT-PCR. 
 
Primer Probe Energy Transfer (PriProET) RT-PCR 
The extracted RNA was screened for PRRSV by a modified PriProET real-time RT-PCR assay 
(Balka et al., 2009). The real-time RT-PCR kit used was the Ultrasense onestep quantitative RT-
PCR system from Invitrogen. The real-time RT-PCR was carried out in a total reaction volume of 
25 µl containing 2 µl extracted RNA. The primer and probes used are listed in app. I. table 2, the 
mixture proportions of the PCR reaction mix is listed in app. I. table 3, and the RotorGeneQ real-
time PCR machine thermal cycle program is listed in app. I. table 4. 
 
  
App. I. table 2. Primer and probes used for screening RNA for PRRSV 
Name Orientation Sequence 5’-3’ 
Primer 1 Forward AGCCTCGTGYTGGGYGGCARA 
Primer 2  Reverse (FAM)-TCAGCAWYTGRCACAGYTGAT 
Probe Type 1 PRRSV Forward TCCGATGGGGAATGGCCAGCCAGTCT-(ATTO663) 
Probe Type 2 PRRSV Forward AAAGAAGGGGGATGGCCAGCCAGTCT-(ATTO663) 
Primer 1, Primer 2, and Probe Type 1 PRRSV sequences are from Balka et. al. (2009). Probe Type 2 PRRSV was 
designed by colleges in the virology group. 
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App. I. table 3. Ultrasense onestep quantitative RT-PCR system reaction mix 
Reagent Final concentration Volume (µl) 
RNAse free water  13.94 
RNA Ultrasense 5x reaction mix 1x 5.0 
Primer 1  (10 µM) 0.4 µM 0.31 
Primer 2 (10 µM) 1.0 µM 1.25 
Probe Type 1 or Type 2 (ATTO663) (10 µM) 1.0 µM 1.25 
RNA Ultrasense Enzyme Mix 1x 1.25 
Final volume   23.0 
 
 
App. I. table 4. The RotorGeneQ real-time PCR machine thermal cycle program 
PCR step Temperature °C Duration 
Calibration 55  
RT-PCR 50 30 minutes 
Denaturation 95 2 minutes 
50 cycles:   
Melt 95 15 seconds 
Annealing 55 30 seconds 
Elongation 72 20 seconds 
Hold 72 5 minutes 
Hold 95 60 seconds 
Melt 50°C -> 90°C w. 1°C rise per step  
 
 
The Ct values were determined and values below Ct: 38 was determined to be positive for 
PRRSV. From the melting curve and comparisons with the positive controls the PRRSV genotype 
could be deduced. 
cDNA synthesis 
Complete genome cDNA was synthesized from PRRSV RNA samples using SuperScript III 
First-Strand Synthesis System for RT-PCR from Invitrogen (Rasmussen et al., 2008, Rasmussen et 
al., 2010). 
Two mixtures were prepared as listed in app. I. table 5. Eight (8) µl RNA incubated with mixture 
1 at 65°C for 5 minutes. Then the PCR tube was placed on ice for 1 minute. Mixture 2 was added 
mixture 1 and the cDNA synthesis was carried out at 50 °C for 90 minutes followed by 85°C for 5 
minutes. The PCR tube was briefly centrifuged and added 1 µl RNase H. The RNase reaction was 
carried out at 37°C for 20 minutes. The cDNA was used for conventional PCR and stored at -20°C. 
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App. I. table 5. cDNA synthesis mixtures 
Reagents Volume (µl) 
  
Mixture 1:  
10 µM RT-primer (Nielsen et al., 2001) 1 
10 mM dNTPs 1 
Final volume 2 µl 
  
Mixture 2:  
10x RT buffer 2 
25 mM MgCl2 4 
0.1 M DTT 2 
RNAseOUT 1 
Superscript III RT 1 
Final volume 10 µl 
 
Conventional PCR  
Conventional PCR was carried out using the AccuPrime Taq DNA Polymerase High Fidelity Kit 
from Invitrogen and complete genome cDNA as template. Short and long range PCR amplicons 
were produced for cycle sequencing and next generation sequencing, respectively. Primers for the 
shorter PCR amplicons, ORF2-7 for Type 1 PRRSV and ORF5, ORF7, and partial NSP2 for Type 2 
PRRSV are listed in app. I. table 6. For the primer sequences for the long range PCR amplicons 
please see table 2 in Manuscript I. 
 
 
App. I. table 6. Primers used for ORF2-7, ORF5, ORF7, and partial NSP2 amplification 
Primer name Forward primer (5’-3’) Reverse primer (5’-3’) 
Type 1 PRRSV:   
ORF2-EU CTG GCA CAG AAT TGC AGG TA GCA CAC TGA TGA GCC ATT GT 
ORF2-3-EU TGC TCC GCG CTT CTC CGT TCG ACA TAG CGT AGA GCT GGA ATT CG 
ORF3-EU ACA ATG GCT CAT CAG TGT GC TGA AGC CTT TCT CGC TCA TT 
ORF4-EU AGC GTG ACC ATG ATG AGT TG AAA AGC CAC CAG AAG CAA GA 
ORF5b-EU TGA GGT GGG CTA CAA CCA TT AGG CTA GCA CGA GCT TTT GT 
ORF6-EU GTC CTC GAA GGG GTT AAA GC CTG TCC TCC CCT AGG TTG CT 
ORF7b-EU GGC AAA CGA GCT GTT AAA CG AAT TTC GGT CAC ATG GTT CC 
Type 2 PRRSV:   
ORF5-US GCT CCA TTT CAT GAC ACC TG AAA GGT GCA GAA GCC CTA GC 
ORF7-US GCC CCT GCC CAI CAC G TCG CCC TAA TTG AAT AGG TGA 
NSP2-partial CTT AAA GAC CAG ATG GAG GAG G CGA TGA TGG CTT GAG CTG AGT AT 
Primer sequences for Type 1 PRRSV were from Diaz et al. (2006). Primer sequences for ORF5-US and ORF7-US were 
from Oleksiewicz et. al. (1998). Primer sequences for NSP2-partial were from Zhou et al. 2009. 
 
The conventional PCR reaction was carried out in a final reaction volume of 50 µl containing 2 
µl cDNA template. The mixture proportions for the AccuPrime Taq DNA Polymerase High Fidelity 
Kit are listed in app. I. table 7. 
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App. I. table 7. AccuPrime Taq DNA Polymerase High Fidelity reaction mix 
Reagent Volume (µl) 
RNAse free water 40.5 
10x AccuPrime PCR buffer I 5 
Forward primer (10 µM) 1 
Reverse primer (10 µM) 1 
AccuPrime Taq High Fidelity 0.5* 
cDNA 2 
 50 µl 
*For PCR amplicons covering the PRRSV genome in two fragments 1 µl polymerase is used.  
 
 
The conventional PCR was carried out on a T3 Thermo cycler (Biometra) with the PCR cycling 
program as listed in app. I. table 8. The PCR products were analyzed by agarose gel electrophoresis 
using E-gel® 0.8 % or 2 % agarose gels from Invitrogen. Five µl of PCR product mixed with 7 µl 
1:40 TrackIt™ loading buffer (Invitrogen) were loaded onto the gel. 10 µl 1 kb Plus DNA ladder 
(Invitrogen) or 100 bp DNA ladder (New England BioLabs) was used as size marker.  
 
 
App. I. table 8. PCR cycling program for conventional PCR amplification 
PCR step Temperature (°C) Duration 
Denaturation 94 15 seconds 
45 cycles of:    
Melt  94 15 seconds 
Annealing 55* 30 seconds 
Elongation  68 1 minute per Kb elongation 
Hold  68 2 minutes per Kb elongation (min. 5 minutes) 
Hold 4 ∞ 
*The annealing temperature can be lowered to e.g. 52°C when amplifying long range amplicons covering the PRRSV 
genome in two fragments. 
 
 
Purification of PCR amplicons 
Prior to cycle or next generation sequencing, primers and buffers from the PCR reaction needed 
to be removed which was done by purifying the PCR products using Roche’s High Pure PCR 
Product Purification kit as follows: 
1.  The PCR reaction volume was adjusted to 100 µl with Milli Q water (MQ) in a 1.5 ml 
eppendorf tube. 
2. 500 µl Binding buffer was added the tube with the PCR reaction. 
3. The solution was mix by vortexing followed by a quick spin. 
4. The sample was transferred to a High Pure filter tube placed in a collection tube. 
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5. The sample was centrifuged at full speed for 1 minute and flow-through was discarded. 
6. 500 µl Wash buffer was added the filter tube and centrifuged at full speed for 1 minute. The 
flow-through was discarded. 
7. An additional 200 µl Wash buffer was added, the filter tube was centrifuged as before and the 
flow-through was discarded. 
8. The filter tube was transferred to a 1.5 ml eppendorf tube and carefully added 30 µl 50°C pre-
heated RNAse free water to the center of the filter and then incubate for 1 minute at RT. 
9. The PCR amplicon was eluted by centrifugation at full speed for 1 minute. 
10. The concentration of the purified PCR amplicon was determined using a spectrophotometer.  
For removal of unspecific PCR amplicons, PCR amplicon of the right molecular size was 
extracted from the gel. 
1. The PCR amplicon was cut from the gel and placed in a 1.5 ml eppendorf tube. 
2. 3 µl Binding buffer from the High Pure PCR Product Purification Kit (Roche) was added for 
each mg of gel slice. 
3. The mixture was vortexed and incubated at 56°C for 10 minutes with a brief vortex every 2-3 
minutes. 
4. Following dissolving of the gel slice the sample was added 1.5 µl isopropanol for every mg of 
gel slice. The sample was vortexed thoroughly. 
5. The rest of the purification followed from section 4 in the first purification protocol described. 
Cycle sequencing 
Cycle sequencing was used for the sequencing of shorter PCR amplicons, e.g. ORF2-7 and 
partial NSP2. 
The sequencing primers were the same as the primers used for the PCR amplification (app.  I. 
table 6). 
200 ng of purified PCR amplicon in 10 µl MQ was prepared with 4 µl 5 µM sequencing primer 
and send to LGC Genomics GmbH (Berlin, Germany) for sequencing. The obtained raw data was 
assembled into contigs using the commercial software CLC Main workbench v. 6.6.2 (CLC BIO, 
Aarhus, Denmark). 
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Next generation sequencing 
Complete genome sequences of PRRSV were sequenced from long range PCR amplicons 
covering the full genome in two or four fragments using next generation sequencing (NGS) 
technologies.  
For the sequencing of PCR amplicons covering the complete genome of PRRSV in two 
fragments, 2.7 µg in total of equimolar concentration were sent to LGC Genomics GmbH (Berlin, 
Germany) for sequencing on the platform Roche 454 FLX.  
The sequencing of PCR amplicons covering the PRRSV genome in four fragments, two NGS 
technologies were utilized; Illumina HiSeq2000 (ARK genomics The Roslin Institute, University of 
Edinburgh) and Ion Torrent GPM sequencer (DTU Multi-Assay Core (DMAC), Kgs. Lyngby, 
Denmark). 
 For sequencing on the Illumina® HiSeq 2000 platform, libraries were prepared from the 
Illumina® TruSeq™ DNA Sample Preparation v2 Kit A and B (Illumina®, cat. no. FC-121-2001-1 
and FC-121-2002) following the TruSeq DNA Sample Preparation v2 Guide with few 
modifications.  
 
Fragmentation of PCR amplicons: 
All 4 PCR amplicons covering the whole genome of one PRRS virus were pooled in equimolar 
quantity to a final amount of 1.1 µg and added 10 mM Tris-Cl, pH 8.5 to a final volume of 55 µl. 
The pooled PCR fragments were sheared  into fragments with an average size of 250 bp in a 
Covaris™ microTUBE with AFA fiber (Covaris, cat. no. 520045) on a Covaris™ S2 Ultra-
sonicator using the following settings: Duty cycle: 10 %, Intensity: 5.0, Cycles/Burst: 200, and 
Duration: 105 seconds.  
 
End repair: 
The dsDNA 5’ or 3’ overhangs generated from Covaris shearing was repaired with NEBNext® 
End Repair Module (New England BioLabs®inc., cat. no. E60510S). 50 µl of sheared PCR 
amplicons were mixed with 1 µl E. coli DNA Ligase for Fragmentase (New England BioLabs®inc., 
cat. no. M0348L), 10 µl NEBNext End Repair Reaction Buffer (10x), 5 µl NEBNext End Repair 
Enzyme Mix, and MQ water to a final volume of 100 µl. Incubate in a thermal cycler for 30 
minutes at 20°C following column purification using MinElute PCR Purification Kit (Qiagen, cat. 
no. 28004) eluting twice in 10 µl and 7.5 µl elution buffer.  
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Adenylate 3’ ends: 
To adenylate 3’ ends, 15 µl of purified end repaired sample was mixed with 12.5 µl A-Tailing 
Mix, and 2.5 µl Resuspension Buffer incubating at 37°C for 30 minutes.  
 
Ligate adaptors: 
To each sample 2.5 µl Resuspension buffer, 2.5 µl Ligation Mix, and 2.5 µl of specific DNA 
Adaptor index were added and mixed by gentle pipeting the entire volume up and down 10 times. 
The samples were incubated on a pre-heated thermal cycler at 30°C for 10 minutes. Following 
incubation the samples were added 5 ml Stop Ligation Buffer and mixed thoroughly by pipeting up 
and down 10 times. The samples were using MinElute PCR Purification Kit eluting twice in 10 and 
12.5 µl elution buffer.  
 
Size selection: 
For size selection the gel method was used. A 2 % Agarose-HR gel with GelRed was made as 
follows: 3 g Agarose-HR was added 150 ml 1x TAE buffer (40 mM Tris, 20 mM Acetic acid, 1 
mM EDTA, pH 8.0) and dissolved by heating in a microwave oven. Cool down a few minutes then 
add 15 µl 1x10.000 GelRed Nucleic Acid Stain (Biotium, cat. no. 41003) and swirl to mix. Load 20 
µl purified adaptor ligated sample with 7 µl loading buffer (50 mM Tris, pH: 8.0, 40 mM EDTA, 40 
% w/v sucrose) and 5 µl diluted (8 µl ladder + 3 µl loading buffer) TrackIt™ 1 kb plus ladder 
(Invitrogen, cat. no. 10488-085) and run the gel for 2 hours at 120 V constant voltage.  
Excise the band from the gel that corresponds to the size determined following fragmentation 
added the 100 bp for the ligated adaptors. Purify the gel slices using QIAquick Gel Extraction Kit 
(QIAGEN, cat. no. 28704) and elute in 25 µl elution buffer.  
 
Enrich DNA fragments: 
Proceeding to the enrichment of the DNA fragments by PCR. The samples were added 5 µl PCR 
Primer Cocktail and 25 µl PCR Master Mix and mixed well. The PCR reaction was carried out as 
follows: [98°C for 30 seconds], 12-16 cycles: [98°C for 10 seconds, 60°C for 30 seconds, 72 °C for 
30 seconds] then finalize with 72°C for 5 minutes and cool down to 10°C. Following enrich PCR, 
the library samples were purified using Agencourt AMPure XP beads (Beckman Coulter, cat. no 
A63881). Transfer the library samples to a 96-well plate. Vortex the Agencourt AMPure XP bead 
Appendix I 
 
165 
 
until well dispersed, then add beads 1:1 to library samples and mix well by gently pipeting. Incubate 
at room temperature for 15 minutes then place the plate on a magnetic stand for 2 minutes at RT or 
until the liquid appears clear. Remove and discard the supernatant with the 96-well plate still on the 
magnetic stand and wash the beads twice with 80 % freshly prepared EtOH. Remove the 96-well 
plate from the magnetic stand and let the plate stand at RT for 15 minutes to dry. Resuspend the 
dried pellet in 32.5 µl 10 mM Tris-Cl, pH 8.5 buffer and incubate at RT for 2 minutes. Place the 
plate on the magnetic stand for 2 minutes or until the liquid appears clear. Transfer 30 µl of the 
purified enrich PCR products to a new tube. 
 
Validation of libraries: 
 To verify the size and determined the approximate concentration of the library  products an 
Agilent DNA 1000 chip (Agilent Technologies, cat. no. 5067-1505) was run on an Agilent 
Technologies 2100 Bioanalyzer using the Agilent DNA 1000 Kit (Agilent Technologies, cat. no. 
5067-1504) following the Agilent DNA 1000 Kit Quick Start Guide. All samples with 
concentration above 10 nM were diluted to 10 nM.  
 
qPCR: 
To accurately quantify the number of amplified molecules in the library sample a qPCR was 
performed using KAPA Library Quantification Kit for Illumina Genome Analyzer platform (KAPA 
Biosystems, cat. no. KK4824). The library samples were diluted 1:3000 in Library Dilution Buffer 
(10 mM Tris-HCl, pH: 8.0 + 0.05 % Tween 20) in a deep well 96-well plate. The plate was sealed 
and incubated at RT on rocking table for 5 minutes. Followed the KAPA Library Quantification Kit 
detailed protocol for the qPCR set-up. The concentrations were calculated from equations’ 
described in the KAPA Library Quantification Kit detailed protocol and further dilutions were 
carried out by the ARK genomic staff. The libraries were ready for cluster generation and 
sequencing on Illumina HiSeq 2000 by ARK genomics, Roslin Institute, University of Edinburgh. 
 
Sequence data analysis: 
After initial removal of adaptors and low quality sequences, the quality of the FastQC files was 
examined using the applicant FastQC (version 0.10.1). The reads were trimmed in regards to the 
FastQC report. Trimming was done by the Prinseq-lite tool and mapping of the reads was 
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performed by the Burrows-Wheeler aligner (BWA) using the Aln algorithm. For further details on 
the data analysis and results please see Manuscript I. 
5’ RACE 
For some Type 2 viruses, it was difficult to amplify the further most 5’ end of the genome using 
the primes designed for long range PCR amplification in that area of the genome (see Manuscript I). 
Hence a method for rapid amplification of cDNA ends (RACE) was performed using Invitrogens 5’ 
RACE System for Rapid Amplification of cDNA Ends, Version 2.0 (cat. no. 18374). An overview 
of the 5’ RACE procedure is shown in app. I. fig. 1. 
 
 
App. I. fig. 1. Overview of the 5’ RACE procedure. 1) cDNA is synthesized from template RNA 
using a gene-specific primer as RT-primer (GSP1). 2) Degradation of RNA with RNAse mix. 3) 3’ 
dC-tailing of purified cDNA. 4) PCR amplification of dC-tailed cDNA using the Abridge Anchor 
Primer and a second gene-specific primer (GSP2). 5) Re-amplifying PCR product obtained from 
step 4 using the AUAP primer and a third gene specific primer (nested GSP). The figure is from the 
5’ RACE System for Rapid Amplification of cDNA Ends, Version 2.0 protocol. 
 
The gene-specific primers for the 5’ RACE were designed using the Primer3Plus web utility 
(Untergasser et al., 2007). The primer sequences are listed in app. I. table 9. 
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App I. table 9. Gene-specific primers for 5’ RACE. 
Primer name Primer sequences (5’-3’) 
RT748 (GSP1) CAA TGT CAT AGA CAG TAG 
GSP2-538 TCA AGA CTG CAG GAG TGA GC 
Nested-458 CCA CTG GTC ATT CGT GCG AT 
 
 
Preparation before start: 
Prepare 1X wash buffer: 
1. Pipette 1 ml of the wash buffer concentrate into a 50 ml graduated cylinder 
2. Add 18 ml of MQ and 21 ml of absolute ethanol (99 %). Mix well 
3. Transfer to a blue cap bottle and store at 4°C 
 
First strand cDNA Synthesis: 
1. Prepare cDNA reagents A and B in two separate PCR tubes and keep reagent mix B on ice 
until use (app. I. table 10). 
 
App. I. table 10. Mixture A and Mixture B for cDNA synthesis 
Components (A) Start concentration Volume (µl) 
RT748 (GSP1) 0.5µM 5.5 
Template (mRNA) ~80 ng/µl 10  
DEPH-treated water - - 
Final volume  15,5 µl 
   
Components (B) Start concentration Volume (µl) 
PCR buffer 10X 2.5 
MgCl2 25 mM 2.5 
dNTP mix 10 mM 1 
DTT 0.1 M 2.5 
SuperScript II - 1 
Final volume  9.5 µl 
 
 
2. Incubate mixture A for 10 minutes at 70°C and place on ice when finished. 
3. Collect mixture A by briefly centrifugation and add mixture B to mixture A. 
4.  Incubate the mixture in a thermo cycler at 42°C for 50 minutes followed by 70°C for 15 
minutes (step 1, app. I. Fig. 1). 
5. Add 1 µl RNAse mix, mix gently but thoroughly, and incubate at 37°C for 30 minutes. Collect 
the reaction by briefly centrifugation and place on ice (step 2, app. I. Fig. 1). 
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6. The procedure can be stopped at this point by storing the cDNA at -20°C or proceed to the 
next step. 
 
S.N.A.P Column purification of cDNA: 
1. Equilibrate the binding buffer to room temperature and cool the wash buffer to 4°C before 
starting the purification of cDNA. 
2. For each sample to be purified, equilibrate ~100 µl RNAse free water at 65°C for use in step 
8. 
3. Add 120 µl binding solution (6 M NaI) t the cDNA reaction. 
4. Transfer the cDNA/NaI solution to a S.N.A.P. column. Centrifuge at 13,000 x g for 20 
seconds. Discard the flow-through. 
5. Add 400 ml of cold 1X wash buffer to the spin column. Centrifuge at 13,000 x g for 20 
seconds. Discard the flow-through. Repeat this step an additional three times. 
6. Wash the column with 400 µl cold 70 % EtOH. Centrifuge at 13,000 x g for 20 seconds and 
discard the flow-through. Repeat the step once more. 
7. Centrifugate the column at 13,000 x g for 1 minute and discard the flow-through.  
8. Transfer the column to a 1.5 ml eppendorf tube and add 50 µl 65°C pre-heated RNAse free 
water to the column and centrifuge at 13,000 x g for 20 seconds.  
9. The procedure can be stopped here by storing the purified cDNA at -20°C or proceed to the 
next step. 
 
dC tailing of cDNA: 
1. Mix the dC tailing mix as described in app. I table 11. 
 
App. I. table 11. dC tailing mix 
Components Volume (µl) 
DEPC-treated water 6.5 
5 x tailing buffer 5.0 
2 mM dCTP 2.5 
S.N.A.P.-purified cDNA  10.0 
Final volume 24.0 µl 
 
2. Incubate the dC tailing mix at 94°C for 3 minutes. Chill on ice for 1 minute. 
3. Add 1 µl terminal deoxynucleotidyl transferase (TdT), mix gently. 
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4. Run the following program on a thermal cycler: 37°C for 10 minutes followed by 65°C for 10 
minutes. Collect the content by briefly centrifugation and place on ice (step 3, app. I. Fig. 1). 
5. This is a safe stopping point. Store the dC-tailed cDNA at -20°C or proceed to the next step. 
 
PCR amplification of dC-tailed cDNA: 
For PCR amplification of the dC-tailed cDNA the AccuPrime Taq DNA Polymerase High 
Fidelity Kit from Invitrogen was used. The reaction mixture was composed as listed in app. I. table 
12. 
 
App. I. table 12. Reaction mixture for PCR amplification of dC-tailed cDNA. 
Components Volume (µl) 
RNAse free water 35.5 
10X AccuPrime PCR buffer I 5.0 
GSP2-538 (10 µM) 2.0 
Abridge Anchor Primer (AAP) (10 µM) 2.0 
AccuPrime Taq DNA polymerase 0.5 
dC-tailed cDNA 5.0 
Final volume 50 µl 
 
The PCR amplification was carried out using the same thermal cycler program as for 
conventional PCR (app. I. table 8) (step 4, app. I. Fig. 1). 
The PCR amplicons were analyzed by agarose gel electrophoresis (2 % E-gel). If multiple bands 
appeared on the gel, amplicons of 500-600 bp in size were cut from the gel and purified using the 
High Pure PCR Product Purification Kit (Roche) following the procedure described in the section 
‘Purification of PCR amplicons’. 
 
Nested PCR amplification: 
The nested PCR amplification was carried out using the AccuPrime Taq DNA Polymerase High 
Fidelity Kit from Invitrogen. The reaction mixture was prepared as listed in app. I. table 13. 
 
App. I. table 13. Reaction mixture for nested PCR amplification. 
Components Volume (µl) 
RNAse free water 37.5 
10X AccuPrime PCR buffer I 5.0 
Nested-458 (10 µM) 1.0 
AUAP (10 µl) 1.0 
AccuPrime Taq DNA polymerase 0.5 
Purified PCR amplicons from the first PCR reaction 5.0 
Final volume 50 µl 
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 The nested PCR amplification was carried out using the same thermal cycler program as for 
conventional PCR (app. I. table 8) (step 5, app. I. Fig. 1). 
The PCR products were analyzed on a 2 % agarose gel and purified as previously described 
(section: ‘Purification of PCR amplicons’). 
The nested PCR amplicons was approximately 500 bp in size and ready for cloning into the 
TOPO vector. This was performed using the TOPO TA Cloning Kit for sequencing from 
Invitrogen. 
 
The TOPO Cloning Reaction: 
1. Mix the TOPO Cloning reaction in the order listed in app. I. table 14. Incubate the mixture for 
5 minutes at RT. 
2. Place the reaction on ice and proceed to Transform One Shot TOP10 Competent cells. 
 
App. I. table 14. The TOPO Cloning reaction mixture. 
Reagents Volume (µl) 
Nested PCR amplicons 4 
Salt Solution 1 
TOPO vector 1 
Final volume 6 µl 
 
Transform One Shot TOP10 Competent Cells: 
1. Add 2 µl of the TOPO Cloning reaction into a vial of thawed One Shot Chemically Competent 
E. coli and mix gently. Do not pipeting up and down! 
2. Incubate on ice for 5 minutes. 
3. Heat-shock the cells at 42°C for 30 seconds, then place on ice. 
4. Add 250 µl of RT equilibrated S.O.C. medium. 
5. Incubate the cells at 37°C for 1 hour. 
6. From each Transformed cell vial 50, 100, and 250 µl cell suspension was spread onto separate 
37°C pre-warmed LB plates containing 100 µg/ml ampicillin.  
7. The plates incubate at 37°C over night. 
8. Next day, single colonies are selected and spread onto new 37°C pre-warmed LB plates 
containing 100 µg/ml ampicillin. The plates incubate at 37°C over night. 
9. The following day, single colonies are selected for colony PCR. One colony was used per 
PCR reaction. 
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10. For the colony PCR the AccuPrime Taq DNA Polymerase High Fidelity Kit from Invitrogen 
was used. The reaction mixture was prepared as listed in app. I. table 15. 
 
App. I. table 15. PCR colony PCR Reaction mixture. 
Reagents Volume (µl) 
RNAse free water 42.5 
10X AccuPrime PCR buffer I 5.0 
M13-Fw (10 µM) 1.0 
M13-Rev(10 µM) 1.0 
AccuPrime Taq DNA polymerase 0.5 
One E. coli colony - 
Final volume 50 µl 
 
11. The colony PCR was carried out using the same thermal cycler program as for conventional 
PCR (table 2.8). The elongation step was extended to 90 seconds. 
12. The colony PCR was examined on a 2 % agarose gel with the expected size of ~680 bp (500 
bp from the nested PCR amplification product + 2 x 90 bp for the M13 sequence). Plasmids from 
plates containing positive colonies were purified using the PureLink Quick Plasmid DNA Miniprep 
kit from Invitrogen. 
 
Purification of plasmid DNA: 
1. Positive colonies were dissolved in 250 ml Resuspension Buffer (R3) with RNAse A by 
vortexing until homogeneous. 
2. 250 ml Lysis Buffer (L7) was added and gently mixed by inverting the tube five times. Do not 
vortex. Incubate at RT for 5 minutes. 
3. 350 µl Precipitation Buffer (N4) was added and mix by immediately inverting the tube until 
homogeneous. Do not vortex. Centrifuge the lysate at 12,000 x g for 10 minutes. 
4. Transfer the supernatant to the spin column. Centrifuge at 12,000 x g for 1 minute. Discard the 
flow-through. 
5. 700 µl Wash Buffer (W9) with EtOH was added the column and centrifuged at 12,000 x g for 
1 minute. The flow-through was discarded and the column was centrifuged an additional time. 
6. The column was transferred to a 1.5 ml eppendorf tube and 75 µl 65°C pre-heated TE Buffer 
(TE) was added to the center of the column. Then incubate at RT for 1 minute. 
7. Elute the plasmid DNA by centrifuge the column at 12,000 x g for 2 minutes.  
8. The concentration of the plasmid DNA was determined using a spectrophotometer. 
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Cycle sequencing of plasmid DNA: 
For cycle sequencing, 1 µg of purified plasmid DNA in 10 µl MQ was prepared with 4 µl 5 µM 
M13 primers and send to LGC Genomics GmbH (Berlin, Germany). The obtained raw data was 
assembled into contigs using the software CLC Main workbench v. 6.6.2 (CLC BIO, Aarhus, 
Denmark). The obtained 5’-end nucleotide sequences were assembled with the nucleotide 
sequences obtained from next generation sequencing to form complete PRRSV genomes. 
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APPENDIX II 
 
App. II. table 1. All Type 1 PRRS viruses sequenced during the PhD project. 
Type 1 PRRSV Isolation 
year 
Sequence material ORF5 ORF7 ORF2-7 Complete 
genome 
ESP-1991-Olot91 1991/Spain Marc-145 > 3. passage - - - KC862570 
DK-1992-PRRS-111_92 1992 PAM 17. passage - - - KC862566 
DK-2003-6-2 2003 PAM 1. passage KC862530 KC862559 - - 
DK-2003-6-3 2003 PAM 1. passage KC862533 KC862560 - - 
DK-2003-6-5     2003 PAM 1. passage - - - KC862571 
DK-2003-7-2 2003 PAM 2. passage - - - KC862572 
DK-2003-8-2 2003 PAM 1. passage KC862531 KC862557 - - 
DK-2003-8-3 2003 PAM 1. passage KC862532 KC862558 - - 
DK-2007-10-1-1 2007 Lung homogenate - KC862554 - - 
DK-2007-10-1-3      1007 Lung homogenate KC862528 KC862555 - - 
DK-2007-80-2-1      2007 PAM 1. passage KC862529 KC862556 - - 
DK-2008-10-5-2    2008 Lung homogenate - - - KC862573 
DK-2008-10-5-3      2008 Lung homogenate KC862526 - - - 
DK-2008-16-6-1     2008 Lung homogenate KC862527 KC862553 - - 
DK-2010-10-9-1 2010 Nasal swab - KC862534 - - 
DK-2010-10-10-3 2010 PAM 1. passage - - - KC862568 
DK-2010-30-11-11   2010 Lung homogenate - - KC862562 - 
DK-2010-30-11-14 2010 Lung homogenate - - KC862563 - 
DK-2010-30-11-17    2010 Lung homogenate - - KC862561 - 
DK-2010-10-12-1     2010 Lung homogenate - - KC862564 - 
DK-2011-05-11-3 2011 Serum KC862504 KC862535 - - 
DK-2011-05-11-5     2011 Serum KC862505 KC862536 - - 
DK-2011-05-11-14 2011 Serum - - - KC862567 
DK-2011-05-11-19    2011 Serum KC862506 KC862537 - - 
DK-2011-05-11-20   2011 Serum KC862507 KC862538 - - 
DK-2011-05-23-2 2011 Serum KC862508 KC862539 - - 
DK-2011-05-23-9     2011 PAM 1. passage - - - KC862569 
DK-2011-05-25-6  2011 Serum KC862509 KC862540 - - 
DK-2011-05-25-8     2011 Serum KC862510 KC862541 - - 
DK-2011-05-25-17    2011 Serum KC862511 KC862542 - - 
DK-2011-05-25-20 2011 Serum KC862512 KC862543 - - 
DK-2011-30-7-1   2011 Nasal swabs KC862513 KC862544 - - 
DK-2011-30-8-12 2011 Serum KC862514 KC862545 - - 
DK-2011-30-9-13 2011 Serum KC862515 KC862546 - - 
DK-2011-30-9-17 2011 Serum KC862516 - - - 
DK-2011-09-02-2 2011 Serum KC862517 KC862547 - - 
DK-2012-01-05-2   2012 Serum - - - KC862574 
DK-2012-01-05-11   2012 Serum KC862518 KC862548 - - 
DK-2012-30-8-8 2012 Nasal swabs KC862519 KC862549 - - 
DK-2012-10-9-3 2012 Oral swab KC862520 - - - 
DK-2012-10-01-27 2012 Serum KC862521 - - - 
DK-2012-08-21-32   2012 Serum KC862522 - - - 
DK-2013-10-1-1 2013 Nasal swabs KC862523 KC862550 - - 
DK-2013-10-2-1 2013 Lung homogenate KC862524 KC862551 - - 
DK-2013-30-3-6 2013 Serum KC862525 KC862552 ORF6: KC862565 
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APPENDIX III 
 
App. III table 1. All Type 2 PRRS viruses sequenced during the PhD project. 
Type 2 PRRSV Isolation 
year 
Sequence material ORF5 ORF7 Partial 
NSP2 
Complete 
genome 
DK-1997-19407B 1997 Marc-145 2. passage - - - KC862576 
DK-2003-1-2 2003 Marc-145 1. passage KC506665 KC506718 KF311033 - 
DK-2003-2-3 2003 Marc-145 1. passage - - - KC862584 
DK-2003-3-3 2003 Marc-145 1. passage KC506667 KC506720 KF311034 - 
DK-2003-4-1 2003 - KC506668 - - - 
DK-2003-5-1   2003 - KC506669 - - - 
DK-2004-1-3-Lu 2004 Marc-145 1. passage KC506661 KC506714 KF311035 - 
DK-2004-1-4-Lu 2004 Marc-145 1. passage KC506662 KC506715 KF311036 - 
DK-2004-1-7-Pl   2004 Marc-145 1. passage - - - KC862578 
DK-2004-2-1 2004 Marc-145 1. passage - - - KC862585 
DK-2004-3-1 2004 - KC577601 KC577602 - - 
DK-2008-10-1-1 2008 Lung homogenate - KC506721 - - 
DK-2008-10-1-2 2008 Lung homogenate - KC506722 -  
DK-2008-10-1-3 2008 Lung homogenate - - - KC862582 
DK-2008-16-2-3 2008 Lung homogenate - KC506724  - 
DK-2008-16-2-4 2008 Lung homogenate KC506671 KC506725 KF311037 - 
DK-2008-16-3-3 2008 Lung homogenate  KC506672 KC506726 - - 
DK-2008-16-4-2 2008 Lung homogenate - KC577603 - - 
DK-2010-10-1-1 2010 Lung homogenate KC506625 KC506674 - - 
DK-2010-10-1-2 2010 Lung homogenate - - - KC862579 
DK-2010-10-2-1 2010 Marc-145 2. passage - - - KC862581 
DK-2010-10-2-2 2010 Lung homogenate KC506628 KC506677 KF311038 - 
DK-2010-10-2-3 2010 Lung homogenate KC506629 KC506678 KF311039 - 
DK-2010-10-3-3 2010 Lung homogenate  KC506630 KC506679 KF311040 - 
DK-2010-10-4-1 2010 Lung homogenate - - - KC862583 
DK-2010-10-4-2 2010 Lung homogenate KC506632 KC506681 KF311041 - 
DK-2010-10-4-3 2010 Lung homogenate KC506633 KC506682 KF311042 - 
DK-2010-10-5-2 2010 Lung homogenate KC506634 KC506683 KF311044 - 
DK-2010-10-6-3 2010 Lung homogenate KC506635 KC506684 - - 
DK-2010-10-7-1 2010 Marc-145 2. passage - - - KC862580 
DK-2010-30-8-4 2010 Serum KC506637 KC506686 - - 
DK-2010-10-13-1 2010 Marc-145 2. passage - - - KF183946 
DK-2010-10-13-2 2010 Lung homogenate KF183948 KF183961 KF311020 - 
DK-2010-10-13-3 2010 Lung homogenate KF183949 KF183962 KF311021 - 
DK-2010-10-13-4     2010 Lung homogenate KF183950 KF183963 KF311022 - 
DK-2010-10-13-5    2010 Lung homogenate KF183951 KF183964 KF311023 - 
DK-2010-10-13-6 2010 Lung homogenate KF183952 KF183965 KF311024 - 
DK-2010-10-13-7     2010 Lung homogenate KF183953 KF183966 KF311025 - 
DK-2010-10-13-8   2010 Lung homogenate KF183954 KF183967 KF311026 - 
DK-2010-10-13-9 2010 Lung homogenate KF183955 KF183968 KF311027 - 
DK-2011-88005-A5 2011 Lung homogenate KF183956 KF183969 KF311028 - 
DK-2011-88005-A6 2011 Lung homogenate KF183957 KF183970 KF311029 - 
DK-2011-88005-A7 2011 Lung homogenate KF183958 KF183971 KF311030 - 
DK-2011-88005-A8 2011 Lung homogenate KF183959 KF183972 KF311031 - 
DK-2011-88005-A8-Pl 2011 Pleura - - - KF183947 
DK-2011-88005-C1 2011 Lung homogenate KF183960 - KF311032 - 
DK-2011-30-1-31 2011 Serum  KC506638 KC506687 KF311045 - 
DK-2011-30-1-34 2011 Serum KC506639 KC506688 KF311046 - 
DK-2011-30-1-35 2011 Serum KC506640 KC506689 KF311047 - 
DK-2011-10-2-1 2011 Lung homogenate KC506641 KC506690 - - 
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Type 2 PRRSV Isolation 
year 
Sequence material ORF5 ORF7 Partial 
NSP2 
Complete 
genome 
DK-2011-030311-1   2011 Lung homogenate - - - KC862577 
DK-2011-030311-2 2011 Lung homogenate KC506643 KC506692 KF311055 - 
DK-2011-030311-3 2011 Lung homogenate KC506644 KC506693 KF311056 - 
DK-2011-030311-4 2011 Lung homogenate KC506645 KC506694 KF311057 - 
DK-2011-30-3-13 2011 Serum KC506646 KC506695 KF311052 - 
DK-2011-30-3-15 2011 Serum KC506647 KC506696 KF311053 - 
DK-2011-30-3-20 2011 Serum KC506648 KC506697 KF311048 - 
DK-2011-30-4-3 2011 Serum KC506649 KC506698 KF311049 - 
DK-2011-30-4-5 2011 Serum KC506650 KC506699 KF311050 - 
DK-2011-30-4-7 2011 Serum KC506651 KC506700 KF311051 - 
DK-2011-10-5-1 2011 Lung homogenate KC506652 KC506701 KF311043 - 
DK-2011-30-6-27 2011 Serum KC506653 KC506702 KF311054 - 
DK-2012-10-1-5 2012 Nasal swab KC506654 KC506703 - - 
DK-2012-10-2-8 2012 Oral swab KC506655 KC506704 - - 
DK-2012-10-2-9 2012 Oral swab KC506656 KC506705 - - 
DK-2012-10-3-1 2012 Oral swab KC506657 KC506706 - - 
DK-2012-10-4-2 2012 Nasal swab - KC506707 - - 
DK-2012-10-5-3 2012 Oral swab - KC506708 - - 
DK-2012-10-5-4 2012 Oral swab - KC506709 - - 
DK-2012-10-6-2 2012 Lung homogenate - KC506710 - - 
DK-2012-30-7-16 2012 Serum KC506658 KC506711 - - 
DK-2012-30-7-18 2012 Serum KC506659 KC506712 - - 
DK-2012-01-11-3     2012 Serum - - - KC862575 
 
 
 
 
